Molecular Mechanism of Prothrombin Activation by von Willebrand Factor-Binding Protein by Kroh, Heather K.
MOLECULAR MECHANISM OF PROTHROMBIN ACTIVATION 
BY VON WILLEBRAND FACTOR-BINDING PROTEIN 
 
By 
 
Heather K. Kroh 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements 
for the degree of 
 
DOCTOR OF PHILOSOPHY 
in 
Pathology 
May, 2010 
Nashville, Tennessee 
 
Approved: 
Richard L. Hoover, Ph.D. 
Albert H. Beth, Ph.D. 
David Gailani, M.D. 
D. Borden Lacy, Ph.D. 
Samuel A. Santoro, M.D., Ph.D. 
Munirathinam Sundaramoorthy, Ph.D. 
                                                                                                
 
 
 
 
 
 
 
 
 
 
Copyright © 2010 by Heather K. Kroh 
All Rights Reserved 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
For my father
 iii
ACKNOWLEDGEMENTS 
 
 I would like to recognize several people whose support during my time at 
Vanderbilt was instrumental for my development as a scientist.  Most significantly, I am 
obliged to my dissertation advisor Paul E. Bock, Ph.D., who first provided me with the 
opportunity to work on numerous projects and gain experience as a research assistant in 
his lab.  Through his encouragement and example, I was able to develop my enthusiasm 
for scientific research and make the decision to attend graduate school to pursue a 
doctorate.  I am also grateful to the members of my thesis committee, Richard Hoover, 
Ph.D., Samuel Santoro, M.D., Ph.D., David Gailani, M.D., Al Beth, Ph.D., D. Borden 
Lacy, Ph.D., and Munirathinam Sundaramoorthy, Ph.D., for the time they dedicated to 
my project, as well as for the critical comments and suggestions which allowed me to 
refine my experiments.  Particular appreciation goes to Peter Panizzi, Ph.D., who was 
responsible for much of my early technical training, and Ingrid Verhamme, Ph.D., who 
was always willing to discuss problematic results and analyses.  I would also like to 
thank other past and present members of the lab—including Sarah Stuart, Karen Wiles, 
Malabika Laha, and Jonathan Creamer, Ph.D.—for their absolute support and 
assistance. 
 Personal thanks must go to my parents, Clarence and Sharon Kroh, for always 
giving me their love—and the ability to make my own decisions, the best gifts of all.  
Most of all, I owe unending gratitude to my husband, Jamie Cufr, for promising to 
support completely my decision to go back to school, whenever I decided that the time 
was right.  The promise was kept.   
Finally, I am grateful for financial support for this project from the National 
Institutes of Health (NIH) through NIH Grant R37 HL071544 from the National Heart, 
Lung, and Blood Institute and Training Grant 2-T32 HL07751. 
 iv
TABLE OF CONTENTS 
 
DEDICATION ....................................................................................................................iii 
ACKNOWLEDGMENTS................................................................................................... iv 
LIST OF TABLES.............................................................................................................vii 
LIST OF FIGURES..........................................................................................................viii 
Chapter 
I.      INTRODUCTION....................................................................................................... 1 
        Initiation and Regulation of Blood Coagulation ......................................................... 1 
        Serine Proteinases and Prothrombin Activation........................................................ 6 
        Pathogenic Bacteria and Blood-Borne Infection ..................................................... 13 
        Staphylocoagulase and the Zymogen Activator and Adhesion Proteins (ZAAPs) .. 20 
        Von Willebrand Factor-Binding Protein – Early Discovery and Characterization .... 27 
        Concluding Remarks and Goal of Thesis Research ............................................... 30 
        References.............................................................................................................. 32 
           
II.     VON WILLEBRAND FACTOR-BINDING PROTEIN IS A HYSTERETIC  
        CONFORMATIONAL ACTIVATOR OF PROTHROMBIN....................................... 42 
 
        Abstract ................................................................................................................... 43 
        Introduction ............................................................................................................. 44 
        Results .................................................................................................................... 46 
               Conformational activation of ProT by VWbp(1-263) and VWbp(1-474) ........... 46 
               Activation of Pre 1 by the NH2-terminal insertion mechanism.......................... 46 
               Kinetic analysis of ProT activation ................................................................... 48 
               Competitive binding of VWbp(1-263) and [5-F]Hir(54-65) to ProT................... 51 
               Clotting of Fbg by ProT·VWbp(1-263) .............................................................. 52 
        Discussion............................................................................................................... 53 
        Materials and Methods............................................................................................ 58 
        Supplemental Data (Published) .............................................................................. 61 
        Supplemental Data (Unpublished) .......................................................................... 69 
        References.............................................................................................................. 74 
 
III.    EFFECT OF ZYMOGEN DOMAINS AND ACTIVE SITE OCCUPATION ON    
        ACTIVATION OF PROTHROMBIN BY VON WILLEBRAND FACTOR-BINDING    
        PROTEIN ................................................................................................................78 
 
        Abstract ................................................................................................................... 79 
        Introduction ............................................................................................................. 80 
        Experimental Procedures........................................................................................ 82 
        Results .................................................................................................................... 86 
               Kinetic analysis of ProT activation by VWbp(1-474) ........................................ 86 
               Binding of VWbp(1-263) or VWbp(1-474) to active ProT derivatives ............... 88 
 v
               Binding of VWbp(1-263) or VWbp(1-474) to active site-blocked ProT   
               derivatives ........................................................................................................ 88 
               Autocatalysis of the ProT-VWbp complex in human plasma............................ 89 
        Discussion............................................................................................................... 97 
        Supplemental Data (Unpublished) ........................................................................ 107 
        References............................................................................................................ 113 
 
IV.    EXPRESSION OF ALLOSTERIC LINKAGE BETWEEN THE SODIUM ION  
        BINDING SITE AND EXOSITE I OF THROMBIN DURING PROTHROMBIN  
        ACTIVATION......................................................................................................... 117 
 
        Abstract ................................................................................................................. 118 
        Introduction ...........................................................................................................119 
        Experimental Procedures...................................................................................... 122 
        Results .................................................................................................................. 127 
               Na+-exosite I linkage for ProT zymogen forms............................................... 127 
               Na+-exosite I linkage for thrombin and FPR-thrombin.................................... 129 
               Analysis of Na+-exosite I linkage for MzT(-F1) ............................................... 129 
               Regulation of MzT(-F1) exosite I affinity by Na+............................................. 133 
               Na+-exosite I linkage for FPR-MzT and FPR-MzT(-F1).................................. 133 
               Effect of Na+ on exosite I of active MzT ......................................................... 135 
               Na+ binding affinity estimated from the kinetics of chromogenic substrate  
               hydrolysis ....................................................................................................... 137 
        Discussion.............................................................................................................141 
        References............................................................................................................ 147 
 
V.    SIGNIFICANCE AND FUTURE PATHWAYS........................................................ 152 
 
       Summary of Research ........................................................................................... 152 
       Significance of the Mechanism of Activation of Prothrombin by VWbp.................. 153 
       Allostery and Thrombin Specificity ......................................................................... 155 
       The Role of von Willebrand Factor in Hemostasis ................................................. 157 
       Recognition of von Willebrand Factor by Pathogens ............................................. 159 
       VWbp: A Bifunctional Staphylococcal Exoprotein .................................................. 161 
       VWbp and Staphylococcal Pathology .................................................................... 163 
       References............................................................................................................. 166 
 
 
 
 
 
 
 
 
 vi
LIST OF TABLES 
 
Table              Page 
2-1.   Summary of kinetic parameters for ProT activation by VWbp(1-263) from  
          the hysteretic mechanism shown in Scheme 1 ..................................................... 50   
 
3-1.   Summary of binding parameters for competitive equilibrium binding of 
          VWbp(1-263) and VWbp(1-474) to unmodified and active site-blocked 
          ProT derivatives .................................................................................................... 94   
 
4-1.   Summary of binding parameters for direct, kinetic, and endpoint titrations of  
         [5F]Hir(54-65) in the presence of ProT and Pre 1 species and varying 
         concentrations of Na+ ........................................................................................... 140 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii
LIST OF FIGURES 
 
Figure              Page 
1-1.   Ordered events in the formation of a blood clot ....................................................... 2 
1-2.   Schematic of extrinsic and intrinsic pathways of blood coagulation......................... 3                        
1-3.   Formation of the active site of a proteinase ............................................................. 7 
1-4.   Schematic of alternative pathways for activation of prothrombin by the  
         prothrombinase complex........................................................................................ 10 
 
1-5.   Different modes of localization and secretion of exoproteins by pathogenic  
          bacteria ................................................................................................................. 17 
 
1-6.   Schematic domain organization of ZAAP family members .................................... 26 
 
1-7.   Sequence alignment of the amino acids of the D1-D2 domains of SC  
         and VWbp ..............................................................................................................29 
 
1-8.   Comparison of SC(1-325) crystal structure to homologous VWbp(1-263)  
         model ..................................................................................................................... 29 
 
2-1.   Active-site specific labeling of ProT·VWbp(1-263) and ProT·VWbp(1-474) 
         complexes assessed by SDS-gel electrophoresis ................................................. 47 
 
2-2.   Pre 1 activation by NH2-terminal truncation mutants of VWbp............................... 47 
 
2-Scheme 1:  The hysteretic mechanism of ProT activation by VWbp ........................... 49 
 
2-3.   Full-time course analysis of the kinetics of ProT activation by VWbp(1-263) ........ 49 
 
2-4.   Competitive binding of native ProT to [5-F]Hir(54-65) and VWbp(1-263) .............. 52 
 
2-5.   Clotting of Fbg by mixtures of ProT and VWbp(1-263) .......................................... 53 
 
2-1S. Proteolytic products generated in ProT·VWbp(1-263) mixtures assessed by  
          SDS-gel electrophoresis ....................................................................................... 62 
 
2-2S. Pre 1 generation in mixtures of 1 nM ProT and 10 μM VWbp(1-263) evaluated 
          by western blotting ................................................................................................ 63 
 
2-3S. Pre 1 generation in mixtures of 1 nM ProT and 1 μM VWbp evaluated by  
          western blotting .....................................................................................................64 
 
2-4S. Analysis of activation progress curves as a function of preincubation time of  
          ProT or Pre 1 with VWbp(1-263) in the absence of substrate............................... 66 
 
 viii
2-5S. Platelet aggregation and activation in PRP ........................................................... 70 
 
2-6S. Autocatalytic cleavage of ProT in the presence of VWbp(1-263)  
          or VWbp(1-474)..................................................................................................... 73 
 
3-1.   Full time-course kinetic analysis of ProT activation by VWbp(1-474) .................... 87 
 
3-2.   Competitive binding of VWbp(1-263) and [5F]Hir(54-65) to native ProT  
          derivatives ............................................................................................................. 90 
 
3-3.   Competitive binding of VWbp(1-474) and [5F]Hir(54-65) to native ProT 
          derivatives ............................................................................................................. 91 
 
3-4.   Binding of VWbp(1-263) to [TMR]FPR-ProT and active site- 
          blocked ProT derivatives....................................................................................... 92 
 
3-5.   Binding of VWbp(1-474) to [TMR]FPR-ProT and active site- 
          blocked ProT derivatives....................................................................................... 93 
 
3-6.   Changes in Gibbs free energy (∆G) from competitive equilibrium binding............. 95 
 
3-7.   Autoproteolytic cleavage of endogenous plasma ProT by VWbp .......................... 96 
 
3-8.   Comparison of fluorescence traces for binding of MzTQQQ or MzT(-F1)  
          by VWbp..............................................................................................................103 
 
3-1S. Approximate molecular masses and sedimentation coefficient distributions 
          (c(s)) from sedimentation velocity experiments................................................... 108 
 
3-2S. Binding of VWbp(1-263) to 102 pM OG-FPR-ProT and native or FPR-Pre 1...... 109 
 
3-3S. Binding of VWbp(1-263) and 48 nM [5F]Hir(54-65) to FPR-ProT........................ 111 
 
3-4S. Binding of VWbp(1-263) and 48 nM [5F]Hir(54-65) to native or FPR-T............... 111 
 
3-5S. Binding of VWbp(1-474) to native or FPR-Pre 1.................................................. 112 
 
4-1.   Effect of Na+ on [5F]Hir-(54-65)(SO3-) binding to ProT zymogen forms............... 128 
 
4-2.   Effect of Na+ on [5F]Hir-(54-65)(SO3-) binding to thrombin and FPR-thrombin.... 129 
 
4-3.   Time courses of [5F]Hir-(54-65)(SO3-) fluorescence changes and MzT(-F1)  
         Activity accompanying activation of Pre 1 by ecarin ............................................ 131 
 
4-4.   Time courses of Pre 1 activation monitored by SDS gel-electrophoresis ............ 132 
 
4-5.   Kinetic and endpoint titrations of [5F]Hir-(54-65)(SO3-) binding to MzT(-F1) 
         in the absence and presence of Na+ .................................................................... 134 
 
4-6.   Effect of Na+ on [5F]Hir-(54-65)(SO3-) binding to FPR-MzT and  
         FPR-MzT(-F1) ...................................................................................................... 135 
 ix
 x
4-7.   Kinetic and endpoint titrations of [5F]Hir-(54-65)(SO3-) binding to MzTR155A in the    
         absence and presence of Na+ .............................................................................. 136 
 
4-8.   Effects of Na+ on chromogenic substrate hydrolysis by thrombin, MzT(-F1),  
         and MzTR155A ........................................................................................................ 139  
  
5-1.   Domain organization of VWF propeptide and mature protein .............................. 159 
 
5-2.   Development of vegetative growths during bacterial infective endocarditis......... 165 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER I 
 
INTRODUCTION 
 
Initiation and Regulation of Blood Coagulation 
 Maintenance of the integrity of the circulatory system is critical after vessel injury.  
Hemostasis is controlled by several components of the vascular system, including 
endothelial cells, platelets, and protein coagulation factors in the blood and on cell 
surfaces.  Damage to the endothelial cell layer disrupts the primarily non-reactive vessel 
lining and uncovers the subendothelium.  This triggers an early primary hemostatic 
response through localization of platelets with the exposed collagen through a tethered 
interaction of the platelet receptor GP Ibα with collagen-bound von Willebrand factor (1).  
Even in the high shear environment found in arteries and capillaries, adhesion of the 
cells into a platelet plug at the site of injury can occur and lead to cellular activation and 
aggregation, stimulating further recruitment and expansion of the platelet mass (Fig. 1).  
The activated platelets serve as foundation for what is called the secondary phase of 
hemostasis, activation of the fluid-phase protein factors responsible for formation of a 
stabilizing fibrin clot (2).  The characteristic balance between procoagulant and 
anticoagulant events is normally sustained by an overlapping system of enzyme-cofactor 
reactions, commonly described as a “waterfall” or “cascade” (3-4).  Highly coordinated 
amplification and feedback responses within this system result in precise temporal and 
spatial control of coagulation.  
Activation of coagulation factors is conventionally segregated into two branches, 
termed the intrinsic and extrinsic pathways, but the line of demarcation only exists for the 
initial activation steps of each system, with ultimate convergence of the pathways at the 
level of factor IX/factor X activation (Fig. 2) (5).  Initiation of the intrinsic (or contact) 
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 Figure 1.  Ordered events in the formation of a blood clot.  Initial injury to the 
endothelial cells exposes tissue factor and triggers binding of platelets (yellow ovals) to 
collagen in the subendothelium.  Growth of the primary plug through platelet-platelet 
interactions helps propagate and amplify the extrinsic coagulation response, eventually 
resulting in fibrin deposition (green) to stabilize the final formed clot. (Adapted from (10)) 
 
 
system can occur upon negatively charged surfaces such as glass or collagen, and it 
involves activation of factor XII and binding of factor XI and prekallikrein to the surface 
by the cofactor high-molecular weight kininogen (HMWK).  Factor XIIa subsequently 
cleaves factor XI to XIa, which activates factor IX, the enzyme responsible for production 
of factor Xa by the Xase complex on platelet membranes (6).   
The fundamental contribution of the intrinsic system to normal induction of 
coagulation is considered to be minimal, compared to the involvement of the 
components of the extrinsic, or factor VIIa-tissue factor initiated, pathway.  Factor VII is 
present in plasma in an inactive zymogen form, but it is thought to be converted to factor 
VIIa through cleavage of a single bond at Arg152 by a number of different proteases, 
including factor Xa (7).  Even though 1-2% of factor VII exists in cleaved form in plasma 
(8), it does not elicit a coagulative response due to several factors.  Activated factor VIIa 
has very little enzymatic activity in the absence of tissue factor, attributable to an 
incomplete structural shift to the enzyme conformation following proteolysis, and it only 
attains catalytic competence when bound to its tissue factor cofactor (9).  Tissue factor 
 2
 
 
Figure 2.  Schematic of extrinsic and intrinsic pathways of blood coagulation.  
After injury, tissue factor can complex with factor VII to initiate the extrinsic pathway to 
lead to thrombin production and fibrin formation.  Factor XIIa in coordination with 
kallikrein and high-molecular weight kininogen mediate the procoagulant response 
through the intrinsic pathway.   
 
 
itself is sequestered from the coagulation machinery in the vasculature, because it is 
only constitutively expressed in the cells within and surrounding the vessel walls, 
including vascular smooth muscle cells and fibroblasts (10).  Factor VIIa and tissue 
factor can only form an active complex following damage to the blood vessel, restricting 
the extrinsic pathway response to just the required areas.  Factor VIIa-tissue factor goes 
on to primarily activate factor X, which coordinates with factor VIIa-tissue factor to 
hydrolyze the necessary cleavage sites on factor IX.  The two products of this “extrinsic” 
Xase complex, factor Xa and factor IXa, play subsequent roles in acceleration of factor 
Xa production through “intrinsic” factor Xase (factor IXa-factor VIIIa complex) and 
thrombin production by the prothrombinase complex (11). 
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Although small amounts of thrombin are produced during the initiation phase of 
coagulation, when only low concentrations of factor Xa and IXa are being produced (12), 
the majority of thrombin is generated in the propagation phase of coagulation once a 
sustainable cycle of factor Xa production is established.  The inactive precursor of 
thrombin, prothrombin, associates with a large macromolecular complex called the 
prothrombinase complex, which contains factor Xa and its cofactor Va on the 
phospholipid surface of activated platelets.   All three proteins involved in thrombin 
production by prothrombinase have specific domains which govern binding to the 
phospholipid surface of the platelet, regulating localization of the proteins to optimize 
complex activity.  The enzyme factor Xa is responsible for cleaving two intramolecular 
bonds in prothrombin, after Arg320 and Arg271, which results in formation and release of 
active thrombin.  Factor V exists as a large single-chain glycoprotein that gains its 
cofactor function upon cleavage of three peptide bonds by enzymes such as thrombin 
and factor Xa (13).  In contrast to the single-domain thrombin molecule, the zymogen 
prothrombin also contains two smaller domains which are lost upon physiological 
activation.  Once thrombin is produced and liberated from the complex, it can bind its 
primary physiological substrate, the glycoprotein fibrinogen, and sequentially cleave off 
fibrinopeptides A and B.  The resultant fibrin monomers associate and are cross-linked 
by the transglutaminase factor XIIIa into a covalent fibrin meshwork that stabilizes the 
forming clot (14). 
The positive feedback reactions involved in the amplification of the coagulation 
response could easily become uncontrollable, if not for an equally efficient subset of 
plasma proteins responsible for diminishing or changing the activity of the procoagulant 
enzymes.  An early regulator of coagulation is tissue factor pathway inhibitor (TFPI), 
which is found in the plasma and directly inhibits the factor VIIa-factor Xa complex, 
effectively stopping the extrinsic response (15).  The serine proteinase inhibitor (serpin) 
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antithrombin is most important for directly inhibiting thrombin, and with assistance from 
glycosaminoglycans such as heparin or heparan sulfate, it forms an irreversible covalent 
complex with the protease (16-17).  Heparin cofactor II, a homologous member of the 
serpin family, also specifically inhibits thrombin in a glycosaminoglycan-dependent 
manner (18).  Other proteases have specific anticoagulant functions of their own, such 
as activated protein C (APC), which degrades the procoagulant cofactors Va and VIIIa to 
target thrombin generation (19).  In addition to its anticoagulant activity, APC also 
exhibits anti-inflammatory and other cytoprotective effects through the endothelial 
protein C receptor (20).  Further pathways for altering procoagulant activity rely on 
proteins that modulate thrombin specificity.  One of the better characterized examples is 
the binding of thrombomodulin, a endothelial cell surface protein, to thrombin, which 
shifts the protease specificity of thrombin from procoagulant cleavage of fibrinogen to 
anticoagulant activation of protein C (21). 
 To enable healing of the vessel injury, the fibrinolytic system in blood is 
responsible for the dissolution of existing clots.  The primary component of this system is 
the protease plasmin, which directly cleaves polymerized, insoluble fibrin into soluble 
degradation products that are easily cleared.  Control of fibrinolysis, like coagulation, is 
achieved through proteolytic feedback and amplification reactions, with plasmin being 
activated from plasminogen by two physiological serine proteinases, tissue-type 
plasminogen activator and urokinase-type plasminogen activator.  Fibrin itself serves as 
a cofactor for the generation of plasmin, because localization of both plasminogen and 
the activators to the fibrin clot must occur to initiate efficient plasmin production.  
Furthermore, fibrinolytic events can be suppressed through direct inhibition of plasmin 
activity, mediated by α2-antiplasmin, or inhibition of the activators themselves by a 
serpin, plasminogen activator inhibitor-1 (22).  Together, fibrinolysis and coagulation 
provide a web of extremely complex, but well-coordinated, protein- and cell-mediated 
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reactions which maintain the integrity of the circulatory system, despite its inherent 
vulnerability to damage and disease. 
 
Serine Proteinases and Prothrombin Activation 
 All of the proteinases included in the procoagulant, anticoagulant, and fibrinolytic 
pathways are classified as members of the serine proteinase family of enzymes.  The 
definitive characteristic of this family is the presence of a serine residue that functions as 
the catalytic nucleophile in the active site cleft of the enzyme.  In coordination with two 
other residues, a conserved histidine and typically an aspartic acid, the serine serves as 
the functional center of the “catalytic triad” of the active site.  While the serine 
proteinases play roles in a large number of physiological processes, from digestion to 
cell differentiation, they can be broadly categorized into groups which share similar 
protein folds, primarily the chymotrypsin-like enzymes and the subtilisin-type enzymes 
(23).  The blood clotting enzymes have chymotrypsin-like conformations represented by 
two domains each containing a six-stranded, anti-parallel β-barrel, with the catalytic triad 
situated in the same orientation at the interface of the two domains.   
Hydrolysis of proteinase substrates occurs through an ordered cycle of reactions 
controlled in large part by the nucleophilicity of Ser195 (chymotrypsinogen numbering).  
This residue attacks the carbonyl atom of the substrate amide bond to produce a 
covalent tetrahedral intermediate, with the imidazole group of His57 (stabilized by Asp102) 
assisting in the reaction.  Hydrogen bonding from the backbone amide atoms of Ser195 
and Gly193 (the oxyanion hole) further stabilizes the intermediate.  The amino portion of 
the substrate is released after receiving a proton from His57, leaving an acyl-enzyme 
derivative, which is subsequently hydrolyzed through a second tetrahedral intermediate 
into the final product and the restored enzyme (24).  Proper orientation of all of the 
residues involved in this mechanism relies on initial proteolytic activation of the zymogen 
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precursor of the enzyme, specifically formation of a new NH2-terminus through cleavage 
of the Arg15-Ile16 bond.  The Ile16 α-ammonium group forms a salt bridge with the 
carboxylate side chain of Asp194 and hydrogen bonds to other residues of the activation 
domain of the enzyme, the portion containing the active site and substrate binding 
regions.  This interaction induces the conformational changes needed to fully activate 
the proteinase and form the substrate specificity pocket (Fig. 3) (25).  Induction of this 
structural transition by just peptides mimicking the NH2-terminus (Ile-Val, Val-Val) has 
been measured for bovine trypsinogen covalently modified with p-guanidinobenzoate 
(26-27), verifying the importance of the NH2-terminal dipeptide in the overall mechanism 
of serine proteinase activation. 
 
 
 
Figure 3.  Formation of the active site of a proteinase.  As a typical serine 
proteinase, thrombin is produced by cleavage of the Arg15-Ile16 bond in prothrombin and 
insertion of the new NH2-terminus into the NH2-terminal binding cleft.  The subsequent 
conformational changes within the activation domain generate the active site and a 
functional oxyanion hole. 
 
 
 
The overall activity and efficiency of a proteinase is impacted by different 
physical attributes of the proteinase itself, not the least of which is the degree to which 
the substrate can access the active site.  In the serine proteinase family, zymogens and 
their corresponding enzymes share almost all of their overall structure, with only a small 
region undergoing most of the conformational change required for proper substrate 
selectivity and proteolytic activity.  Crystallographic comparisons of trypsinogen and 
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trypsin have detailed a disordered substrate-binding cleft in the zymogen that becomes 
defined after formation of the new NH2-terminus (25, 28).  Functional analysis of 
trypsinogen and chymotrypsinogen with active-site titrants also demonstrated much 
slower acylation rates, but similar deacylation rates, for the zymogens compared to the 
enzymes, consistent with rearrangement of the substrate-binding site being a primary 
step in activation, not significant shifts in the catalytic triad (29-30).   
Additional residues within the proteinase also determine the specificity of 
substrate recognition and cleavage, including those which contact the substrate and 
residues which act at a distance through influencing the overall structure of the core of 
the protein.  The concept of multiple individual subsite interactions which govern 
substrate recognition was first specified for the cysteine proteinase papain, with 
correlation between the amino acids on either side of the scissile bond for both the 
substrate and enzyme (31). The residues of the substrate are referred to as P4-P3-P2-
P1-P1’-P2’ (scissile bond at P1-P1’), with the corresponding enzyme subsites named as 
S4-S3-S2-S1-S1’-S2’.  The primary specificity of the enzyme is determined by the 
interactions at the S1/P1 subsite, especially in members of the chymotrypsin-like serine 
proteinases, which exhibit a fairly restricted preference for substrates with particular 
amino acids at the P1 position (23).  Specificity for certain residues at the P1 subsite 
allows classification of the serine proteinases into groups displaying trypsin, 
chymotrypsin, or elastase-like preferences, with the coagulation and fibrinolysis 
proteinases exhibiting the P1-Arg or Lys selection of trypsin.  Trypsin-like proteinases 
also contain a deeply-pocketed substrate binding cleft with the Asp189 residue at the 
bottom, a characteristic that helps select for the basic residues at P1 and is not found in 
chymotrypsin (32).  A large proportion of the residues responsible for specific active site 
recognition of substrates, as well as other critical functions such as stabilization of the 
catalytic domain or Asp102 of the catalytic triad, have been localized to the COOH-
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terminal sequence (~50 amino acids) of many model serine proteinases, including 
trypsin and thrombin (33). 
 As one of the better characterized members of the chymotrypsin-like serine 
proteinases, thrombin shares many features with the prototypical proteinases, but it also 
displays a number of unique attributes which not only shape substrate specificity but 
ultimately alter the function of thrombin.  Prothrombin, the zymogen precursor of 
thrombin, contains a primary catalytic domain and two smaller covalently attached 
domains called fragment 1 and fragment 2.  Fragment 1 includes the NH2-terminal 
portion of the sequence (to residue 155) and mediates binding of prothrombin to platelet 
membranes for processing by the prothrombinase complex.  Proper folding and function 
of fragment 1 is regulated by the presence of ten γ-carboxyglutamic acid residues which 
bind Ca2+ and form the Gla domain, allowing both association with acidic phospholipids 
in the platelet membrane (primarily phospatidylserine) and stabilization of the domain 
structure.  The fragment 2 domain extends to residue 271, sharing a very similar global 
kringle-like structure with fragment 1 including conserved disulfide bonds, but without the 
ability to bind calcium ions.  After proteolytic cleavage at Arg320, the catalytic domain of 
(pro)thrombin is composed of two disulfide linked peptide chains referred to as the A-
chain and B-chain.  The B-chain is homologous to the structure of trypsin, but neither 
trypsin nor elastase contains a portion equivalent to the thrombin A-chain (34).  The 
catalytic triad of Ser195, His57, and Asp102 is found between the β-barrel structures of the 
B-chain, but the active site cleft is comparatively narrow and deep, due to several 
additional insertion loops not found in trypsin.  These loops border the substrate-binding 
site and effectively narrow the substrate specificity of thrombin by blocking access to the 
catalytic machinery of the enzyme (35).  Accessory contact sites are also present on 
parts of the thrombin molecule distant from the active site, in particular two 
electropositive regions on nearly opposite sides of thrombin called anion-binding 
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exosites I and II.  These sites function as focal points for the allosteric regulation of 
thrombin activity and binding of numerous substrates, regulatory macromolecules, and 
inhibitors, affecting not only the immediate structure, but also the general substrate 
specificity of thrombin (36-37).  Further allosteric control is exerted through the binding of 
a single sodium ion (Na+), which directs the procoagulant/anticoagulant activities of 
thrombin through effects on both the exosites and the active site (38). 
 
 
Figure 4.  Schematic of alternative pathways for activation of prothrombin by the 
prothrombinase complex.  Initial cleavage by factor Xa at Arg320 generates the active 
intermediate meizothrombin (MzT).  Alternate cleavage at Arg271 produces inactive 
prethrombin 2 (Pre 2) and fragment 1.2.  
 
 
 
 The conventional pathway of activation of prothrombin to thrombin requires 
proteolysis of two essential bonds, Arg320-Ile321 and Arg271-Thr272, by factor Xa in the 
prothrombinase complex, resulting in formation of the new Ile321 NH2-terminus and 
release of the fragment 1 and 2 domains of the zymogen (Fig. 4).  Detailed biochemical 
studies have been performed on the temporal and spatial requirements for proteolysis of 
prothrombin by the prothrombinase complex to determine the chronological order of 
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peptide bond cleavage.  Early studies on bovine prothrombin had shown that in the 
absence of factor Va, the reaction order is through initial cleavage at Arg271, creating a 
noncovalently bound fragment 1.2 species and the inactive catalytic domain, which is 
now called prethrombin 2 (39-41).  Subsequent studies were confounded by the ability of 
thrombin to cleave additional bonds in prothrombin at Arg155 and Arg284, producing the 
secondary feedback intermediates prethrombin 1 (prothrombin without fragment 1) and 
prethrombin 2’ (prethrombin 2 lacking the first 13 residues) (42).  Use of a reversible 
thrombin inhibitor eventually allowed qualitative evaluation of only the factor Xa-
generated products, revealing meizothrombin, the proteolytically active product of initial 
cleavage at Arg320, as the principal intermediate in the sequential formation of thrombin 
from prothrombin (43).  Differences were observed with reactions performed with 
prethrombin 1, however, which showed evidence of intermediates from both proteolytic 
pathways during activation with factor Xa alone (44).  Later reports focused on the 
individual components of the human prothrombinase complex to help reveal which 
pathway intermediate, meizothrombin or prethrombin 2, was physiologically relevant.  
Kinetic analysis in the presence and absence of factor Va indicated that the cofactor 
altered the rate limiting step in the overall reaction to favor initial cleavage at Arg320 (45).  
Similarly, addition of saturating concentrations of phospholipid membrane vesicles 
increased the rate of cleavage at Arg320 approximately 60-fold, compared to the 5-fold 
change in rate seen at Arg271, supporting meizothrombin as the more pertinent 
intermediate (46). 
 More recent investigations have attempted to build a comprehensive model of 
the overall activation mechanism for prothrombin, with two opposing views at the 
forefront.  Development of different recombinant prothrombin mutants that have one or 
both of the factor Xa cleavage sites modified to a non-cleavable Gln residue has allowed 
examination of the kinetics of proteolysis and product inhibition at each individual site.  
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The first model supports a sequential mechanism initiated by cleavage at Arg320 by a 
single form of prothrombinase complex, driven by differences in accessibility of the two 
cleavage sites in the prothrombin substrate.  Generation of meizothrombin changes the 
structure of the substrate, facilitating subsequent cleavage at Arg271 through a 
mechanism termed conformational “ratcheting” (47-49).  The second perspective 
espouses the existence of two interconverting conformational forms of prothrombinase, 
each recognizing and cleaving one of the factor Xa bonds on prothrombin.  Each 
catalytic cycle would generate one of the intermediates, forming a prothrombinase 
poised to catalyze the succeeding reaction (50-51).  An alternate component to either of 
these models is “channeling”, where production of intermediate cleaved forms of 
prothrombin from prothrombinase is not obligatory and a percentage of the substrate is 
completely converted to thrombin without release of intermediates (52).  Whether one of 
these models is more appropriate to explain the events necessary for prothrombin 
activation in vivo remains to be answered.  
 Efficiency of substrate recognition by prothrombinase has been linked with 
additional protein-protein interactions on the enzyme complex, not simply binding of the 
substrate to the active site of factor Xa (53-54).  Not only does free factor Xa express 
exosites on its surface, analogous to several other coagulation factors, but new exosites 
are also induced by binding of factor Va, which influences binding to both factor Va and 
prothrombin (37).  Examination of meizothrombin and prethrombin 2 in the presence or 
absence of an active site inhibitor indicated prothrombinase exosite interactions would 
likely dictate the sequence of bond cleavage, in support of the ordered cleavage model 
described previously (55-56).  Further experimental evidence supported a role for one or 
both of the fragment domains of prothrombin in mediating binding to factor Va through 
effects on the anion-binding (pro)exosite I of prothrombin (57-59).  The significance of 
these exosite-mediated interactions in regulating not only the production of thrombin, but 
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also its function and specificity though multiple ligand binding, is now at the forefront of 
coagulation and serine proteinase research. 
 
Pathogenic Bacteria and Blood-borne Infection 
 The finely tuned balance afforded by the opposing arms of the coagulation, 
anticoagulation, and fibrinolytic systems can be altered by numerous pathological 
processes, from genetic abnormalities leading to production of dysfunctional coagulation 
factors to acquired conditions such as bacterial infection.  Many species of pathogenic 
bacteria can prompt the breakdown of hemostatic regulation though expression and 
secretion of multiple proteins which function as virulence factors.  Gram-negative and 
gram-positive organisms can modulate both the intrinsic (contact) and extrinsic 
pathways of coagulation, through inherent cell wall components, cell wall-bound 
receptors which bind adhesion proteins, or secreted factors which modify the function of 
host cells or coagulation factors.  Bacteria also express surface and secreted proteins 
which serve as defense against elements of the innate and acquired immune systems, 
amplifying their ability to invade, proliferate, and disseminate in the human host.  
Changing the balance between coagulation, fibrinolysis, and inflammation can trigger 
severe infections such as systemic sepsis or septic shock, but almost any organ can 
serve as the focal point for blood-borne infection, especially in highly vascularized areas 
such as the lungs or heart.  
 Pathogens can initiate the intrinsic pathway of coagulation both directly and 
indirectly, through either serving as a surface for assembly of contact factors or by 
secreting proteinases which activate or degrade the factors.  Assembly of factor XII, 
factor XI, prekallikrein, and HMWK has been shown on the surfaces of the gram-
negative bacteria Escherichia coli and Salmonella typhimurium, mediated by fibrous 
surface proteins (60).  Activation of factor XIIa and kallikrein results in cleavage of 
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HMWK and release of the potent proinflammatory and hypotensive peptide bradykinin, 
which ultimately increases vascular permeability.  Cysteine proteinases have been 
identified from several bacterial species, including Streptococcus pyogenes (speB) and 
Staphylococcus aureus (staphopain), which directly cleave plasma kininogens to release 
bradykinin (61-62).  Bacterial cell wall components, such as endotoxin (gram-negative) 
or peptidoglycan-polysaccharide polymers (gram-positive), have also been linked with 
stimulation of the intrinsic pathway (63).  The end result of contact activation is 
enhanced permeability and leakage of plasma from the vasculature, which may improve 
bacteria survival and dissemination.   
  Activation of the extrinsic pathway and the fibrinolytic system by pathogens can 
be promoted by both endogenous proteins and secreted factors from bacteria, as well. 
Expression of tissue factor on monocytes and endothelial cells has been detected in 
response to a number of bacterial species, possibly through induction of pro-
inflammatory cytokines by bacterial cell wall products.  The consequence of this atypical 
pattern of tissue factor activity is a strong procoagulant stimulus, which may be a 
fundamental step in the development of coagulant disorders (64).  In contrast to 
generation of fibrin clots through the procoagulant pathway, the abnormal breakdown of 
fibrinogen is employed by bacteria as well.  The central fibrinolytic zymogen 
plasminogen can be recruited to the bacteria through cell surface-localized glycolytic 
enzymes and receptors such as the Streptococcus pyogenes M-like protein PAM, which 
function to localize the zymogen with the non-proteolytic plasminogen activator, 
streptokinase (65).  Secreted by several species of streptococci, streptokinase forms a 
conformationally activated streptokinase·plasminogen complex which can cleave other 
molecules of plasminogen to plasmin; a similar, although proteolytic, mechanism is 
employed by staphylokinase from Staphylococcus aureus.  Invasive bacteria can use 
recruited plasmin on their surface to degrade fibrin barriers formed in the initial 
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procoagulant response, extracellular matrix, and components of the immune system, 
contributing to expansion of the infection (66). 
 Investigations on the gram-positive bacterium Staphylococcus aureus have 
established its substantial role as a human pathogen, influenced in large part by its 
broad colonization of nasal passages in many human populations.  S. aureus instigates 
not only skin and wound infections, but also serious or chronic conditions such as 
infectious endocarditis and septic arthritis.  Certain subsets of the population are at 
higher risk for staphylococcal infection, including intravenous drug users and patients 
with compromised immune systems, with infections often originating from surgical 
procedures or injuries to the skin surface which allow entry into the bloodstream.  Recent 
years have brought increased risk of both community- and hospital-acquired infection, 
compounded by the development of significant antibiotic resistance in some strains of S. 
aureus (67).  Methicillin resistance was first detected in the 1960’s, and methicillin-
resistant S. aureus (MRSA) is now a major concern in environments where people live in 
close proximity, such as communal homes or resident hospitals.  Resistance can derive 
from high bacterial production of β-lactamases, enzymes which break down β-lactam 
antimicrobial agents such as penicillin and methicillin, but it is also dictated by bacterial 
expression of membrane-bound penicillin-binding proteins (PBPs) which govern 
recognition by the antibiotics (68).  While the emergence of methicilin resistance has 
precipitated the use of stronger antibiotics such as vancomycin, often thought of as a 
last-resort treatment, this course of action has also advanced the development of 
vancomycin resistance, first found in S. haemolyticus and S. epidermidis, but eventually 
detected in several strains of S. aureus.  Vancomycin functions through a different 
mechanism than methicillin (by inhibiting protein synthesis), but it suffers from low 
therapeutic efficacy due to low bactericidal activity against staphylococci and difficulty in 
achieving suitable concentrations in tissues during therapy (69).  As conventional 
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antimicrobials such as methicillin and vancomycin lose value as therapeutics, other 
approaches for preventing and treating staphylococcal disease must be found. 
S. aureus produces a very wide repertoire of secreted and cell-surface proteins 
which provide survival advantages in the host, not the least of which is conferring 
protection from the host immune system during an infection.  The most basic example is 
the presence of a polysaccharide microcapsule in most strains, which functions in both 
biofilm formation and avoidance of phagocytosis by immune cells (67).  Some high 
virulence strains of staphylococci can also directly survive phagocytosis by neutrophils 
through upregulation of whole arrays of protein factors which provide resistance to 
oxidative stress, regulate capsule synthesis, or function as virulence factors (70).  The 
components of the complement system function in both innate and acquired immunity, 
through recruitment of molecules that target foreign cells for destruction.  These 
processes may be bypassed by production of proteins that either inhibit complement, 
such as Efb (extracellular fibrinogen-binding protein) or Ehb (Efb homologous protein) 
(71), or functionally deplete it, like Spi (72).  Likewise, staphylococcal protein A is a 
surface-anchored protein which binds immunoglobulin (specifically IgG) to cover the 
bacteria with atypically oriented IgG, preventing neutrophil recognition (73). 
A common characteristic among staphylococcal surface-associated and secreted 
proteins is the ability to bind host proteins involved in adhesion or matrix formation, such 
as fibrinogen, fibronectin, and collagen.  Proteomic analysis of extracellular protein 
production from two highly virulent methicillin-resistant S. aureus strains has identified 
variation in expression of a number of known virulence factors, including adhesins (74).  
These pathogenic bacterial extracellular proteins are divided into two major groups 
defined by their localization (Fig. 5).  Proteins remaining associated to the surface of the 
bacteria, either through covalent binding to cell wall peptidoglycan, ionic interactions, or 
transmembrane domains, have been termed MSCRAMMs (microbial surface 
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components recognizing adhesive matrix molecules).  Secreted exoproteins that do not 
associate with the bacterial surface, but are released into the surrounding medium, are 
called SERAMs (secretable expanded repertoire adhesive molecules) (75).  These 
“exoproteins” can alter infectivity and disease progression through both initiating 
bacterial adherence to host matrix and interfering with immune recognition. 
 
 
 
Figure 5.  Different modes of localization and secretion of adhesive exoproteins by 
pathogenic bacteria.  Cell surface-associated proteins (MSCRAMMs) can be 
transmembrane, covalently-attached through the action of sortases, or ionically-bound to 
other proteins or peptidoglycans on the cell itself.  SERAMs have no cell-wall binding 
motif and are secreted into the surrounding medium, but some (such as Emp and Eap) 
can also bind back to the bacterial surface through secondary interactions.  
 
 
Some of the most investigated exoproteins are those in the MSCRAMM family, in 
particular those that were initially identified as recognizing fibronectin.  Most strains of S. 
aureus express two related products, FnBP-A and FnBP-B, which have been strongly 
linked with fibronectin-dependent host cell invasion.  Binding of the adhesion molecule 
by FnBP on the bacterial surface assists in localizing the pathogen to host cells through 
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the cellular fibronectin integrin α5β1, which instigates signaling pathways in the host cell 
that promote engulfment of the bacteria.  This invasive phenotype can protect the 
pathogen from immune defenses and antibiotic treatments (76), and it can contribute to 
procoagulant responses by increasing tissue factor activity in the vasculature through 
recruitment of monocytes to the invaded endothelial cells (77).  Additional regions in 
FnBP-A have also been found to bind to fibrinogen (78), illustrating the promiscuity that 
is often found in both the MSCRAMMs and SERAMs that may allow them to function in 
multiple environments and pathologies.  In addition, not only can FnBP directly 
recognize both fibronectin and fibrinogen, but it has also been found to serve as a 
substrate for factor XIIIa, the transglutaminase responsible for cross-linking of fibrin.  
Factor XIIIa can form covalent bonds between FnBP and fibronectin/fibrin, potentially 
stabilizing attachment of bound bacteria to the matrix (79). 
Other MSCRAMMs also have diverse prospective roles in the infectivity and 
eventual pathology of S. aureus.  Clumping factor A (ClfA) is another cell-wall bound 
protein which shares a similar structural organization to FnBP.  They both contain 
COOH-terminal LPXTG motifs for covalent attachment to the bacteria surface and an  
NH2-terminal domain that mediates fibrinogen recognition (80).  In contrast to FnBP, ClfA 
does not facilitate host cell invasion; it likely protects against neutrophil phagocytosis by 
coating the bacteria in fibrinogen, blocking antibody and complement attachment (81).  
ClfA is found in all clinical isolates of S. aureus, and it elicits physical clumping of the 
bacteria in plasma and may contribute to platelet aggregation through fibrinogen-
bridging of the pathogen (and IgG) to the platelet integrin αIIbβ3 (82).  Protein A, also 
covalently anchored to the bacterial surface, is generally associated with high-affinity 
binding of immunoglobulin that effectively reduces pathogen opsonization through 
blockage of the Fc region on IgG.  It has additionally been shown to bind von Willebrand 
factor, which may also play a part in adhesion of staphylococci during infection (83). 
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The SERAM family of staphylococcal exoproteins has been less significantly 
characterized, which may be due to the uncertainty of assigning pathological functions to 
proteins which can act at sites remote from the centralized site of infection.  The 
prevailing hypothesis is that the secreted proteins can, through interactions with 
extracellular matrix, establish colonization to certain tissues or organs.  Unlike some of 
the MSCRAMMs, there is no pattern of structural homology among most of the 
SERAMs, although they all bind to adhesion proteins (84).  One of the most ubiquitous 
secreted exoproteins is Efb (extracellular fibrinogen binding protein); it is found in all 
clinical isolates and shows constitutive expression, unlike other proteins which recognize 
fibrinogen (85).  In an animal wound-infection model, inactivation of the Efb gene was 
found to decrease S. aureus virulence (86), supporting a potential role as a 
staphylococcal virulence factor.  It was later found to interact with fibrinogen bound 
directly to platelets, as well as to an unidentified platelet surface receptor, causing 
inhibition of platelet aggregation through non-functional fibrinogen presentation (87).  
Furthermore, immune responses may be disturbed by the presence of Efb, due to the 
ability of the exoprotein to bind to complement component C3 and inhibit its activity (88).  
Another frequently-examined factor is Eap, or extracellular adherence protein, which 
displays uniquely widespread recognition of not only several adhesion proteins, including 
fibrinogen and fibronectin, but also prothrombin and the endothelial cell adhesion 
molecule ICAM-1 (84).  Eap has been found to oligomerize and bind to bacterial 
surfaces, initiating cell aggregation (89), and like FnBP, its broad binding capacity could 
be a factor in internalization by host cells (90).  Numerous S. aureus strains express 
slightly different variants of the Eap product, resulting from varied numbers of repeat 
sequences and early translation termination (91).  This variability may be important in 
the overall function of Eap in infection and its potential ability to serve as a bridging 
molecule between cells and other secreted factors. 
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Staphylocoagulase and the Zymogen Activator and Adhesion Proteins (ZAAP’s) 
Secretion of the SERAM exoprotein staphylocoagulase (SC) is acknowledged as 
a defining clinical characteristic of Staphylococcus aureus, and has long been 
considered to have a function in the pathology of the bacteria.  The potent instigation of 
blood coagulation by a substance secreted from staphylococci has been recognized for 
many decades, beginning with initial observations in the 1930’s and 1940’s.  
Identification and isolation of a coagulase from staphylococcal cultures that could 
interact with an “activator” present in plasma and produce fibrin formation was the first 
step in characterization of what would eventually become known as staphylocoagulase.  
Many studies aimed to establish the identity of the plasma component, the “coagulase-
reacting factor” or CRF, putting forth hypotheses that included conversion of the 
coagulase itself to a thrombin-like agent (92).  Differential precipitation procedures 
quickly eliminated both fibrinogen and albumin as direct agents (93), but another largely 
disputed target was the thrombin precursor, prothrombin, which became the focus of 
numerous investigations.  Although kinetic similarities existed between physiological 
prothrombin activation and formation of the thrombin-like activator, comparison of the 
efficiency of several known inhibitors of thrombin activation, including heparin and 
calcium removal, seemed to indicate that prothrombin was not involved in the activity 
(94-95).  Despite this finding, the isolation of prothrombin and CRF fractions from human 
plasma showed some functional overlap, suggesting that at least a portion (but not all) of 
the prothrombin molecule may be required for coagulase activity (96).   
Improved purification of the free SC fraction from S. aureus provided better 
descriptions of the specificity of the procoagulant activity.  Early tests had reported 
potent in vivo activity, which was confirmed by Duthie and Haughton in both human 
plasma and intravenous injection into rabbits (97).  Along with a previous study by the 
same authors, this also gave one of the first indications of species specificity in SC, with 
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mice requiring ~30-fold higher doses to see similar effects (98).  A rigorous comparison 
of human thrombin with “thrombin-coagulase” was carried out in 1967 to delineate the 
differences between the two species, including susceptibility to inhibition, clotting activity, 
and activity towards some physiological thrombin substrates.  The coagulase species 
could not activate factor XIII, factor V, or factor VIII, nor could it aggregate platelets.  The 
highly-efficient thrombin inhibitors antithrombin III, α2-macroglobulin, and hirudin also 
had no effect on the coagulase activity, despite its similarities to thrombin in clotting of 
fibrinogen (99).  The enhanced specificity of the coagulase complex even led to 
suggestions for its use as a hemostatic agent for bleeding conditions, due to a 
hypothetically lower risk of coagulation factor depletion (100). 
Further advances in expression and purification started the first stringent 
biochemical characterization of the complex formed between SC and prothrombin.  
Several very important features were described, including optimal activity at an 
equimolar stoichiometry, a complex molecular weight corresponding to the sum of the 
individual protein molecular weights, and corresponding amino acid compositions and 
NH2-terminal sequences.  In addition, antibodies against the coagulase-prothrombin 
complex did not precipitate thrombin, just the assumed components, implying that 
proteolysis was not a factor in the activity (101).  The first suggestion of a role for 
conformational changes in the catalytic domain of prothrombin came from kinetic studies 
in 1983, which showed high affinity binding of prothrombin and protection of human 
thrombin, but not factor Xa or bovine thrombin, from antithrombin inhibition (102).  
Competitive complex formation studies with different proteolytic fragments of 
prothrombin confirmed localization of SC binding to the thrombin domain, primarily to the 
COOH-terminal end of the thrombin B-chain.  The specificity of this interaction was 
underscored by the inability of other structurally similar coagulation factors, including 
factor X, factor IX, and protein C, to inhibit complex formation (103).  The concept of SC-
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mediated structural changes specifically within the active site of prothrombin was 
furthered through the discovery of differences in the enzymatic activity of SC-thrombin 
and SC-prethrombin 1 with both fibrinogen and small tripeptide substrates compared to 
α-thrombin (104-105).  The major structural requirements within SC itself that regulated 
prothrombin recognition and activation were also determined.  Chymotryptic 
fragmentation of SC revealed the minimal functional portion necessary for prothrombin 
binding and procoagulant activity equivalent to the full-length protein, which 
corresponded to an NH2-terminal fragment consisting of residues 1-324 of SC (106-107). 
Correlation of the function of SC with its full primary structure was possible after 
nucleotide sequencing of three different strains of S. aureus, strains BB, 213, and 8325-
4 (108-110).  Surprisingly, the regions containing the NH2-terminal prothrombin binding 
domain showed only ~50% conservation between the strains, with higher homology in 
the central region of SC (111).  The strain-specific sequence differences in the NH2-
terminal section of SC may be the basis for antigenic diversity detected between SC 
proteins, in both early analyses and more recent surveys of staphylococcal genetics 
(112-114).  The COOH-terminal halves also shared a very similar pattern of repeated 
units, composed of 27 residues each, with varying numbers of repeats between strains 
(108).  These repeats were later described as specifically binding fibrinogen, with the 
overall degree of affinity governed by the number of repeats (115).   
Concomitant with the in vitro behavior of SC becoming more defined, the in vivo 
role of coagulase in staphylococcal pathology was investigated in several different 
models of infection. Use of coagulase-negative strains or mutants in rat models of 
experimental endocarditis show no significant role for coagulase in affecting the course 
of the disease, despite a role hypothesized from its activity on fibrinogen (116-117).  
Moreover, no association has been seen between coagulase expression and 
development of S. aureus-induced septic arthritis (118).  In contrast, coagulase-deficient 
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mutants of S. aureus demonstrated markedly reduced virulence in a mouse model of 
mastitis, especially when paired with loss of α-hemolysin, resulting in reduced necrosis 
in the mammary lesions (119).  In addition, a clear connection has been observed in a 
murine model of hematogenous pulmonary infection, where the level of coagulase 
production correlated with increased proliferation of the bacteria and potential 
development of a protective fibrin membrane around the infecting bacteria colony (120).  
More recently, reduction of coagulase expression through targeting of the mRNA with 
short interfering RNA also reduced bacterial viability in the same pulmonary model of 
infection, suggesting a functional role for SC in this pathology (121).  Like many of the 
secreted exoproteins, uncovering a clear role for SC in the infectivity of such a widely-
pathogenic bacterium as S. aureus is problematic, and further investigation of SC as a 
virulence factor in other models of disease is warranted. 
Previous biochemical observations on SC had indicated that prothrombin 
activation occurred in the absence of proteolysis (101), suggesting an uncommon 
pathway that had only been hypothesized in studies on activation of trypsin and one 
other secreted bacterial product, the streptococcal protein streptokinase (25).  A peptide 
corresponding to the NH2-terminal residues of trypsin was found to generate a zymogen-
enzyme conformational transition in bovine trypsinogen, in the absence of actual 
proteolysis of the activation bond, leading to proposal of a mechanism called “molecular 
sexuality” (26).  In this, activation could be mediated by insertion of the NH2-terminus of 
a secondary protein into the Ile-16 binding pocket of the target serine proteinase 
zymogen.  The result would be a conformationally, but reversibly, activated zymogen 
that could display at least some of the enzymatic specificity of the proteolytically 
activated enzyme.  This process has been examined indirectly for streptokinase-induced 
activation of plasminogen, even though the overall mechanism includes proteolysis of a 
secondary “substrate” molecule of plasminogen which has made detection of the initial 
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conformational steps difficult (122).  The first confirmation of a strict requirement for the 
first NH2-terminal residues in the activity of streptokinase was found through deletion of 
the first isoleucine residue, which prevents functional expression of the active site on the 
plasminogen complex (123-124).  Later kinetic studies have explored the contribution to 
affinity from the first 10 residues of streptokinase, concluding a role for both NH2-terminal 
insertion and high affinity interactions with the remainder of the streptokinase molecule 
(125). 
The most recent investigations have more fully described the mechanism of 
prothrombin activation by SC through a combination of biochemical and structural 
analyses, including X-ray crystallography, enzyme kinetics, and equilibrium binding.  
Crystal structures of α-thrombin·Met-SC(1-325) and prethrombin 2·SC(1-325), each with 
a thrombin-specific tripeptide chloromethyl ketone inhibitor in the active site, were solved 
to 2.2 Å resolution.  Prethrombin 2, which contains only the inactive catalytic domain of 
the prothrombin molecule, showed rearrangement of the normally disordered activation 
domain into a conformation similar to thrombin, reflecting the conformational changes 
that occur in the presence of both SC and the active site inhibitor.  Most significantly, the 
Ile1 SC NH2-terminus was fully defined in the structure, where it created the salt bridge 
with Asp194 characteristic of classical serine proteinase activation.  Additional binding 
interactions were also identified in the complex structures, in particular the association of 
SC with both the 148-loop and the anion binding exosite I of (pre)thrombin.  The 
structural results were verified with kinetic analysis, which showed loss of >98% of the 
SC activity upon deletion of the first two NH2-terminal residues (Ile-Val) and a 
requirement for the 1-146 portion of SC to give full conformational activation of 
prothrombin.  In contrast, SC(147-234) was associated with high affinity binding of 
prothrombin.  Equilibrium binding experiments with an exosite I-specific fluorescence 
probe (fluorescein-labeled hirudin(54-65)) also confirmed the ability of SC to bind to 
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exosite I through competition with the hirudin probe.  This report provided the first 
structural evidence of the molecular sexuality mechanism, strengthening the concept of 
non-proteolytic zymogen activation by an exogenous bacterial activator (126).   
Subsequent investigations have delineated further aspects of SC-induced 
prothrombin activation, including the complementary roles of the different regions of the 
NH2-terminal half of SC (the D1-D2 domains) in contributing to prothrombin binding and 
activation (127).  In addition, the behavior of the prothrombin·SC complex with both 
small tripeptide chromogenic substrates and fibrinogen has been compared to thrombin.  
The prothrombin·SC complex exhibits increased affinity for fibrinogen, and the NH2-
terminal domains seem to form a unique fibrinogen-recognition exosite in the complex, 
all of which may be important factors in the in vivo specificity of the complex (128).  
Finally, a structural basis for the species specificity of SC has also been defined with 
bovine prothrombin, where SC derived from a human pathogenic strain of S. aureus is 
not able to completely insert its NH2-terminal peptide, resulting in incomplete formation 
of the active site and poor enzymatic activity (129). 
The crystal structures of SC in complex with thrombin and prethrombin 2 
revealed a unique structural fold that has led to its classification with a number of 
structurally homologous bacterial proteins into a new functional family called the 
zymogen activator and adhesion proteins, or ZAAPs (Fig. 6).  SC(1-325), the 
prothrombin-binding NH2-terminal half of SC, contains two distinct rod-like domains 
(D1 and D2) angled in relation to each other, that each consist of three α-helices; D2 
also contains three additional smaller α-helices clustered near the distal end of the 
domain.  The SC helices make contact with portions of (pre)thrombin critical for 
substrate and cofactor recognition, including the majority of the 148 loop (which shifts  
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 Figure 6.  Schematic domain organization of ZAAP family members.  All contain 
homologous D1-D2 domains in the NH2-terminus, and putative adhesion binding regions 
in the COOH-terminal half. 
 
 
between two SC helices) and Tyr76 in exosite I, which is surrounded by a hydrophobic 
cavity between helices (126).  The predominantly helical nature of SC is completely 
different from that of streptokinase, which is a three-domain β-sheet structure.  SC has a 
predicted domain organization composed of the two NH2-terminal helical domains, a 
central region that is most likely structurally unorganized, and the COOH-terminal region 
containing seven 27-amino acid repeats (and one pseudorepeat sequence) that also 
governs fibrinogen binding.  With this pattern as a guide, one secreted factor, von 
Willebrand factor-binding protein (which will be discussed in the following section), and 
three additional bacterial products from two species of streptococcus are predicted to 
exhibit similar NH2-terminal zymogen-associated activity and COOH-terminal adhesion 
protein recognition.  Streptococcus pyogenes expresses a cell-wall bound protein called 
SfbX, which is expected to have two D1-D2 domains in its NH2-terminus and a distal 
fibronectin-binding region.  Unpublished preliminary studies suggest that SfbX is also 
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able to interact with both prothrombin and thrombin.  Two uncharacterized proteins from 
Streptococcus agalactiae, NP_687847 and CAD46494, are predicted to have D1-D2 
structure, but the potential COOH-terminal binding partners have not yet been identified 
for either protein (130).  The occurrence of this domain organization within exoproteins 
from several different species of pathogenic bacteria suggests a possible advantage for 
expression of these multi-functional proteins. 
 
Von Willebrand Factor-Binding Protein – Early Discovery and Characterization 
 As the only other S. aureus ZAAP to be identified so far, von Willebrand factor-
binding protein (VWbp) was originally isolated and characterized in 2002 through a 
putative COOH-terminal interaction with the multimeric adhesion protein von Willebrand 
factor (VWF) (131).  The basis of this original study by a group from Sweden was to 
identify new exoproteins from S. aureus which could directly bind VWF, building on 
recent research that revealed staphylococcal protein A as a specific cell-surface receptor 
for this adhesion protein (83).  Fragmented genomic DNA from S. aureus strain Newman 
was ligated into a phagemid vector and transformed into E. coli to produce a “shotgun” 
phage-display library of approximately 107 clones, each displaying a portion of S. aureus 
gene product on the surface of the cell (132).  Selection of phagemids which expressed 
proteins that could recognize VWF was performed through incubation of the library in 
microtiter wells coated in VWF, removal of unbound material, and elution of positive 
phages.  Enriched phage stocks were produced and used for subsequent panning 
sessions to isolate phages with high specificity for the adhesion protein.  After 
sequencing, 26 clones were found to contain portions of the same gene (designated vwb 
for von Willebrand factor binding), which was subsequently cloned from the parental S. 
aureus strain DNA.  Sequence alignments identified a specific 26-residue portion within 
the COOH-terminal half of the protein responsible for binding of VWF (131). 
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 The resulting recombinant protein was named VWbp and expressed in two 
different forms, a full-length product encoding residues 1-482 and a truncation including 
only 124-392, for functional characterization.  Polyclonal antibodies against the 
truncation were produced and used to detect native VWbp in western blots of S. aureus 
culture supernatant; the protein was also purified from the cultures on immobilized 
antibodies.  A single band of ~66 kDa was detected, and the identity and specificity of 
the interaction with VWF was validated through treatment of the blots with VWF and 
VWF-specific antibodies.  Binding of VWF was further examined in specific phagemid 
panning against a number of other adhesion proteins, including fibronectin, fibrinogen, 
and vitronectin, giving the highest number of phagemids against VWF.  Lastly, the 
authors also demonstrated that VWF could be purified from human serum over a column 
containing immobilized recombinant VWbp (131). 
Soon after publication of the initial report on VWbp, the predicted structural 
homology and low sequence identity of VWbp with SC (Fig. 7 and 8), and its potential as 
a prothrombin activator, was revealed in the SC crystallography study (126).  With this 
as a starting point, the Swedish researchers subsequently described VWbp as a 
functional coagulase.  Efficient clotting of human and porcine plasma was demonstrated, 
with varying degrees of efficiency with plasma from other species.  This species-specific 
procoagulant activity was most evident with bovine plasma, which took 6 hours to clot, 
and mouse, rabbit, and rat plasmas which did not clot at all within 18 hours.  Fibrinogen-
plasma plate coagulation assays denoted species-specificity as well, with human plasma 
plates showing the most evident formation of fibrin.  Use of truncated VWbp constructs 
in the basic coagulation assays isolated the coagulase function to the NH2-terminal 
portion of the protein, in agreement with the proposed domain structure from the SC 
study.  Furthermore, the importance of prothrombin in the procoagulant activity of VWbp 
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 Figure 7.  Sequence alignment of the amino acids of the D1-D2 domains of SC and 
VWbp.  VWbp (S. aureus strain Mu50) shares 26% sequence identity (green) and an 
additional 25% sequence conservation (yellow) with SC (S. aureus strain Tager 104).  
The COOH-terminal sequences show almost no homology.  (Alignment constructed with 
CLUSTALW.) 
 
 
 
Figure 8.  Comparison of SC(1-325) crystal structure to homologous VWbp(1-263) 
model.  Domain organization and homology between SC and VWbp.  Model provided by 
Drs. Pablo-Fuentes Prior and Wolfram Bode. 
 
 
was indicated in clotting assays with plasma from other species supplemented with 
human prothrombin (133). 
VWbp is the only S. aureus SERAM thus far which recognizes VWF, and few 
bacterial proteins specifically binding VWF have been identified from S. aureus or other 
pathogens.  Two cell-surface proteins, staphylococcal protein A (83) and a protein 
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expressed by the coagulase-negative species Staphylococcus lugdunensis (134), have 
VWF-binding sections located in regions containing repetitive sequences, but there is no 
sequence homology or common motif between these sites or the VWF recognition 
sequence in VWbp.  It is straightforward to propose a role for cell surface proteins in 
directly contributing to localization of bacterial cells through interactions with extracellular 
matrix or plasma proteins, but not so for secreted proteins which are not restricted in 
their distribution during an endovascular infection. The dual functionality of VWbp as a 
coagulase and an adhesin may present both illumination and difficulty in assigning a role 
for VWbp in the pathology of S. aureus.  
 
Concluding Remarks and Goal of Thesis Research 
 Given that VWbp is a comparatively recent addition to the staphylococcal family 
of SERAMs, very little has been established about either the significance of its 
interaction with VWF or the consequences of its procoagulant activity.  Definition of its 
disparate functions is necessary to first recognize any similarities or differences of VWbp 
to other known proteins, in particular SC, and to understand what physiological 
processes could be influenced by the presence of VWbp.  The fact that the gene for 
VWbp has been found in all of the clinical and laboratory strains of S. aureus that have 
been examined so far, even though these strains also secrete SC (131), is indicative of 
distinct functions for each protein, despite a general similarity for initiating blood 
coagulation.  Whether VWbp is capable of directly manipulating prothrombin to elicit 
clotting of fibrinogen, in a manner similar to that of SC, is significant to the field of serine 
proteinase biochemistry, as SC and streptokinase are the only proteins associated with 
allosteric zymogen activation.  In addition, the predicted structural homology between 
the two proteins (and the other ZAAP members) presents opportunities to uncover 
additional targets for therapeutic intervention during infection and to expand the present 
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body of knowledge on the tactics employed by pathogenic bacteria within their arsenal of 
secreted exoproteins.     
This work resulted in three first-author manuscripts (two published and one in 
preparation):  
Heather K. Kroh, Peter Panizzi, Paul E. Bock.  “Von Willebrand factor-binding protein is 
a hysteretic conformational activator of prothrombin.”  Proceedings of the National 
Academy of Science, U.S.A. (2009) May 12;106(19):7786-7791.  (Chapter 2) 
 
Heather K. Kroh, Paul E. Bock.  “Effect of zymogen domains and active site occupation 
on conformational activation of prothrombin by von Willebrand factor-binding protein.”  
Journal of Biological Chemistry (2010), in preparation.  (Chapter 3) 
 
Heather K. Kroh, Guido Tans, Gerry A. F. Nicolaes, Jan Rosing, Paul E. Bock.  
“Expression of allosteric linkage between the sodium ion binding site and exosite I of 
thrombin during prothrombin activation.”  Journal of Biological Chemistry. (2007) Jun1; 
282(22):16095-104.  (Chapter 4) 
 
The focus of this thesis is the characterization of the molecular mechanism of 
prothrombin activation by VWbp--first and foremost the ability of VWbp to 
conformationally activate the zymogen form through insertion of its own NH2-terminus 
into the NH2-terminal binding cleft (the molecular sexuality mechanism).  The 
descriptions of this and the unique, substrate-driven, hysteretic kinetic mechanism of 
prothrombin activation by VWbp are covered in Chapter 2, along with identification of 
fibrinogen as the specific substrate of the prothrombin-VWbp complex.  Chapter 3 
addresses the role of allostery in regulating binding and activation of prothrombin by 
VWbp, specifically illustrating the effect of the small zymogen domains of prothrombin on 
the function of VWbp, as well as the cofactor effect of substrate on complex formation.  
Finally, Chapter 4 presents a detailed mechanistic study of allosteric regulation of 
exosite expression in proteolytic intermediates of canonical prothrombin activation.
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Abstract 
 Von Willebrand factor-binding protein (VWbp), secreted by Staphylococcus 
aureus, displays secondary structural homology to the three helix bundle, D1 and D2 
domains of staphylocoagulase (SC), a potent conformational activator of the blood 
coagulation zymogen, prothrombin (ProT).  In contrast to the classical proteolytic 
activation mechanism of trypsinogen-like serine proteinase zymogens, insertion of the 
first two residues of SC into the NH2-terminal binding cleft on ProT (molecular sexuality) 
induces rapid conformational activation of the catalytic site.  Based on plasma clotting 
assays, the target zymogen for VWbp may be ProT, but this has not been verified and 
the mechanism of ProT activation is unknown.  We demonstrate that VWbp activates 
ProT conformationally in a mechanism requiring its Val1-Val2 residues.  By contrast to 
SC, full time-course kinetic studies of ProT activation by VWbp demonstrate that it 
activates ProT by a substrate-dependent, hysteretic kinetic mechanism.  VWbp binds 
weakly to ProT (KD 2.5 μM) to form an inactive complex, which is activated through a 
slow conformational change by tripeptide chromogenic substrates and its specific 
physiological substrate, identified here as fibrinogen (Fbg).  This mechanism increases 
the specificity of ProT activation by delaying it in a slow reversible process, with full 
activation requiring binding of Fbg through an exosite expressed on the activated 
ProT*·VWbp complex.  The results suggest that this unique mechanism regulates 
pathological fibrin (Fbn) deposition to VWF-rich areas during S. aureus endocarditis.
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Introduction 
The tightly regulated balance between procoagulant, anticoagulant, and 
fibrinolytic pathways in blood is kinetically controlled by the rates of proteolytic activation 
of zymogens of the chymotrypsinogen family.  The classical proteolytic activation 
mechanism is initiated by cleavage at Arg15-Ile16 (chymotrypsinogen numbering), 
followed by insertion of the Ile16 NH2-terminus into the NH2-terminal binding cleft, and 
formation of a critical salt bridge with Asp194 (1-3).  This triggers folding of segments of 
the catalytic domain, which forms the substrate binding site and oxyanion hole required 
for activity.  The mechanism is fundamentally conformational in that zymogens are in 
unfavorable equilibrium between conformationally active forms which vary in equilibrium 
constants from 108 (trypsinogen) (4) to ~7 (single-chain tissue-type plasminogen 
activator) (5).  Dipeptides that mimic the conserved NH2-termini (Ile-Val or Val-Val) 
induce structural changes in trypsinogen toward the active proteinase conformation (1, 
3), and tight-binding inhibitors like bovine pancreatic trypsin inhibitor convert trypsinogen 
fully to the conformation of trypsin (3).   
 By contrast, staphylocoagulase (SC) from Staphylococcus aureus activates the 
coagulation zymogen prothrombin (ProT) non-proteolytically, and formation of the tightly-
bound ProT·SC complex initiates direct cleavage of Fbg into Fbn (6, 7).  The ProT·SC(1-
325) complex expresses a new exosite that mediates specific substrate recognition of 
Fbg, while full length SC(1-660) also interacts with Fbg as an adhesion protein through 
COOH-terminal repeat sequences (8, 9).  This benefits the pathogen by facilitating 
escape from the host defense system through formation of protective Fbn-platelet-
bacteria vegetations in acute bacterial endocarditis (10).  
 VWbp, also secreted by S. aureus, was first identified by phage-display of an S. 
aureus (Newman) DNA library screened against von Willebrand factor (VWF) (11), 
leading to its classification as an adhesion protein.  Binding to both immobilized and 
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soluble VWF is mediated by a 26-amino acid region within VWbp (11), but the 
physiological significance of this interaction has not been established.  VWbp was further 
recognized as a putative member of the bifunctional zymogen activator and adhesion 
protein (ZAAP) family for which SC is the prototype (12, 13).  It was subsequently 
postulated to be an SC homolog from its 25% sequence identity with SC and clotting of 
human plasma (14).    
 The structure of the NH2-terminal half of SC, SC(1-325), is unique, with a 
characteristic elbow-like fold between two domains (D1-D2) comprised of 3-helix 
bundles (13).  Secondary structure modeling of the corresponding D1-D2 domains of 
VWbp(1-263) revealed a high degree of similarity (13).  Structural and kinetic studies of 
SC demonstrated insertion of the first two NH2-terminal residues of SC into the NH2-
terminal binding cleft in the ProT catalytic domain (13).  The NH2-terminus forms a salt 
bridge with Asp194 (13), triggering the conformational change that activates the catalytic 
site.  This “molecular sexuality” mechanism (1) has only been demonstrated for SC and 
the plasminogen activator streptokinase (15), whereas essentially nothing is known 
about the mechanism of plasma clotting by VWbp. 
 The specific interactions responsible for the procoagulant activity of VWbp have 
not been defined, and the mechanism of its activation of ProT is unknown.  In the 
present studies, we defined the molecular basis and unusual hysteretic kinetic 
mechanism of ProT activation by VWbp and identified Fbg as its specific substrate, 
which are postulated to play a role in the pathology of S. aureus infection. 
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Results 
Conformational Activation of ProT by VWbp(1-263) and VWbp(1-474)  
Whether VWbp(1-263) and full length VWbp(1-474) activate ProT through a 
conformational change was examined using three-step active site-specific labeling: (1) 
inactivation of active species in ProT-VWbp mixtures with Nα-[(acetylthio)acetyl]-D-Phe-
Pro-Arg-CH2Cl (ATA-FPR-CH2Cl), (2) generation of a free thiol with NH2OH, and (3) 
covalent attachment of 5-(iodoacetamido)fluorescein (5-IAF) (16).  SDS-gel 
electrophoresis of samples from reactions including all three steps showed specific, 
covalent incorporation of fluorescein into ProT only (Fig. 1, lanes 4), with no proteolysis 
of the zymogen for either VWbp(1-263) or VWbp(1-474).  Stringent controls omitting one 
of the steps of the labeling scheme confirmed that all of the labeling steps were 
necessary for probe incorporation (Fig. 1, lanes 3, 5-7).   
Activation of Pre 1 by the NH2-terminal insertion mechanism  
To ascertain whether VWbp activates ProT through the molecular sexuality 
mechanism, VWbp(1-474) was compared in kinetic assays of prethrombin 1 (Pre 1; ProT 
lacking the fragment 1 domain) activation to the NH2-terminal deletion mutants, VWbp(2-
474) and VWbp(3-474).  Initial rates of ProT activation could not be employed 
quantitatively in this analysis due to their inherent curvature, whereas initial rates of Pre 
1 activation by VWbp(1-474) were nearly linear.  Deletion of the first NH2-terminal Val 
residue of VWbp reduced its activity at saturation ~78%, while deletion of both Val1 and 
Val2 completely inactivated VWbp (Fig. 2).  Qualitatively similar results were obtained 
with ProT, with no detectable activity for VWbp(3-474). 
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 Figure 1. Active-site specific labeling of ProT·VWbp(1-263) and ProT·VWbp(1-474) 
complexes assessed by SDS-gel electrophoresis. Fluorescence (A and C) and 
protein-stained (B and D) SDS gels for reactions containing 15 µM ProT and 50 µM 
VWbp(1-263) (A and B) or VWbp(1-474) (C and D). Reduced samples of ProT (lane 1) 
and VWbp (lane 2), ProT-VWbp inactivated with ATA-FPR-CH2Cl (lane 3), and inhibited 
complex incubated with NH2OH and 5-IAF (lane 4). Control samples were ProT 
incubated without VWbp (lane 5), omission of the NH2OH step (lane 6), or the complex 
blocked with excess FPR-CH2Cl before sequential incubation with ATA-FPR-CH2Cl and 
5-IAF (lane 7).  
 
 
 
Figure 2. Pre 1 activation by NH2-terminal truncation mutants of VWbp. Initial 
velocities (vobs) of hydrolysis of 100 μM D-Phe-Pip-Arg-pNA are shown for mixtures of 1 
nM Pre 1 as a function of VWbp(1-474) (●), VWbp(2-474) (○), or VWbp(3-474) (▲) 
concentration. The lines represent the least-squares fits of the quadratic binding 
equation. 
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Kinetic analysis of ProT activation  
The rates of tripeptide-p-nitroanilide (pNA) chromogenic substrate hydrolysis by 
ProT activated by either VWbp(1-263) or VWbp(1-474) showed upward curvature over 
time.  While this could be a result of a slow equilibration time for ProT·VWbp complex 
formation, varying the preincubation time of the reaction before substrate addition up to 
1 h had very little effect on the curvature (see Supplemental Data).  Due to the apparent 
effect that binding of substrate by ProT·VWbp(1-263) had on the activation kinetics, 
progress curves collected as a function of substrate and VWbp(1-263) concentration 
were truncated at ≤ 10% substrate depletion and analyzed individually with the classical 
hysteresis equation (Eqn. 1, Materials and Methods) (17, 18).  The excellent nonlinear 
least-squares fits indicated that the curvature initiated by substrate was a single 
exponential process (not shown).  The observed rate constants increased hyperbolically 
with increasing VWbp(1-263) concentration and decreased with increasing substrate 
concentration (not shown).  This ruled out a mechanism involving an unfavorable pre-
existing conformational equilibrium between active and inactive forms of ProT in which 
VWbp(1-263) bound only the active form that also bound substrate.  This mechanism 
predicts a decrease in kobs with increasing VWbp(1-263) concentration, rather than the 
observed increase.  The decease in kobs with increasing substrate concentration 
suggested that substrate binding followed the slow conformational change.   
 To evaluate the mechanism further, two chromogenic substrates (D-Phe-Pip-Arg-
pNA and Tosyl-Gly-Pro-Arg-pNA) having a ~5-fold difference in Km for thrombin were 
employed in full time-course activation progress curve analysis.  Progress curves 
collected as a function of substrate and VWbp(1-263) concentration were analyzed 
simultaneously by numerical integration of the differential rate equations for candidate 
mechanisms combined with nonlinear least-squares fitting with DYNAFIT (19).  The 
hysteretic mechanism shown in Scheme 1 produced a consistent fit to the data for both 
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substrates (Fig. 3), with the parameters listed in Table 1.  To obtain the best fit, product 
inhibition was included in the mechanism as a single binding step (not shown in Scheme 
1).  Including a conformational equilibrium succeeding product binding did not improve  
Scheme 1. 
 
 
Figure 3. Full time-course analysis of the kinetics of ProT activation by VWbp(1-
263). (A) Progress curves for hydrolysis of D-Phe-Pip-Arg-pNA by mixtures of VWbp(1-
263) and ProT, at 200 µM substrate (black points), contained 1 nM ProT and 0.025, 
0.075, 0.15, 0.3, 0.6, 3, or 10 μM VWbp. Substrate depletion assays (red points) 
contained 1 nM ProT, 1 μM VWbp, and concentrations of 7, 20, 40, 78, or 116 µM 
substrate. (B) Progress curves for hydrolysis of 200 µM Tosyl-Gly-Pro-Arg-pNA (black 
points) contained 1 nM ProT and 0.1, 0.3, 0.5, 0.75, 1, 3, or 10 μM VWbp. Substrate 
depletion assays (red points) contained 1 nM ProT, 5 μM VWbp, and 25, 50, 75, 100, 
150, or 500 µM substrate. Representative examples of the whole data set are shown for 
each substrate, which contained 17-24 progress curves over 0.025-10 μM VWbp and 5-
500 μM substrate. Data are shown as every tenth point, and the fit with the mechanism 
in Scheme 1 and parameters in Table 1 is represented by solid lines.  
 
 
the fit.  In Scheme 1, the initial inactive ProT·VWbp(1-263) complex is formed with low 
affinity (KD 2.2-2.4 μM) in a rapid equilibrium step.  ProT·VWbp(1-263) is in an 
unfavorable, slow equilibrium with active ProT*·VWbp(1-263), and tight binding of 
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substrate to the ProT*·VWbp(1-263) complex shifts the equilibrium towards the active 
form.  The slow shift in equilibrium increases the rate of substrate hydrolysis, responsible 
for the upward curvature of the progress curves.  The fitted parameters showed that both 
substrates exhibited 2- to 4-fold lower Km for the ProT*·VWbp(1-263) complex compared 
to thrombin (Table 1).  The analysis also revealed an unfavorable equilibrium constant 
(Kcon 9 ± 1 and 9 ± 6) for the slow conformational change, and excellent agreement 
between the individual rate constants (kC1, kC2) to form ProT*·VWbp(1-263) for the two 
substrates (Table 1).  In addition, the apparent affinity (KD) of ProT for formation of the 
initial inactive ProT·VWbp(1-263) complex was nearly identical with either substrate (2.4 
μM and 2.2 μM) (Table 1).  
 
Table 1.  Summary of kinetic parameters (± 2 S.D.) for ProT activation by VWbp(1-
263) from the hysteretic mechanism shown in Scheme 1, where KI is the 
dissociation constant for competitive product inhibition. 
 
Parameters D-Phe-Pip-Arg-pNA Tosyl-Gly-Pro-Arg-pNA 
Km (thrombin) 2.5 ± 0.2 μM 11.3 ± 0.3 μM 
kcat (thrombin) 77 ± 1 s-1 164 ± 1 s-1 
KD 2.4 ± 0.1 μM 2.2 ± 0.2 μM 
Kcon (kC2/kC1) 9 ± 1 9 ± 6 
kC1 0.0052 ± 0.0001 s-1 0.0053 ± 0.0004 s-1 
kC2 0.049 ± 0.005 s-1 0.047 ± 0.028 s-1 
Km 0.6 ± 0.2 μM 6 ± 4 μM 
kcat 95 ± 1 s-1 50 ± 1 s-1 
KI 2.2 ± 0.3 μM 30 ± 20 μM 
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Results obtained with other substrates with Km in the 100-300 μM range were not 
fit well by the mechanism in Scheme 1 because of the importance of obtaining near-
saturation within the experimentally accessible concentration range.  A more complex 
mechanism involving significant activity for the inactive complex failed to produce 
consistent fits or reasonable parameters.  The possibility that autocatalytic cleavage of 
ProT to Pre 1, previously reported for SC (6) and SC(1-325) (20), accounted for the 
hysteresis was evaluated by western blotting under conditions identical to those used for 
collecting the progress curves (see Supplemental Data).  At the highest VWbp(1-263) 
concentration (10 µM) in the kinetic studies, 23 ± 9% (mean and range) of ProT was 
converted into Pre 1 over the whole time-course for both substrates.  At 1 µM VWbp(1-
263), Pre 1 formation was reduced to 1-10%.  Analysis of individual progress curves at 
10 µM VWbp showed little effect on their shape, demonstrating that Pre 1 formation did 
not account for the observed hysteresis. 
Competitive binding of VWbp(1-263) and [5-F]Hir(54-65) to ProT  
To investigate the binding interactions involved in ProT activation by VWbp, 
independent of substrate-mediated effects, competitive binding titrations of the 
proexosite I-specific probe [5-F]Hir(54-65) and VWbp(1-263) with ProT were performed 
(Fig. 4).  The decrease in fluorescence of [5-F]Hir(54-65) titrated with ProT in the 
absence of VWbp(1-263) gave a KD consistent with previous results (2.8 ± 0.3 μM) (21).  
Analysis of the fluorescence changes in the presence and absence of VWbp(1-263) as a 
function of native ProT concentration gave a KD of VWbp(1-263) for proexosite I on ProT 
of 2.5 ± 0.3 μM, nearly identical to the values determined kinetically.  Furthermore, the 
ability of VWbp(1-263) to compete with the labeled peptide for binding to ProT indicates 
that VWbp binds to proexosite I (13). 
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 Figure 4. Competitive binding of native ProT to [5-F]Hir(54-65) and VWbp(1-263). 
Fractional change in fluorescence (∆F/Fo) of 48 nM [5-F]Hir(54-65) as a function of total 
native ProT concentration ([ProT]o) at 0 (●), 10 (○), and 20 μM (▲) VWbp(1-263). The 
lines represent the simultaneous fit by the cubic equation with the parameters given in 
the text.  
 
 
Clotting of Fbg by ProT·VWbp(1-263)  
We examined human Fbg as a potential substrate by monitoring the clotting of 
Fbg by mixtures of ProT and VWbp(1-263), as detected by the increase in turbidity (Fig. 
5).  The capacity of VWbp(1-263) to trigger formation of a Fbn clot demonstrates that 
Fbg is the first substrate identified for the ProT·VWbp(1-263) complex.  The complex 
displayed efficient clotting of Fbg at 10 nM ProT, and in contrast to immediate cleavage 
of Fbg by 10 nM thrombin or ProT·SC(1-325) complex, which showed a brief ~30 sec 
lag, all of the ProT·VWbp(1-263) assays showed a much longer, reproducible lag in the 
time-course (Fig. 5).  No increase in turbidity was seen until ~220 sec after addition of 
ProT at 1 μM VWbp(1-263), implicating the hysteretic mechanism in recognition of the 
natural substrate.  Although an exhaustive survey of other potential substrates was not 
done, kinetic assays revealed no activation of the thrombin substrates, protein C, factor 
V, or factor XI, or two other coagulation zymogens (factor IX and factor X) by 
ProT·VWbp(1-263).  In addition, the thrombin-selective serpins antithrombin and heparin 
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cofactor II did not inhibit the activity of the ProT·VWbp(1-263) complex in the presence 
or absence of heparin (not shown). 
 
 
Figure 5. Clotting of Fbg by mixtures of ProT and VWbp(1-263). Increase in turbidity 
for mixtures of 0.5 mg/ml Fbg and 10 nM thrombin (blue), 10 nM ProT (black), 10 nM 
ProT·SC(1-325) (red), or 10 nM ProT and VWbp concentrations of 0.1 (a), 0.3 (b), 0.5 
(c), or 1 μM (d) (green).  
 
 
Discussion 
 Our results support the conclusion that VWbp is a new non-proteolytic ProT 
activator that utilizes molecular sexuality and employs a unique substrate-activated 
hysteretic kinetic mechanism.  Active site-specific labeling of ProT with a fluorescent 
probe in mixtures with VWbp(1-263) or VWbp(1-474) provided a direct demonstration of 
non-proteolytic activation of the zymogen.  These experiments also indicate that the 
SC(1-325)-homologous D1 and D2 domains of VWbp(1-263) are sufficient for ProT 
activation.  Total loss of activity accompanying deletion of the first two NH2-terminal 
residues of VWbp shows that it activates the ProT derivative, Pre 1, and ProT through 
the molecular sexuality mechanism. 
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Our studies and previous reports indicate that SC(1-325) has the same maximal 
chromogenic substrate activity as SC(1-660) (22) (P.P., H.K.K., and P.E.B, unpublished 
results).  In contrast, ProT activation by full-length VWbp(1-474) displays higher activity 
than VWbp(1-263) (not shown), although VWbp(1-474) also shows hysteresis.  The 
finding that Pre 1 activation by VWbp(1-474) shows less hysteresis than ProT implicates 
the fragment 1 domain in the mechanism.  The COOH-terminal region of VWbp is 
associated with the higher activity of the ProT·VWbp complex, possibly through 
additional interactions that increase substrate affinity and/or hydrolysis.  Kinetic analysis 
of ProT activation by VWbp demonstrates a hysteretic model of enzyme activation, 
where there is a slow response to an abrupt stimulus that controls the observed rate of 
catalysis (17).  The hysteretic kinetic concept is applicable to a number of enzymes 
involved in metabolic regulation, and can result from isomerization, ligand displacement, 
or enzyme polymerization (17).  While slow hysteretic transitions have been examined 
for several monomeric enzymes (18, 23), our results are the first to demonstrate 
hysteresis in serine proteinase zymogen activation. 
 As predicted from the kinetic model (Scheme 1), the KD for formation of the 
inactive ProT·VWbp(1-263) complex and the rate constants for the slow conformational 
change were independent of the structures and kinetic parameters for two tripeptide-
pNA substrates.  The relatively low affinity of ProT·VWbp(1-263) complex formation 
revealed an additional disparity between the behavior of VWbp(1-263) and SC.  
Whereas SC(1-325) binds to native ProT with extremely high affinity (KD 17-72 pM) (24), 
the initial affinity of ProT and VWbp(1-263) was 2.2-2.4 μM from the kinetic analysis and 
2.5 μM from competitive binding experiments.  The kinetic mechanism suggests that 
VWbp(1-263) binds the native ProT zymogen with a weaker affinity than the zymogen 
with a substrate occupying the active site.  The weak affinity of VWbp(1-263) for ProT 
and the hysteretic generation of proteolytic activity represent a unique regulatory 
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mechanism in which the initially low affinity prevents premature activation of ProT, and 
the hysteresis delays the response to substrate, restricting Fbn formation.  The 
hysteretic mechanism thus functions to increase the specificity of VWbp for Fbn 
formation compared to SC. 
 The NH2-terminal insertion pocket, catalytic site, and certain regulatory exosites 
on coagulation proteinases are allosterically linked (25, 26).  In the classical zymogen 
activation mechanism, these sites are rapidly expressed as part of the zymogen to 
proteinase conformational transition.  Based on the linkage between these sites, the 
hysteretic conformational change between inactive and active forms of ProT·VWbp 
complex represents these events as a slow transition, unique among zymogen activation 
mechanisms.  The need for substrate binding to complete the conformational change 
indicates that either NH2-terminal insertion is an unfavorable intramolecular equilibrium 
or that the VWbp Val-Val NH2-terminus inserts normally, but does not result in an optimal 
structure to effect full activation.  Mutation of VWbp(1-474) Val1 to Ile to mimic the SC 
NH2-terminal dipeptide did not detectably affect the hysteretic behavior (not shown), 
indicating that the difference in the dipeptides is not responsible.  For α-chymotrypsin, 
interconversion of an inactive conformation at high pH to the active form at neutral pH is 
controlled by protonation of the α-amino group of Ile16 (27).  In pH-jump experiments, the 
rate constants for formation of the chymotrypsin active site correspond to kC1 and kC2 of 
3 s-1 and 0.6 s-1, respectively, and Kcon of 0.2 (27).  If the values for chymotrypsin are 
taken as representative of the rate of NH2-terminal insertion and activation of the 
catalytic site for ProT, the values for ProT·VWbp(1-263) are 590-fold (kC1) and 12-fold 
(kC2) slower.  This suggests that the activating conformational change for ProT·VWbp(1-
263) is not limited by the rate constants for insertion and conformational activation, but 
by additional interactions of ProT with VWbp(1-263) that slow the activation process. 
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 Screening of other coagulation zymogens for direct activation by VWbp indicates 
that it does not activate protein C, factor IX, factor X, or factor XII.  The finding that 
VWbp binds to the low affinity precursor form of exosite I on ProT, and the established 
role of exosite I in thrombin interactions with protein substrates (including Fbg), 
inhibitors, and regulatory proteins (25) indicates that ProT·VWbp will exhibit highly 
restricted substrate and inhibitor specificity, preventing interactions with thrombomodulin, 
factor V, factor VIII, heparin cofactor II, and protease activated receptor-1 (25).  Fbg 
substrate recognition by activation of proexosite I in the ProT·VWbp complex is not 
possible because this site is blocked by VWbp.  Neither VWbp nor ProT alone bind Fbg, 
indicating that Fbg substrate recognition by the ProT·VWbp complex is mediated by 
expression of a new exosite.  The occupation of exosite II in ProT by the fragment 2 
domain restricts further the substrate specificity of VWbp by blocking heparin-
accelerated inhibition by antithrombin, as well as exosite II-dependent binding of factors 
V, factor VIII, and the platelet receptor GPIbα (25).  The studies show that Fbg is the 
only established substrate of the ProT·VWbp(1-263) complex that binds with sufficient 
affinity to shift the hysteretic conformational equilibrium to the active complex.  The lag 
observed in the time-course of Fbg clotting assays initiated with ProT-VWbp(1-263) 
mixtures suggests that the dependence of the hysteretic kinetic mechanism on a protein 
substrate restricts activation of ProT by VWbp to areas rich in Fbg.  Localized depletion 
of Fbg in an endocarditis vegetation may result in shutting off ProT·VWbp by the more 
rapid reversal of the conformational change.  Additional results with VWbp(1-474) show 
no significant effect of the plasma concentration of VWF (150 nM) on the hysteretic 
mechanism of ProT activation, for either untreated VWF or the extended conformation 
induced by vortexing VWF under conditions that enhance VWF cleavage by ADAMTS13 
(28). 
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 The results of this study are the first to characterize the coagulation-specific 
molecular mechanisms behind a potential new virulence factor from S. aureus.  As the 
first additional member of the ZAAP family of bifunctional conformational zymogen 
activators and adhesion proteins, elucidation of the role of VWbp in activation of 
coagulation during endocarditis may aid in the development of mechanism-based 
therapies.  Further clarification of the interactions of VWbp with both ProT and plasma 
adhesion proteins will offer insight into how VWbp may serve to specifically localize ProT 
activation in the course of S. aureus infection.  This raises the question of why are there 
two ProT activators, VWbp and SC, secreted by S. aureus.  All S. aureus strains that 
contain the gene for VWbp also contain the gene for SC (11).  The evolutionary 
advantage responsible for maintaining both activators is likely due to the differences in 
the adhesion protein targets and the kinetic mechanisms of ProT activation.  In the 
context of endocarditis, the initial vascular injury of the endothelium on heart valves at 
high shear rates activates coagulation, with VWF mediating the early stages of platelet 
accumulation by tethering through exposed subendothelial collagen and the platelet 
GPIbα receptor, followed by conversion of Fbg to Fbn within the thrombus (29).  
Additional binding of platelets by VWF occurs after platelet activation by thrombin and is 
dependent upon the platelet integrin αIIbβ3 (30).  S. aureus concurrently adheres to 
multiple extracellular matrix proteins, including fibronectin, collagen, and Fbn, through 
microbial surface components recognizing adhesive matrix molecules (MSCRAMMs) 
(31).  Through initial association with VWF at transient sites of vascular injury, VWbp 
could restrict pathologic Fbn deposition to focal points in the vasculature, establishing 
new locations for bacterial dissemination.  Thus, VWbp may catalyze the first assault in 
Fbn deposition, followed by rampant SC-mediated Fbn deposition and vegetation 
growth.  
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Materials and Methods 
Protein and peptide purification  
Human ProT, Pre 1, thrombin, Fbg, Y63-sulfated fluorescein-labeled hirudin(54-
65) ([5-F]Hir(54-65)), and ATA-FPR-CH2Cl were prepared as described (16, 24, 32). 
Cloning, expression, and purification of VWbp constructs 
The VWbp(1-474) gene was amplified from S. aureus Mu50 strain (ATCC) 
genomic DNA and cloned into a modified pET30b(+) vector (Novagen) (24) using NcoI 
and XhoI restriction sites.  VWbp was expressed with an NH2-terminal His6-tag and 
tobacco etch virus (TEV) proteinase cleavage site in Rosetta 2 (DE3) pLysS E. coli 
(Novagen) with isopropyl-D-thiogalactopyranoside induction.  Recombinant VWbp 
protein was extracted from inclusion bodies by the use of 3 M NaSCN buffer, pH 7.4, 
and purified by Ni2+-iminodiacetic acid chromatography.  The His6-tag was removed by 
overnight incubation with a 1:10 molar ratio of TEV proteinase to fusion protein similar to 
the procedure described for recombinant streptokinase (33).  Mutants of VWbp(1-474) 
(VWbp(2-474), VWbp(3-474), and VWbp(1-263)) were generated by QuickChange site-
directed mutagenesis (Stratagene).  NH2-terminal sequencing of all the VWbp constructs 
confirmed the correct Val-Val-Ser-Gly-Glu sequence.  VWbp concentration was 
determined from the 280 nm-absorbance using the following calculated absorption 
coefficients ((mg/ml)-1cm-1) (34) and molecular weights: VWbp(1-263), 0.582, 30,700; 
VWbp(1-474), 0.488, 55,000. 
Active-site specific labeling of ProT  
VWbp(1-263) or VWbp(1-474) (50 μM) were incubated with ProT (15 μM) and 
ATA-FPR-CH2Cl (125 μM) to covalently inactivate the ProT catalytic site formed in the 
active complex.  The inhibited complex was incubated with 0.1 M NH2OH in the 
presence of 33 μM 5-IAF to label the generated thiol.  Probe incorporation (0.84-0.86 
mol probe/mol ProT) was determined as described (16).  
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Pre 1 activation kinetic titrations 
Titrations of Pre 1 activity as a function of VWbp(1-474), VWbp(2-474), or 
VWbp(3-474) concentration were measured by the increase in the initial rate of 
hydrolysis of 200 μM D-Phe-Pip-Arg-pNA at 405 nm and 25 oC.  Pre 1 was incubated 
with VWbp for 20 min in 50 mM Hepes, 110 mM NaCl, 5 mM CaCl2, 1 mg/ml 
polyethylene glycol (PEG) 8000, pH 7.4, before substrate addition.  The maximum 
velocity was determined by nonlinear least-squares analysis of the hyperbolic titrations. 
ProT activation kinetics  
Progress curves for hydrolysis of two thrombin-specific chromogenic substrates 
(D-Phe-Pip-Arg-pNA and Tosyl-Gly-Pro-Arg-pNA) by mixtures of ProT and VWbp(1-263) 
were measured in the buffer described above.  Full time-course assays were performed 
under both saturating and limiting substrate concentrations, with continuous data 
collection for 2 h, or until A405 nm = 1.0.  Proteins were incubated for 20 min at 25 oC 
before initiating the reactions by addition of substrate.  Analysis of individual progress 
curves was performed on data truncated to ≤ 10% substrate depletion by fitting the 
integrated equation for the classical hysteresis mechanism, 
   obs/1 obs kevvtvP tkofft   (Eqn.1), where Pt is the product formed at time t, vf and 
vo are the final and initial velocities, and kobs is the observed first-order rate constant 
(17).  This equation is only applicable under conditions of minimal substrate depletion 
and product inhibition.  Analysis of progress curves from full time-course assays under 
saturating and substrate depletion concentrations, and as a function of VWbp(1-263) 
concentration, were analyzed by simultaneous nonlinear least-squares fitting of the 
numerically-integrated differential rate equations for candidate mechanisms with 
DYNAFIT (19).  The rate constants for initial binding of ProT and VWbp and binding of 
substrate were assumed to be diffusion controlled (108 M-1s-1) rapid equilibrium steps. 
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Fluorescence titrations 
Competitive binding of [5-F]Hir(54-65) and VWbp(1-263) to ProT was measured 
in titrations of mixtures of 48 nM labeled peptide and VWbp as a function of ProT 
concentration in the same buffer used for the kinetics.  Continuous time-course 
measurements were taken for each point in the titration that included a buffer blank, [5-
F]Hir(54-65) alone, addition of VWbp(1-263), and addition of native ProT.  This 
separated the fluorescence change measured in the first 2 min, representing the rapidly 
established competitive binding equilibria, from slower proteolysis of the ProT·VWbp 
complex.  Fluorescence (8 nm slits) at 520 nm with excitation at 491 nm was measured 
with an SLM 8100 spectrofluorometer at 25 oC, in PEG 20,000-coated acrylic cuvettes. 
The fluorescence changes expressed as (Fobs – Fo)/Fo = ΔF/Fo in the absence and 
presence of two fixed concentrations of VWbp(1-263) (10 and 20 μM) were fit 
simultaneously by the cubic equation for tight competitive binding to obtain the KD’s for 
[5-F]Hir(54-65) binding to ProT (KP) and VWbp(1-263) binding to ProT (KC), with the 
stoichiometry fixed at 1 (32). 
Fibrin turbidity assays  
Cleavage of Fbg by either thrombin, ProT·SC(1-325), or ProT·VWbp(1-263) 
complexes was monitored from the increase in turbidity at 450 nm at 25 oC in the above-
described buffer using a microtiter plate reader.  Fbg was added (0.5 mg/ml) to various 
concentrations of VWbp(1-263), 10 nM SC(1-325), or buffer and reactions were started 
immediately by addition of 10 nM ProT or thrombin. 
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Introduction 
Previous studies of conformational activation of ProT by staphylocoagulase (SC) 
(35) and its fully active fragment SC(1-325) (20) showed that activation was associated 
with slow autocatalytic cleavage of ProT.  Early studies demonstrated that at micromolar 
concentrations of ProT and SC, cleavage at the thrombin-sensitive Arg155-Ser156 bond in 
ProT to form prethrombin 1 (Pre 1) and fragment 1 (F1) was accompanied by a large 
increase in fluorogenic substrate (Boc-Val-Pro-Arg-4-methylcoumaryl-7-amide) 
hydrolysis that was concluded to represent higher activity of the Pre 1·SC complex 
compared to the ProT·SC complex (35).  These studies, performed at 0 C, reported that 
bovine fibrinogen clotting activity was generated in less than 5 min, whereas maximum 
fluorogenic substrate activity was observed at 60 min.  This slow time-dependence was 
not observed with Pre 1, for which clotting and fluorogenic substrate activity were both 
rapidly formed on addition of SC.  Studies of SC(1-325) at micromolar concentrations 
and at 25 C in the same buffer used in the VWbp experiments, showed that formation of 
Pre 1 was followed by much slower generation of prethrombin 2’ (Pre 2’) and fragment 2 
(F2) resulting from cleavage of the second thrombin-sensitive bond in ProT at Arg284-
Thr285 (20).  The kinetics of ProT activation by SC(1-325) at nanomolar concentrations, 
after preincubation in the absence of substrate for 20 min, were inconsistent with the Pre 
1·SC(1-325) complex having significantly increased activity with a chromogenic 
substrate (D-Phe-Pip-Arg-pNA) compared to ProT·SC(1-325) (20).  On the basis of 
these previous studies, the possibility that autoproteolytic cleavage of ProT to Pre 1 in 
mixtures with VWbp accounted for the observed hysteretic kinetics of ProT activation by 
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VWbp was investigated by SDS-gel electrophoresis, western blotting with a polyclonal 
anti-ProT antibody, and analysis of activation progress curves. 
 
Results and Discussion 
Proteolysis in mixtures of 10 µM VWbp(1-263) and 5 µM ProT was assessed by 
SDS-gel electrophoresis (Fig. 1S).  ProT was initially cleaved to Pre 1 and fragment 1 
slowly over 180 min, with much smaller accumulation of Pre 2’.  Incubation for 24 h 
resulted in full conversion of ProT and Pre 1 to Pre 2’, fragment 1, and fragment 2. 
 
 
Figure 1S.  Proteolytic products generated in ProT-VWbp(1-263) mixtures 
assessed by SDS-gel electrophoresis.  Nonreduced samples (7.2 µg ProT) of 
mixtures of 5 µM ProT and 10 µM VWbp incubated at 25 C in 50 mM Hepes, 110 mM 
NaCl, 5 mM CaCl2, 1 mg/ml PEG 8000, pH 7.4 were taken at the indicated times after 
mixing, subjected to electrophoresis on a SDS 4-15%-gradient gel, and stained with 
GelCode Blue protein stain (Thermo Scientific).  Bands representing ProT, Pre 1, Pre 2’, 
F1, and F2 are indicated. 
 
 
Western blotting was used to quantitate the autocatalytic cleavage of ProT in the 
presence of VWbp under conditions identical to those used for the full time-course 
progress curve experiments (Fig. 3 of the chapter).  Samples were removed from 
mixtures of 1 nM ProT and 10 µM VWbp(1-263) that were preincubated for 20 min 
before continued incubation in the absence or presence of 200 µM D-Phe-Pip-Arg-pNA 
or Tosyl-Gly-Pro-Arg-pNA (Fig. 2S).  At the highest VWbp concentration used in the  
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 Figure 2S.  Pre 1 generation in mixtures of 1 nM ProT and 10 µM VWbp(1-263) 
evaluated by western blotting.  ProT and VWbp were incubated under the same 
conditions used in the progress curve studies at final concentrations of 1 nM and 10 µM, 
respectively.  Samples taken at the indicated times were denatured under reducing 
conditions, separated by SDS 4-15% gradient gel electrophoresis, transferred onto 
polyvinyldiene difluoride membranes, and developed with a polyclonal anti-ProT 
antibody as described in Materials and Methods.  Lanes S1 and S2 on each gel are the 
equimolar standard mixtures of 1.5 ng ProT and1.0 ng Pre 1 (S1); and 0.3 ng ProT and 
0.2 ng Pre 1 (S2) used for quantitation.  (A) ProT and VWbp incubated in the absence of 
substrate.  (B) ProT and VWbp preincubated for 20 min in the absence of substrate, 
followed by incubation in the presence of 200 µM D-Phe-Pip-Arg-pNA.  (C) As in B 
except that the substrate was Tosyl-Gly-Pro-Arg-pNA.  (D) Relative concentrations of 
ProT remaining (%) as a function of incubation time as in A (●), B, (○), and C (▲).   
 
 
progress curve experiments (10 µM), 20% of ProT was converted into Pre 1 during the 
20 min preincubation, which increased in the absence of substrate to 59% after 60 min 
(Fig 2S A and D).  The experiment in which D-Phe-Pip-Arg-pNA was added after 20 min 
preincubation showed a similar, 29% conversion to Pre 1, which remained essentially 
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constant between 13-28% after addition of substrate for the subsequent 30 min of 
incubation, the time during which the progress curve was collected (Fig. 2S B and D).  
Similar results were obtained with Tosyl-Gly-Pro-Arg-pNA, with 18% conversion to Pre 1 
during the preincubation, which remained nearly constant at 14-32% over the total 60 
min incubation time (Fig. 2S C and D).  The possibility that Pre 1 generation was due to 
trace levels of thrombin in the ProT preparation was ruled out by the absence of ProT 
cleavage in the standards containing equimolar ProT and Pre 1 that were incubated 
under the same conditions (Fig. 2S, lanes S1 and S2).  Additional experiments  
 
 
Figure 3S.  Pre 1 generation in mixtures of 1 nM ProT and 1 µM VWbp evaluated by 
western blotting.  (A), (B), (C), and (D), as described in the legend to Fig. 2S except 
that the concentration of VWbp was 1 µM.   
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performed at 1 nM ProT and 1 µM VWbp, a concentration of VWbp more representative 
of the progress curve experiments, showed less than 5% conversion of ProT to Pre 1 in 
the 20 min preincubation period (Fig. 3S A and D), which was similarly inhibited after 
addition of either of the two chromogenic substrates, reaching 1-10% after 60 min (Fig. 
3S B, C, and D). 
The results indicated that only a low level of 23 ± 9% (mean and range) of ProT 
was converted to Pre 1 at the highest VWbp concentration used in the progress curve 
experiments.  Much lower levels of 1-10% Pre 1 were generated at 1 µM VWbp, 
conditions under which the progress curves were clearly hysteretic.  The results support 
the conclusion that Pre 1 formation does not account for the concluded hysteretic 
mechanism.  
To evaluate the effect of such low levels of Pre 1 on the progress curves, 
individual curves were collected after addition of substrate as a function of preincubation 
time of 1 nM ProT and 10 µM VWbp in the absence of substrate (Fig. 4S A).  All of the 
progress curves, truncated at ≤ 5% substrate depletion for this analysis, were fit well by 
the hysteresis equation without significant deviations (not shown).  Analysis of the 
progress curves gave vo, the initial velocity, vf, the final velocity, and kobs, the apparent 
first-order rate constant.  The dependence of these parameters on preincubation time, 
i.e. Pre 1 generation, showed no significant changes in vf , and slight increases in vo and 
kobs (Fig. 4S B).  During the 20 min preincubation period, vo relative to vf  increased by ≤ 
6% and kobs increased 1.3-fold. These values were compared to those obtained for 1 nM 
Pre 1 activation by 10 µM VWbp as a function of preincubation time.  Pre 1 activation by 
VWbp(1-263) also displays hysteresis, with kobs values 1.5-3-fold faster than ProT.  Pre 1 
showed essentially no changes in vo, vf, or kobs over 60 min (Fig. 4S C).  The final 
velocity (vf) for Pre 1 activation was only ~4% larger than that for ProT, indicating 
indistinguishable rates of hydrolysis of the chromogenic substrate by the Pre 1·VWbp  
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 Figure 4S.  Analysis of activation progress curves as a function of preincubation 
time of ProT or Pre 1 with VWbp(1-263) in the absence of substrate.  (A) Progress 
curves of hydrolysis of 200 µM D-Phe-Pip-Arg-pNA (pNA) initiated by addition of 
substrate to mixtures of 1 nM ProT and 10 µM VWbp preincubated for 5 (red), 10 
(green), 20 (dark blue), 30 (light blue), and 60 min (black).  (B and C) Parameters for 
ProT or Pre 1 (1 nM) preincubated for the indicated time with 10 µM VWbp before 
addition of 200 µM D-Phe-Pip-Arg-pNA. (B ) vo (●) , vf (○), and kobs (▲) as a function of 
preincubation time for ProT reactions, and (C) Pre 1 reactions as in B.  The lines 
represent linear least-squares fits. 
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and ProT·VWbp complexes.  This contrasts the observations of Kawabata and 
coworkers for SC and a fluorogenic substrate (35).  As can be seen by the raw data (Fig.  
4S A), where the ordinate maximum represents 0.1 A405 nm, the indistinguishable 
chromogenic substrate activity of the Pre 1·VWbp and ProT·VWbp complexes, and the 
small effects of low levels of Pre 1 generation on the hysteresis parameters resulted in 
only modest changes in the shapes of the curves, which were within experimental error. 
We conclude that the hysteretic kinetic behavior of ProT activation by VWbp 
cannot be accounted for by autocatalytic generation of Pre 1.  The close 
correspondence between the best fit parameters of the mechanism in Scheme 1 in the 
paper that are independent of both chromogenic substrates, KD, kC1, and kC2, 
strengthens the conclusion that relatively low levels of Pre 1 generation did not 
substantively affect the validity of the concluded hysteretic mechanism of ProT activation 
by VWbp. 
 
Materials and Methods 
SDS-gel Electrophoresis and Western Blotting   
Time-course reactions were performed in 50 mM Hepes, 110 mM NaCl, 5 mM 
CaCl2, 1 mg/ml PEG 8000, pH 7.4 at 25 oC.  Samples were quenched directly into hot 
SDS treatment buffer containing 2-mercaptoethanol, boiled for 2 min, and separated on 
4-15% gradient gels (Biorad).  The protein bands were transferred onto polyvinyldiene 
difluoride membranes in Tris-glycine buffer containing 10% (v/v) methanol, and the 
membranes were blocked for 2 h in 50 mM Tris, 150 mM NaCl, pH 7.5, 0.1% (v/v) 
Tween-20 (TBS-T) containing 5% (w/v) nonfat dry milk.  The membranes were incubated 
with a 1:500 dilution of anti-ProT polyclonal antibody (Abcam, ab48627) overnight, 
washed with TBS-T, and incubated with goat anti-rabbit IRDye 680 (Li-Cor) for 2 h.  After 
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thorough washing of the membranes in TBS-T, the bands were visualized using a Li-Cor 
Odyssey Infrared Imaging System in the 700 nm detection channel.   
Image Analysis and Quantitation   
The integrated intensity for each detected band was determined with the 
Odyssey Imager software (v3.0).  The signal ratio for the equimolar mixtures of ProT and 
Pre 1 (S1, S2) was used to correct the intensity of the Pre 1 bands for each lane to that 
of ProT, and the percentage of each band relative to the total intensity of each lane was 
calculated. 
Progress Curve Analysis   
Individual progress curves were collected in 50 mM Hepes, 110 mM NaCl, 5 mM 
CaCl2, 1 mg/ml PEG 8000, pH 7.4 at 25 C, truncated to ≤ 5 % substrate depletion, and 
fit by the hysteresis equation (Eqn. 1) as described in the Materials and Methods section 
of the chapter.  Progress curves were collected as a function of preincubation time for 
mixtures of 10 µM VWbp(1-263) and 1 nM ProT or Pre 1, initiated by addition of 200 µM 
D-Phe-Pip-Arg-pNA. 
Supplementary Data (Unpublished) 
  
Effect of VWbp and SC on platelet aggregation and secretion 
 Rapid clotting of human plasma has been demonstrated for SC and VWbp, which 
is elicited by the formation of active ProT complexes with the bacterial proteins that 
directly bind and cleave fibrinogen into fibrin.  The ProT-activator complexes can display 
this thrombin-like activity, despite restricted specificity for several typical thrombin 
substrates.  Thrombin is known to activate platelets through their surface-bound 
protease-activated receptors (PARs) (36), and some early studies on SC explored its 
effect on basic platelet aggregation, but no conclusive association was found (37).  
Whether SC and VWbp have the capacity to trigger platelet aggregation and/or 
activation has not been fully investigated. Consequently, both proteins were assessed 
for platelet-specific activity in human platelet-rich plasma (PRP) and isolated washed 
platelets.     
Platelet aggregation and activation were measured in an optical lumi-
aggregometer (Chrono-Log) with the assistance of Dr. David Gailani in the Clinical 
Coagulation Laboratory at Vanderbilt University.  Aggregation was monitored by optical 
density, and activation was simultaneously detected through the increase in 
fluorescence of a luciferase/luciferin reagent (Chrono-Lume®), an effect generated by the 
release of ATP from the dense granules of the activated platelets.  PRP was produced 
from citrated whole blood, which was centrifuged at 900 rpm for 15 min and adjusted to 
~300,000 cells/mL with platelet-poor plasma for use.  Washed gel-filtered platelets were 
also isolated from PRP from citrated whole blood, which was subjected to additional 
centrifugation steps to gently pellet the cells.  The cells were washed with Tyrode’s 
buffer (126 mM NaCl, 2.7 mM KCl, 0.98 mM MgCl2, 0.376 mM NaH2PO4, 15 mM 
HEPES, 5.6 mM dextrose, 0.35% BSA, pH 6.5), and citric acid and inhibitors were 
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added to prevent activation during purification.  The platelet solution was applied to a 
Sepharose CL-4B gel-filtration column equilibrated in Tyrode’s buffer (pH 7.4), and the 
filtered platelets were collected and counted.  All platelet solutions were used within 3 h 
of preparation.  VWbp(1-474) and SC(1-325) were diluted into 50 mM HEPES, 125 mM 
NaCl, pH 7.4 buffer, and varying concentrations of either protein were added to 450 μL 
of PRP or washed platelets with 50 μL of luciferase reagent.  All data were collected at 
37 oC with constant stirring in the aggregometer cuvette. 
 
                                    
A 
   
B C
Figure 5S.  Platelet aggregation and activation in PRP.  (A) Thrombin standard 
showing characteristic rapid aggregation (blue) and dense granule ATP release (black).  
(B) Assays with SC(1-325), representative of rapid clotting of the plasma (blue, red) with 
slow ATP release at both 1 μM (black) and 10 μM SC (green).  (C) VWbp(1-474) also 
rapidly forms a plasma clot (blue, red), but with even more delayed granule release at 2 
μM (black) and 20 μM VWbp (green). 
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Initial assays with PRP indicated that SC and VWbp quickly generated fibrin 
clots, detected by the change in optical density of the plasma.  Addition of either 
bacterial protein also prompted a very slow activation response, illustrated by the 
relatively delayed release of the dense granule ATP (Fig. 5S B and C) compared to the 
thrombin control (Fig. 5S A).  A second set of assays was performed with washed gel-
filtered platelets to isolate the interactions of SC/VWbp with the platelets themselves.  
Upon addition of low concentrations of equimolar mixtures of ProT and SC or VWbp, no 
activation was detected.  When a relatively high concentration of ProT·SC was used (1 
μM), extremely slow granule release (after 8-10 min, data not shown) was measured, but 
this could not be replicated by higher (2 μM) concentrations of ProT·VWbp.  A final set of 
assays was carried out with PRP in the presence of the therapeutic thrombin inhibitor 
lepirudin (hirudin) or the factor XIa blocking antibody O1A6 to rule out thrombin or factor 
XIa involvement.  Slow granule release by SC and VWbp was again detected, which 
could not be blocked by lepirudin or O1A6.  Comparison of these traces to those 
generated by reptilase, a snake venom enzyme which directly cleaves fibrinopeptide A 
from fibrinogen to cause clotting (38, 39), revealed a comparable slow release of granule 
ATP (not shown). 
 The pattern of slow platelet activation in the presence of SC and VWbp 
suggested that addition of the proteins to PRP triggered a process which resulted in 
granule release, but the absence of activation with the filtered platelet preparation ruled 
out a specific interaction of the active ProT·VWbp complex with receptors on the 
platelets.  Release could be mediated by other enzymatic species in the plasma, but any 
contribution from trace amounts of thrombin or factor XIa was eliminated by the use of 
inhibitors and blocking antibodies.  The ability of reptilase to generate similar slow 
platelet granule release, even though this enzyme interacts directly with fibrinogen to 
form a clot, indicates that such low level activity SC and VWbp is likely the result of an 
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interaction of the fibrin clot itself with the platelets.  The fibrinogen receptor on platelets, 
integrin αIIbβ3, undergoes both local conformational changes and relocalization on the 
platelet surface during cell activation, which allows a high affinity interaction with the 
adhesion protein that affects cellular signaling (40).  But rapid formation of a dense clot, 
such as that seen with SC and VWbp, could trap quiescent platelets within the fibrin 
mesh.  Through processes that may be related to the activation of platelets on adsorbed 
fibrinogen and plasma proteins (41, 42), this could result in integrin activation that would 
produce minor levels of platelet activation, but be independent of specific PAR or integrin 
interactions with the ProT·SC or ProT·VWbp complex. 
 
Autocatalytic proteolysis in mixtures of ProT and VWbp 
 Time-dependent conversion of ProT to the proteolytic derivatives Pre 1 and 
prethrombin 2’ (Pre 2’) has been shown to occur in mixtures of fluorescently-labeled 
(active site-blocked) ProT, native ProT, and SC(1-325) (24).  The same pattern of 
proteolysis has been identified in mixtures of native ProT and VWbp(1-263) (43), 
suggesting a similar autocatalytic activity is generated within the conformationally 
activated ProT complexes.  To explore whether cleavage of the thrombin-sensitive 
bonds between ProT fragment 1 and fragment 2 is occurring through intra- or 
intermolecular proteolysis, reactions containing both native and active site-blocked ProT 
analogs were examined to see whether species incapable of proteolysis were also 
converted to the smaller derivatives.  Reactions containing Oregon Green-488-FPR- 
ProT (4 μM) and native ProT (4 μM) were initiated by addition of either VWbp(1-263) (16 
μM) or VWbp(1-474) (8 μM) in 50 mM HEPES, 110 mM NaCl, 5 mM CaCl2, 1 mg/mL 
PEG 8000, pH 7.4, and incubated at 25 oC.  Samples were taken periodically up to 3 h 
and immediately quenched with Phe-Pro-Arg-CH2Cl and hot SDS-PAGE loading buffer.  
The reactions were incubated overnight before a final sample was collected, then 
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samples for all time-points were examined by SDS-PAGE.  The gels were visualized for 
fluorescence, followed by staining with Gel-Code Blue (Pierce) protein stain. 
 Both the fluorescence and protein-stained gels show fairly rapid generation of 
Pre 1 in both reactions, with much slower appearance of Pre 2’, consistent with what had 
been previously observed with SC(1-325) (Fig. 6S).  In mixtures with VWbp(1-263), all of 
the ProT is converted to Pre 2’ after overnight incubation (Fig. 6S B), but a slightly 
different time-course is seen with VWbp(1-474).  In this reaction, Pre 1 is formed rapidly, 
but the second cleavage event at Arg284 appears to occur at a much slower rate, with  
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Figure 6S.  Autocatalytic cleavage of ProT in the presence of VWbp(1-263) or 
VWbp(1-474).  Time-course reactions of mixtures of Oregon Green 488-FPR-ProT (4 
μM), native ProT (4 μM), and 16 μM VWbp(1-263) (A, B) or 8 μM VWbp(1-474) (C, D).  
Figure shows the fluorescent (A, C) and stained protein bands (B, D) for both reactions.  
Samples were removed at 0, 5, 20, 40, 60, 90, 120, and 180 min (lanes 1-8) and after 18 
h (lane 9), and analyzed by SDS-PAGE. 
 
 
some Pre 1 remaining after 18 h (Fig. 6S D).  This may be the result of the COOH-
terminal half of VWbp altering accessibility of this cleavage site through interactions with 
the fragment domains of ProT, something which would not occur with VWbp(1-263).  
The fact that all of both the native and active site-blocked ProT is proteolytically 
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converted indicates that intermolecular events play a significant role in the autocatalysis 
of ProT·VWbp. 
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Abstract 
Prothrombin (ProT) is conformationally activated by von Willebrand factor-binding 
protein (VWbp) from Staphylococcus aureus through insertion of the NH2-terminal 
residues of VWbp into the ProT catalytic domain.  The rate of ProT activation by 
VWbp(1-263) has been shown to be controlled by a hysteretic kinetic mechanism 
initiated by substrate binding, and the present study evaluates activation of ProT by full-
length VWbp(1-474) through activity progress curve analysis.  Additional interactions 
from the COOH-terminal half of VWbp(1-474) strengthened the initial binding of VWbp to 
ProT, resulting in higher activity and an ~100-fold enhancement in affinity.  The affinities 
of VWbp(1-263) or VWbp(1-474) were compared by equilibrium binding to the ProT 
derivatives prethrombin 1 (Pre 1), prethrombin 2, thrombin, meizothrombin, and 
meizothrombin desF1, and their corresponding active site-blocked analogs.  In 
particular, loss of fragment 1 in Pre 1 enhanced affinity for both VWbp(1-263) and 
VWbp(1-474), resulting in a 12-26% increase in Gibbs free energy, implicating a 
regulatory role for fragment 1 in the activation mechanism.  Active site labeling of all 
ProT derivatives with D-Phe-Pro-Arg-chloromethyl ketone, analogous to binding of a 
substrate, decreased their KD’s for VWbp into the subnanomolar range, reflecting the 
dependence of the activating conformational change on substrate binding.  Further, 
generation of ProT proteolysis products in the presence of VWbp in human plasma was 
characterized by western blotting and demonstrated slow autocatalytic generation of Pre 
1.  The results suggest a role for ProT domains in the potential pathophysiological 
activation of ProT by VWbp, and may reveal a function for autocatalysis of the 
ProT•VWbp complexes during initiation of blood coagulation. 
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Introduction 
As the inactive precursor of the serine proteinase thrombin, the zymogen 
prothrombin (ProT) occupies a central role in the regulation of blood coagulation.  
Sequential activation of upstream coagulation factors provides a web of feedback 
reactions which function in the temporal and spatial control of thrombin production, but 
additional mechanisms exist which modify the function of thrombin itself in response to 
specific physiological environments.  Allostery, the regulation of protein function through 
binding of a ligand or another protein to a site distal from the active site (1), is a principal 
modulator of proteinase activity, and a large number of allosteric ligands have been 
identified for thrombin (2).  A high degree of allosteric linkage has been found between 
the catalytic site of thrombin and the two electropositive exosites I and II that mediate 
substrate, inhibitor, and regulatory cofactor interactions with thrombin.  The function of 
exosite I in particular is linked with proper formation of the active site following 
proteolysis of ProT at Arg320-Thr321 (3-4), from a lower affinity conformation of this 
exosite (proexosite I) in the zymogen (5-6).   
Comparable to what is observed with many proteinases, ProT exhibits a 
continuum of conformational changes in response to direct proteolytic events that can 
alter the specificity of exosite I for its ligands, such as the lower activity and affinity for 
fibrinogen seen with MzT (7).  Loss of the two smaller domains of ProT (fragments 1 and 
2) during activation exposes exosite II and may produce conformational shifts that affect 
association of other ligands, although this long distance effect has been debated (8-9).  
Conversely, the action of ligand binding to the exosites can change the recognition of 
substrates by the active site, as illustrated by the capacity of thrombomodulin to switch 
thrombin from procoagulant to anticoagulant by targeting cleavage of protein C (10).  
Thrombin ligands can interact with only one of the exosites to affect thrombin activity, or 
with both exosites through different regions of the ligand itself.  The platelet receptor 
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GP1b binds to both exosite I and II through distinct regions on the receptor (11-12), 
yielding a two-pronged but linked association with the exosites that may generate 
responses unique from those seen with binding of a single exosite.  Furthermore, 
allostery not only influences the interactions of thrombin with substrates, inhibitors, and 
regulatory macromolecules, but it also impacts binding of exogenous ligands such as the 
leech-derived inhibitor hirudin and some effectors from snake venoms (2). 
 The human pathogen Staphylococcus aureus is known to secrete two proteins 
which can each interact with (pro)exosite I on ProT, staphylocoagulase (SC) and von 
Willebrand factor-binding protein (VWbp) (13-15).  Both are potent procoagulant factors 
capable of triggering rapid clotting of human plasma through direct cleavage of 
fibrinogen into fibrin by the ProT-activator complex, but this activity is not reliant on 
proteolysis of the activation loop of ProT.  Instead, conformational activation of the 
zymogen occurs through direct binding interactions with the activator and, ultimately, 
insertion of the NH2-terminus of either SC or VWbp into the NH2-terminal binding cleft in 
the catalytic domain of ProT (15-16), forming the salt bridge with Asp194 
(chymotrypsinogen numbering) that is characteristic of proteolytic activation (3).  In 
contrast to the usually minor effects seen with other ligands, binding of SC or VWbp to 
ProT generates what could be described as a definitive allosteric transition, where an 
inactive zymogen precursor is completely converted to an active species though a non-
proteolytic alternative to its common activation pathway. 
In a previous study, we described the molecular mechanism of VWbp 
procoagulant activity, and in addition, identified the role for a distinctive substrate-
induced hysteretic kinetic mechanism for activation of ProT by VWbp (15).  Hysteresis 
has been classically defined for a number of regulatory metabolic enzymes as a slow 
transition or conformational change initiated by various processes, including 
polymerization and ligand displacement (17-18).  The key initiator of hysteretic behavior 
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in VWbp-mediated ProT activation is a tight-binding substrate that alters a 
conformational equilibrium between inactive and active forms of the ProT·VWbp complex 
(15), which represents the first example of such hysteretic control in serine proteinase 
activation.   
In addition to the recognized effect of substrate, preliminary kinetic and binding 
data indicated that the presence of the fragment domains of ProT, in particular fragment 
1, imparts either a steric or allosteric impediment to fully productive binding of VWbp.  
The present study defines the contribution to protein-protein affinity of fragment 1 and 2 
and the catalytic domain of ProT, and the predominantly unstructured COOH-terminal 
half of VWbp, as well as the magnitude of influence that active site occupation by a 
structural substrate mimic has on the binding behavior of VWbp.  The preferential 
binding of certain ProT proteolysis products to VWbp likely has a significant influence on 
the pathophysiolgical behavior of VWbp, and may be essential to understanding its 
potential role as a staphylococcal virulence factor. 
 
Experimental Procedures 
Materials 
HEPES was purchased from Research Organics (Cleveland, OH), and D-Phe-
Pro-Arg-CH2Cl (FPR-CH2Cl) and Gly-Pro-Arg-Pro peptide (GPRP) were purchased from 
Bachem (Torrance, CA).  H-D-Phe-Pip-Arg-pNA was obtained from Diapharma (West 
Chesterfield, OH).  Purified ecarin, the ProT activator from the venom of Echis carinatus, 
was purchased from Pentapharm (Basal, Switzerland).  Dansylarginine N-(3-ethyl-1,5-
pentanediyl)amide (DAPA) was from Haematologic Technologies, Inc. (Essex Junction, 
VT).  Tetramethylrhodamine-5-iodoacetamide dihydroiodide (5-TMRIA) was from 
Invitrogen (Carlsbad, CA). The rabbit polyclonal antibody directed against full length 
native human ProT (ab48627) was purchased from Abcam (Cambridge, MA), and 
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fluorescent secondary goat anti-rabbit IR 680 antibodies were from LI-COR Biosciences 
(Lincoln, NE).  Immobilon-FL polyvinyldiene difluoride (PVDF) membranes were 
purchased from Millipore Corp. (Billerica, MA). Human factor I-deficient plasma was 
purchased from George King Biomedical, Inc. (Overland Park, KS). 
Proteins 
VWbp(1-263) and VWbp(1-474) were expressed and purified as described 
previously (15).  Y63-sulfated, fluorescein-labeled hirudin (54-65) ([5F]Hir(54-65)) was 
prepared as described (19).  Native human ProT, Pre 1, and T were purified according to 
established procedures (4, 20).  Native human Pre 2 was prepared by a modification of 
published methods (4, 21), adding a final chromatography step on a HiPrep 16/10 SP XL 
cation-exchange column (GE Healthcare) in 50 mM MES, 50 mM NaCl, pH 6.0 buffer.  
Pre 2 was separated from residual inhibited thrombin with a 0-700 mM NaCl gradient, 
concentrated, and dialyzed into 50 mM HEPES, 125 mM NaCl, pH 7.4 buffer for storage.  
The active site-blocked (FPR-) analogs and [TMR]FPR-ProT was produced by 
established methods (13, 20).  Absorption coefficients (E0.1% 280 nm) and molecular 
weights of the ProT derivatives used were as follows: ProT, 1.47 and 71,600; Pre 1, 1.78 
and 49,900; Pre 2, 1.73 and 37,000; T, 1.74 and 36,600; MzT, 1.47 and 71,600; MzT(-
F1), 1.78 and 49,900. 
Preparation of recombinant MzT and FPR-MzT 
A HEK-293 cell line stably transfected with a pCDNA 3.1 expression vector 
containing the recombinant human ProT(R155Q/R271Q/R284Q) mutant (rProTQQQ) 
construct (22) was kindly provided by Dr. Sriram Krishnaswamy (Children’s Hospital of 
Philadelphia, PA).  The rProT mutant was expressed and purified as previously 
described (23), and stored in 5 mM MES, 150 mM NaCl, pH 6.0.  To generate stable 
active MzTQQQ, rProTQQQ (20 µM) was incubated with purified ecarin (6 EU/mL) and 200 
μM DAPA in 0.1 M HEPES, 0.1 M NaCl, 1 mg/mL PEG 8000, pH 7.4, supplemented with 
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1/10 volume of 1 M HEPES, pH 7.6, for 2 h at 25 oC.  The reaction was quenched by 
addition of 50 mM EDTA and immediately diluted 5-fold with 20 mM MES, 20 mM NaCl, 
pH 6.0 buffer.  The MzTQQQ was separated from residual unreacted rProTQQQ and ecarin 
by chromatography on a 1-ml Resource Q column (GE Healthcare) in 20 mM MES, pH 
6.0 buffer, eluted with a 0-0.5 M NaCl gradient (24).  To produce FPR-MzTQQQ, a portion 
of the active enzyme was incubated with a 10-fold molar excess of FPR-CH2Cl for 1 h at 
22 oC.  Active MzTQQQ and FPR-MzTQQQ were dialyzed against 5 mM MES, 150 mM 
NaCl, pH 6.0 buffer, and stored at -80 oC. 
Preparation of FPR-MzT(-F1) 
Native Pre 1 (20 µM) was activated by ecarin (6 EU/mL) in the presence of FPR-
CH2Cl (200 µM) for 2 h at 25 oC, and activation was quenched by addition of 50 mM 
EDTA.  The quenched reaction was dialyzed overnight against 25 mM NaH2PO4, pH 6.5, 
and loaded onto an SP-Sephedex C-50 column equilibrated with the same buffer.  
Unreacted Pre 1 was eluted with 50 mM NaH2PO4, pH 6.5, followed by elution of FPR-
MzT(-F1) with a 50 mM-300 mM NaH2PO4 gradient (24).  The peak was pooled, 
concentrated, and dialyzed against 5 mM MES, 150 mM NaCl, pH 6.0, for storage. 
Kinetic titrations of ProT activation 
Full time-course progress curves for activation of ProT by VWbp(1-474) were 
collected, monitoring the rate of hydrolysis of H-D-Phe-Pip-Arg-pNA (S-2238) at 405 nm 
and 25 oC.  Reactions contained either 1 nM ProT, varying concentrations of VWbp(1-
474), and 200 µM H-D-Phe-Pip-Arg-pNA, or 1 nM ProT, 10 nM VWbp(1-474), and 
varying concentrations of H-D-Phe-Pip-Arg-pNA.  Data were collected for 1 h, or until 
A405 nm = 1.0.  The progress curves of p-nitroaniline formation were analyzed by 
simultaneous nonlinear least-squares fitting in KinTek Global Kinetic Explorer using the 
hysteretic kinetic model described previously (15), assuming diffusion-controlled rapid 
equilibrium binding steps. 
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Fluorescence titrations with active ProT derivatives 
Continuous fluorescence measurements were taken in 50 mM HEPES, 110 mM 
NaCl, 5 mM CaCl2, 1 mg/mL PEG 8000, pH 7.4 at 25 oC.  Fluorescence was monitored 
for a buffer blank, [5F]Hir(54-65) alone, after addition of VWbp(1-263) or VWbp(1-474), 
and immediately after addition of Pre 1, Pre 2, T, or MzTQQQ.  Data were collected with 
either a SLM 8100 or PTI QuantaMaster spectrofluorometer at λex = 491 nm and λem = 
520 nm.  The fractional change in fluorescence was calculated as (Fobs – Fo)/Fo = ∆F/Fo, 
and the data for each experiment were fit globally with the cubic equation for tight 
competitive binding to obtain the dissocation constants for each competitor and the 
stoichiometric factor. The Gibbs free energy of binding (∆Gbinding) was calculated, using 
the equation ∆Gbinding = RTln(KD), where R = 1.98 cal·mol-1·degree-1 and T = 298.15 K 
(25 oC).   
In situ production of MzT(-F1) 
Because autocatalysis of thrombin-sensitive cleavage sites within ProT or Pre 1 
occurs rapidly during conversion to MzT or MzT(-F1), active MzT(-F1) was produced in 
situ during the fluorescence experiments through activation of native Pre 1 by ecarin.  
Control time-course gel experiments mimicking the conditions used for the binding 
assays showed complete conversion of Pre 1 to MzT(-F1) within 20 min, with no 
detectable degradation of the proteins over this time period.  Fluorescence 
measurements were collected in the same manner as for the active ProT derivatives 
above, but with inclusion of ecarin (2 EU/mL) in the cuvette before addition of Pre 1 and 
measurement of the final fluorescence values at 20 min after initiation of activation. 
Fluorescence titrations with active-site blocked ProT derivatives 
Titrations were performed in 50 mM HEPES, 110 mM NaCl, 5 mM CaCl2, 1 
mg/mL PEG 8000, pH 7.4, 1 mg/mL BSA, 10 µM FPR-CH2Cl at 25 oC.  Increasing 
concentrations of either VWbp(1-263) or VWbp(1-474) were titrated in the presence of 
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fixed concentrations of [TMR]FPR-ProT and either FPR-ProT, FPR-Pre 1, FPR-Pre 2, 
FPR-T, FPR-MzTQQQ, or FPR-MzT(-F1).  Data were collected at λex = 558 nm and λem = 
580 nm, with the fractional change in fluorescence, binding parameters, and free energy 
calculated as for the active ProT derivatives. 
Western Blots with Factor I-deficient Human Plasma 
Reactions contained 50% citrated human factor I-deficient plasma, 24 mM CaCl2, 
5 mM GPRP, and either 10 µM VWbp(1-263) or 1 µM VWbp(1-474) in 50 mM HEPES, 
110 mM NaCl, 5 mM CaCl2, 1 mg/mL PEG, pH 7.4.  Incubations were performed at 25 
oC for 1 h.  Samples were removed from the reactions every 10 min, immediately 
quenched into hot SDS-PAGE loading buffer, and boiled for 2 min.  Quenched reactions 
and standards were electrophoresed on 4-15% Tris-glycine gradient gels, and 
transferred to Immobilon-FL polyvinyldiene difluoride (PVDF) membranes in Tris/glycine 
western transfer buffer containing 10% methanol.  Membranes were blocked for 1 h in 
20 mM Tris, 150 mM NaCl, pH 7.5, 0.1% Tween-20 (TBS-T) containing 5% dry milk, 
washed with TBS-T, and incubated overnight with a primary rabbit anti-human ProT 
antibody (ab48627).  The membranes were washed with TBS-T and incubated for 1 h 
with a goat anti-rabbit secondary LI-COR IR 680 antibody.  Bands were visualized using 
a LI-COR Odyssey Infrared Imaging System in the 700-nm detection channel. 
 
Results    
Kinetic analysis of ProT activation by VWbp(1-474) 
To confirm the role of hysteresis in the functional activity of full-length VWbp, 
VWbp(1-474) was employed in ProT activation assays.  Although the degree of 
curvature in the rate of substrate cleavage seen with VWbp(1-474) is less than that of 
VWbp(1-263), the data were fit very well by the established hysteretic kinetic mechanism 
(Scheme 1) (Fig. 1).  The calculated KD for the initial formation of the mature ProT·VWbp 
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complex was 25.3 ± 0.1 nM, approximately 100-fold tighter binding than VWbp(1-263) 
(15), verifying that the COOH-terminal half of VWbp contributes greatly to the affinity of   
 
 
 
Figure 1.  Full time-course kinetic analysis of ProT activation by VWbp(1-474). 
Progress curves for hydrolysis of D-Phe-Pip-Arg-pNA (S-2238), represented as the 
concentration of pNA, by mixtures of ProT and VWbp(1-474) include both saturating and 
limiting substrate assays. Mixtures of 1 nM ProT, 200 µM substrate, and 0.3, 0.5, 1, 2, 3, 
4, 5, 10, 20, 30, or 40 nM VWbp are shown in black, with the data represented as every 
10th point and the fit as a solid line.  Mixtures of 1 nM ProT, 10 nM VWbp, and 25, 50, 
75, 100, or 150 µM substrate are shown in red.  Data were collected and analyzed as 
described in “Experimental Procedures”. 
 
 
VWbp for ProT.  The overall equilibrium constant for the conformational change between 
active ProT*·VWbp and inactive forms of the ProT·VWbp complex was also over 3-fold 
more favorable for the active form (Kcon 3.1 ± 1.8), primarily due to an almost 3-fold 
slower reverse rate constant (kC2 0.0185 ± 0.0005 s-1) with a similar forward rate 
constant (kC1 0.00592 ± 0.0004 s-1) for the slow conformational change (15).  The 
remaining parameters for chromogenic substrate hydrolysis (Km 3.61 ± 0.01 µM; kcat 63 ± 
1 s-1) showed a ~6-fold increase in Km and a 34% decrease in kcat compared to those 
determined for VWbp(1-263), giving only a slightly lower (6-fold) specificity constant 
(kcat/Km) (15). 
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Kcon KD Km kcat   (kC2/kC1) 
 ProT + VWbp          ProT·VWbp                ProT*·VWbp            ProT·VWbp·substrate           ProT·VWbp 
  + product 
 
Scheme  1. 
   
Binding of VWbp(1-263) or VWbp(1-474) to active ProT derivatives 
The affinity of VWbp(1-263) for native ProT was previously determined with 
[5F]Hir(54-65) as a competitive ligand for proexosite I, supporting the relatively weak 
affinity determined from kinetic analysis with the same chromogenic substrate (KD 2.5 ± 
0.3 µM) (15).  This experiment revealed that VWbp(1-263) binds directly to proexosite I 
on ProT, allowing an identical experimental design to be used to examine binding to all 
of the active ProT derivatives.  Both VWbp(1-263) and VWbp(1-474) successfully 
competed with the labeled hirudin peptide for binding to all the derivatives (Figs. 2 and 
3), with the results of the analyses summarized in Table 1.  The stoichiometric factor 
was consistent throughout the experiments (0.8-1.2), representative of a 1:1 molar 
complex formed between VWbp and all of the ProT derivatives.  The free energy 
changes (∆G) (Fig. 6) for VWbp(1-263) decreased approximately 1.6-fold from -7.6 
kcal/mole for native ProT to -12.0 kcal/mole for the active enzyme forms (T, MzT, MzT(-
F1)).  VWbp(1-474) revealed a similar relationship, with values ranging from -9.4 
kcal/mole (ProT) to -12.9 kcal/mole (T) (Table 1). 
Binding of VWbp(1-263) or VWbp(1-474) to active site-blocked ProT derivatives 
To isolate the effect of active site occupation on the affinity of ProT and its 
derivatives for VWbp, both the zymogen and active enzyme forms were labeled with the 
covalent active site inhibitor FPR-CH2Cl.  The conformational changes associated with 
labeling with the inhibitor mimic the catalytic transition state representative of the 
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presence of a bound substrate (25), a process expected to substantially increase the 
affinity of VWbp for ProT due to the influence of substrates on the kinetic mechanism of 
activation.  The resulting higher affinities for the active site-blocked analogs precluded 
use of the same experimental approach used for the active ProT derivatives.  The 
fluorescent hirudin peptide could not effectively compete with either VWbp construct for 
binding, because of the massively higher affinity of the FPR-derivatives.  To address this 
problem, [TMR]FPR-ProT was employed as a competitive ligand with the FPR-analogs, 
due to its similar high affinity for VWbp.  Both VWbp(1-263) and VWbp(1-474) bound to 
all active site-blocked ProT derivatives (Fig. 4 and 5) with extremely tight, subnanomolar 
KD’s (Table 1), with VWbp(1-474) binding with lower picomolar affinities.  As with the 
active ProT derivative experiments, the calculated parameters support formation of a 1:1 
molar complex between the proteins.  Free energy values were nearly identical for all 
active site-inhibited forms, for both VWbp(1-263) (-12.9 to -13.3 kcal/mole) and VWbp(1-
474) (-13.2 to -15.9 kcal/mole) (Table 1, Fig. 6).  
Autocatalysis of the ProT-VWbp complex in human plasma 
As a potent procoagulant factor, VWbp triggers rapid clotting of human plasma.  
To examine the ability of VWbp to elicit autocatalytic activity within a complex with 
endogenous ProT, without interference from the physiological thrombin substrate 
fibrinogen, plasma congenitally deficient in fibrinogen (factor I) was used as a source of 
human ProT.  Figure 7 shows that the ProT ·VWbp(1-474) complex produced detectable 
levels of Pre 1 in plasma mixtures, with a visible reduction in the amount of full-length 
ProT.  A similar pattern was produced with VWbp(1-263), but to a lesser extent, with 
slower appearance of a Pre 1 band and less obvious disappearance of ProT.   
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Figure 2.  Competitive binding of VWbp(1-263) and [5F]Hir(54-65) to native ProT 
derivatives. Titrations of the change in fluorescence (∆F/Fo) of 48 nM [5F]Hir(54-65) as 
a function of total concentration of ProT derivative. A, ProT with 0 (●), 10 (○), and 20 µM 
(▲) VWbp, as previously published in Ref. (15), reproduced with permission. B, Pre 1 
with 0 (●), 2.2 (○), and 4.3 µM (▲) VWbp. C, Pre 2 with 0 (●), 2.2 (○), and 4.3 µM (▲) 
VWbp. D, T with 0 (●), 273 (○), and 431 nM (▲) VWbp. E, MzTQQQ with 0 (●), 273 (○), 
and 486 nM (▲) VWbp. F, MzT(-F1) with 0 (●), 273 (○), and 486 nM (▲) VWbp.  The 
solid lines represent fits by the cubic binding equation with the parameters listed in Table 
1.  Binding experiments were performed and analyzed as described in “Experimental 
Procedures”. 
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Figure 3.  Competitive binding of VWbp(1-474) and [5F]Hir(54-65) to native ProT 
derivatives. Titrations of the change in fluorescence (∆F/Fo) of 48 nM [5F]Hir(54-65) as 
a function of total concentration of ProT derivative. A, ProT with 0 (●), 4 (○), and 8 µM 
(▲) VWbp. B, Pre 1 with 0 (●), 2 (○), and 4 µM (▲) VWbp. C, Pre 2 with 0 (●), 2 (○), and 
3.5 µM (▲) VWbp. D, T with 0 (●), 154 (○), and 255 nM (▲) VWbp. E, MzTQQQ with 0 
(●), 154 (○), and 353 nM (▲) VWbp. F, MzT(-F1) with 0 (●), 154 (○), and 353 nM (▲) 
VWbp.  The solid lines represent fits by the cubic binding equation with the parameters 
listed in Table 1.  Binding experiments were performed and analyzed as described in 
“Experimental Procedures”. 
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Figure 4.  Binding of VWbp(1-263) to [TMR]FPR-ProT and active site-blocked ProT 
derivatives. Titrations of the change in fluorescence (∆F/Fo) of 10 nM [TMR]FPR-ProT 
as a function of total concentration of VWbp(1-263). A, FPR-ProT at 0 (●), 10 (○), and 30 
nM (▲). B, FPR-Pre 1 at 0 (●), 11 (○), and 26 nM (▲). C, FPR-Pre 2 at 0 (●), 11 (○), and 
26 nM (▲). D, FPR-T at 0 (●), 10 (○), and 31 nM (▲). E, FPR-MzTQQQ at 0 (●), 10 (○), 
and 21 nM (▲). F, FPR-MzT(-F1) at 0 (●), 11 (○), and 21 nM (▲).  The solid lines 
represent fits by the cubic binding equation with the parameters listed in Table 1.  
Binding experiments were performed and analyzed as described in “Experimental 
Procedures”. 
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Figure 5.  Binding of VWbp(1-474) to [TMR]FPR-ProT and active site-blocked ProT 
derivatives. Titrations of the change in fluorescence (∆F/Fo) of 10 nM [TMR]FPR-ProT 
as a function of total concentration of VWbp(1-263). A, FPR-ProT at 0 (●), 11 (○), and 21 
nM (▲). B, FPR-Pre 1 at 0 (●), 11 (○), and 20 nM (▲). C, FPR-Pre 2 at 0 (●), 15 (○), and 
30 nM (▲). D, FPR-T at 0 (●), 10 (○), and 26 nM (▲). E, FPR-MzTQQQ at 0 (●), 10 (○), 
and 25 nM (▲). F, FPR-MzT(-F1) at 0 (●), 11 (○), and 24 nM (▲).  The solid lines 
represent fits by the cubic binding equation with the parameters listed in Table 1.  
Binding experiments were performed and analyzed as described in “Experimental 
Procedures”. 
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Table 1.   
Summary of binding parameters 
Dissociation constants (KD) and other binding parameters are listed for competitive equilibrium binding of [5F]Hir(54-65) and VWbp(1-263) 
or VWbp(1-474) to unmodified ProT derivatives.  Also listed are parameters obtained using [TMR]FPR-ProT as the probe with active site-
blocked ProT analogs.  Errors represent ± 2 SD.  *Parameters from previous analysis found in (15). 
 
Protein Probe KD n ∆Fmax/Fo ∆G 
∆∆G 
 (∆Gder - ∆GProT) 
VWbp(1-263)  nM mol VWbp/mol ProT  kcal/mol kcal/mol (% change) 
ProT* [5F]Hir(54-65) 2501 ± 336 1 (fixed) -0.19 ± 0.01 -7.6 0.0 
Pre 1 [5F]Hir(54-65) 84 ± 23 0.78 ± 0.05 -0.22 ± 0.01 -9.6 -2.0 (26%) 
Pre 2 [5F]Hir(54-65) 55 ± 21 0.81 ± 0.05 -0.24 ± 0.01 -9.9 -2.3 (30 %) 
T [5F]Hir(54-65) 1.5 ± 0.3 0.74 ± 0.02  -0.29 ± 0.01 -12.0 -4.4 (58%) 
MzT [5F]Hir(54-65) 1.6 ± 0.6 0.85 ± 0.03 -0.37 ± 0.01 -11.9 -4.3 (57%) 
MzT(-F1) [5F]Hir(54-65) 1.3 ± 0.7 0.76 ± 0.04 -0.30 ± 0.01 -12.1 -5.3 (70%) 
FPR-ProT [TMR]FPR-ProT 0.153 ± 0.078 1.18 ± 0.07 1.00 ± 0.05 -13.3 -5.7 (75%) 
FPR-Pre 1 [TMR]FPR-ProT 0.161 ± 0.088 1.24 ± 0.09 0.98 ± 0.05 -13.3 -5.7 (75%) 
FPR-Pre 2 [TMR]FPR-ProT 0.210 ± 0.160 1.06 ± 0.12 1.00 ± 0.07 -13.1 -5.5 (72%) 
FPR-T [TMR]FPR-ProT 0.376 ± 0.184 0.84 ± 0.09 0.97 ± 0.04 -12.8 -5.2 (68%) 
FPR-MzT [TMR]FPR-ProT 0.318 ± 0.118 0.79 ± 0.07 0.98 ± 0.02 -12.9 -5.3 (70%) 
FPR-MzT(-F1) [TMR]FPR-ProT 0.252 ± 0.091 1.04 ± 0.07 0.95 ± 0.03 -13.0 -5.4 (71%) 
VWbp(1-474)       
ProT [5F]Hir(54-65) 112 ± 85 1.05 ± 0.10 -0.17 ± 0.01 -9.4 0.0  
Pre 1 [5F]Hir(54-65) 19 ± 7 1.24 ± 0.05 -0.22 ± 0.01 -10.5 -1.1 (12%) 
Pre 2 [5F]Hir(54-65) 7 ± 5 1.03 ± 0.04 -0.25 ± 0.01 -11.1 -1.7 (18%) 
T [5F]Hir(54-65) 0.30 ± 0.17 0.94 ± 0.02 -0.29 ± 0.01 -12.9 -3.5 (37%) 
MzT [5F]Hir(54-65) 0.30 ± 0.17 1.15 ± 0.02 -0.37 ± 0.01 -12.9 -3.5 (37%) 
MzT(-F1) [5F]Hir(54-65) 0.44 ± 0.23 1.14 ± 0.03 -0.29 ± 0.01 -12.7 -3.3 (35%) 
FPR-ProT [TMR]FPR-ProT 0.008 ± 0.048  1.23 ± 0.10 0.95 ± 0.02 -15.1 -5.7 (61%) 
FPR-Pre 1 [TMR]FPR-ProT 0.073 ± 0.085 1.00 ± 0.10 0.98 ± 0.03 -13.8 -4.4 (47%) 
FPR-Pre 2 [TMR]FPR-ProT 0.002 ± 0.004 0.99 ± 0.03 0.96 ± 0.02 -15.9 -6.5 (69%) 
FPR-T [TMR]FPR-ProT 0.015 ± 0.022 1.11 ± 0.06 0.96 ± 0.03 -14.7 -5.3 (56%) 
FPR-MzT [TMR]FPR-ProT 0.188 ± 0.091 0.68 ± 0.06 1.00 ± 0.03 -13.2 -3.8 (41%) 
FPR-MzT(-F1) [TMR]FPR-ProT 0.157 ± 0.080 0.81 ± 0.07 0.98 ± 0.03 -13.3 -3.9 (41%) 
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Figure 6.  Changes in Gibbs free energy (∆G) from competitive equilibrium 
binding. Calculated free energy (kcal/mole) for experiments with VWbp(1-263) (A) and 
VWbp(1-474) (B). Native ProT proteolytic derivatives are in orange, FPR-derivatives are 
in green. Error bars represent ∆G determined from KD ± 2 S.D (listed in Table 1), using 
the equation given in “Experimental Procedures.” 
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Figure 7.  Autoproteolytic cleavage of endogenous plasma ProT by VWbp. Plasma 
ProT detected by western blotting in reactions containing 50% recalcified human factor I-
deficient plasma and (A) 10 µM VWbp(1-263) or (B) 1 µM VWbp(1-474).  Standards 
(Std) are equimolar amounts of native purified ProT, Pre 1, and Pre 2, equivalent to the 
expected initial molarity of plasma ProT.  Electrophoresis and blotting were performed as 
described in “Experimental Procedures”. 
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Discussion 
   The current study reveals a substantial role for both the fragment 1 domain and 
activation-associated conformational changes in the mechanism of binding and 
activation of ProT by VWbp.  A previous study characterized VWbp as interacting with 
proexosite I on ProT, due to its ability to compete for binding with the COOH-terminal 
peptide of hirudin, Hir(54-65) (15).  Consistent with the pattern of behavior shown by 
many exosite I-specific ligands, including Hir(54-65), the increased affinity of VWbp for 
ProT derivatives with a more proteinase-like conformation suggests that VWbp can 
exploit the same steric and allosteric processes that govern thrombin recognition of other 
physiological ligands.   
While VWbp is capable of binding (pro)exosite I and potentially altering the 
specificity of ProT through this interaction alone, a thorough analysis of the kinetics of 
ProT activation by VWbp(1-474) (Fig. 1) indicates that other regions of the zymogen are 
directly affected by the COOH-terminal half of VWbp.  Whereas the NH2-terminal half of 
VWbp is predicted to have a staphylocoagulase-homologous secondary structure 
composed of two alpha-helical bundles (26), multiple prediction analyses on the rest of 
VWbp assign almost no regular structure, apart from a 1-2 helix segment (~50 residues) 
at the distal end.  The higher activity and ~100-fold higher affinity of VWbp(1-474) in 
forming the initial ProT·VWbp complex revealed in the kinetic analysis (Scheme 1) likely 
results from additional binding interactions which may affect the conformation of exosite I 
or facilitate insertion of the NH2-terminus of VWbp into the activation pocket on ProT.  
The unstructured region of VWbp may sterically compete with or rearrage the small 
fragment domains to increase the overall affinity of VWbp for the zymogen.  Whether this 
process is mediated by the largely disordered region or the relatively small COOH-
terminal helical portion of VWbp remains unknown. 
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The small fragment domains of ProT themselves present a potential steric 
hindrance to binding by a macromolecular ligand such as VWbp, but release of these 
domains is normally strictly regulated during ProT activation.  When it is not bound to a 
membrane surface through Ca2+-mediated interactions between γ-carboxyglutamic acid 
residues and phosphatidylserine (27), the orientation of fragment 1 relative to the rest of 
the zymogen is largely undefined, although crystal structures of fragment 1, fragment 2, 
and MzT(-F1) have been solved (27-29).  Release of the fragment 1 domain alone 
through cleavage at Arg155 is greatly inhibited in the presence of Ca2+ (30-31), and 
fragment 1 typically remains associated with fragment 2 in a proteolytic species termed 
fragment 1.2 (32).  In canonical ProT activation, fragment 1.2 blocks exosite II until it is 
removed through cleavage by factor Xa at Arg271, releasing thrombin from the 
prothrombinase complex.  If cleavage at Arg271 occurs prior to proteolysis of the 
activation bond at Arg320, fragment 1.2 retains a ~20-fold higher affinity (200 nM) (22) for 
the inactive catalytic domain compared to thrombin, which decreases the rate of its 
release from the activation complex.  This proteolytic regulation is the key to temporal 
control of thrombin production as well as to limiting ligand interaction with an improperly 
activated thrombin molecule.  Loss of one or both fragment domains not only relieves 
potential blocking interactions for binding of VWbp, but also produces minor allosteric 
effects within the activation domain of ProT itself (33) that could favor ligand-exosite 
association. 
A potential role for these allosteric changes is indicated by the results of the 
competitive binding studies using ProT analogs with unmodified active sites, which 
revealed substantial increases in the affinity of VWbp as the fragment domains are 
removed (Table 1).  The greatest enhancement results from loss of fragment 1, with 
~30-fold higher affinity for VWbp(1-263) and a 6-fold change with VWbp(1-474).  It is 
worth noting that even though VWbp(1-474) is capable of binding to all of the ProT 
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derivatives with higher affinities than VWbp(1-263), there is still an effect of the loss of 
fragment 1 despite the significant contribution of the COOH-terminus of VWbp to activity 
and affinity.  A direct comparison of the Gibbs free energy values (∆G) shows that there 
is a 12-26% increase in binding free energy upon loss of fragment 1 alone (Pre 1) for 
both VWbp constructs, but only a 4-6% increase upon subsequent loss of fragment 2 
(Pre 2) (Table 1).  The same pattern is not seen upon examination of the three active 
enzyme forms, T, MzT, and MzT(-F1), which all contain catalytic domains that have 
undergone conformational changes associated with proteolytic activation.  VWbp(1-263) 
binds indistinguishably to all three species (KD 1.3-1.6 nM), suggesting that the existence 
of a proteinase-like activation domain promotes an equally favorable structure for ligand 
binding.  An identical relationship can be seen with VWbp(1-474), where even though it 
is capable of binding the active enzymes with ~5-fold tighter KD’s than VWbp(1-263), the 
presence of the fragment domains has no obvious detrimental effect.  These results are 
consistent with previous studies of the influence of the fragment domains on the 
expression of exosite I, where loss of fragment 1 in Pre 1 increases the affinity of the 
exosite 7-fold for a fluorescently-labeled hirudin peptide, but any modulating effect of 
fragment 1 is canceled out by proteolytic activation of the zymogen (33). 
What does this binding behavior indicate within the context of the hysteretic 
mechanism of activation by VWbp?  A model of an optimal ProT conformation that 
supports initial high affinity association of VWbp would be implied from the binding 
studies alone, but VWbp likely both initiates allosteric changes in ProT and exploits 
structural alterations elicited by other ligands or proteolytic events.  Several changes are 
needed to form a properly folded thrombin activation domain for substrate-binding, 
including shifts in the segment containing the Arg15-Ile16 cleavage site and the flexible 
loops 142-152, 186-194, and 216-226 (3-4).  Typically, formation of the salt bridge 
between Ile16 and Asp194 would conformationally link the new thrombin NH2-terminus with 
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the substrate specificity pocket (3, 34), not requiring any other effectors to trigger the 
structural transition.  In contrast, the key step in the model of activation by VWbp occurs 
upon binding of a substrate into what is presumed to be an imperfectly formed, inactive 
active site within a relatively low affinity ProT·VWbp complex, and this contact serves to 
generate a more catalytically competent, high affinity complex.  The additional binding 
requirements for this slow transition to an active proteinase conformation share 
characteristics with substrate- and cofactor-mediated induced fit mechanisms of 
activation, such as those seen with the complement protease factor D or the factor 
VIIa/tissue factor complex (35-36).  The activity of factor D is regulated by distortions 
within the catalytic triad and a unusually narrow substrate-binding (S1) cleft that are only 
relieved upon binding of its substrate, C3b-complexed factor B (37), analogous to the 
substrate-enhanced activity that is observed with VWbp in complex with ProT.  Similarly, 
an altered active site is found in factor VIIa, and the enzyme exists in a state of 
incomplete activation with a conformation resembling an intermediate stage between 
zymogen and protease (38-39).  Contact with its cofactor, tissue factor, favorably shifts 
the architecture of the factor VIIa active site, allowing the enzyme to cleave its natural 
substrates factor X and factor IX (40).  This pathway shows parallels to the unfavorable 
equilibrium that exists between inactive and active forms of the ProT·VWbp complex in 
the absence of substrate (Scheme 1).  The requirement for additional protein-protein 
interactions in mediating the activity of serine proteinases directs the specificity of the 
proteinase complex towards a more limited assemblage of substrates than would be 
seen with the canonical configuration of the enzyme alone.   
The concept of substrate binding as a fundamental amplifier of ProT activation by 
VWbp is further strengthened by the equilibrium binding experiments with FPR-blocked 
ProT derivatives.  Hydrolysis of substrate amide bonds by members of the trypsin family 
of enzymes, including thrombin, follows a well-defined chemical pathway initiated by 
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formation of a Michaelis complex and subsequent attack of the substrate carbonyl atom 
by Ser195 in the oxyanion hole, assisted by His57, to give a hemiketal tetrahedral 
intermediate.  The ensuing acyl-enzyme complex releases the first product, followed by 
hydrolysis of the acyl-enzyme through a second tetrahedral intermediate to restore the 
enzyme and release the second product (41).  The tetrahedral intermediates resemble 
the transition state for the reactions, and this structure can be mimicked by several 
classes of covalent inhibitors, including tripeptide chloromethyl ketone inhibitors highly 
specific for serine proteinases (25, 42).  Structural studies have shown that inhibition of 
thrombin by D-Phe-Pro-Arg-chloromethyl ketone (PPACK/FPR) gives a similar 
orientation of residues in the substrate-binding cleft of the enzyme as is seen with 
binding of substrates, but distinctly different from changes seen with binding of hirugen 
to exosite I alone (43).  Thus, corresponding FPR-analogs of all the enzyme and 
zymogen derivatives of ProT were produced through either direct inhibition with FPR-
CH2Cl or through formation of a reversible, conformationally activated complex of the 
zymogen with staphylocoagulase (26), allowing incorporation of the inhibitor into the 
induced active site on the zymogen-activator complexes.  The active site itself serves as 
the focus for the significant conformational changes which occur upon conversion of the 
inactive catalytic domain into thrombin, and the substrate-bound structural mimicry of the 
FPR-analogs allowed VWbp(1-263) and VWbp(1-474) to bind with 4-6-fold higher affinity 
than to the active enzymes, even with the zymogens containing fragments 1 or 2.  
Therefore, the ProT·VWbp complex does not simply require an “enzyme-like” orientation 
of the activation domain between the catalytic residues, oxyanion hole, and substrate-
specificity site, but it also calls for occupation of the S1 site by an appropriate substrate, 
consistent with the hysteretic mechanism of activation. 
The equilibrium binding studies confirm the ability of VWbp to bind to ProT with 
dramatically increased affinity in the presence of a substrate mimic, but the question 
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remains of whether the presence of fragment 1 or 2 has any detectable effect on the 
binding of VWbp with derivatives containing an active catalytic domain.  The design of 
the binding assays with the active ProT derivatives allowed observation of changes in 
fluorescence immediately upon addition of the ProT analog to the [5F]Hir(54-65) and 
VWbp ligand mixture, and most of the assays showed very rapid equilibrium between 
the competing proteins.  The only discrepancies were witnessed upon either addition of 
active MzTQQQ or in situ activation of Pre 1 to MzT(-F1), where a noticeably longer time 
period was required to reach equilibrium and a stable fluorescence change.  Panel A in 
Figure 8 shows two representative fluorescence traces for MzTQQQ binding, with the 
assay containing VWbp(1-474) requiring an additional 40-50 sec to reach equilibrium.  
The fact that VWbp(1-263) does not show a lag indicates that the C-terminal half of 
VWbp has steric opposition from the fragment domains still found on MzT, and that the 
kinetics of binding are affected but not the fundamental equilibrium dissociation constant.  
A slightly different mechanism may be at work during conversion of Pre 1 to MzT(-F1) 
(Fig. 7B), where VWbp(1-263) and VWbp(1-474) both alter the kinetics of activation by 
ecarin to different degrees, compared to Pre 1 in the presence of [5F]Hir(54-65) alone.  
Whether this is a consequence of partial blockage of areas on the zymogen required for 
interaction with ecarin is unknown, but it could also be influenced by conformational 
changes in Pre 1 induced by VWbp which may alter accessibility of the activation bond 
or orientation of the fragment 2 domain.  These findings suggest that the fragment 
domains introduce some degree of hindrance to VWbp, even with an optimal catalytic 
domain and exosite I conformation that ultimately favors high affinity binding. 
Although VWbp can form an active complex with ProT exclusively through NH2-
terminal insertion and substrate-dependent changes in conformation, previous studies 
on both VWbp (15) and staphylocoagulase (13) have identified a pattern of autocatalysis 
consistent with cleavage at two thrombin-sensitive sites.  In the presence of VWbp,  
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Figure 8.  Comparison of fluorescence traces for binding of MzTQQQ or MzT(-F1) by 
VWbp. A, Fluorescence of [5F]Hir(54-65) in the presence of 273 nM VWbp(1-263, 
immediately after addition of 152 nM MzTQQQ (black line), or 353 nM VWbp(1-474) after 
addition of 417 nM MzTQQQ (red line). B, Change in fluorescence of [5F]Hir(54-65) with 
433 nM Pre 1 activated in situ to MzT(-F1) (black line), 143 nM Pre 1 activated in the 
presence of 273 nM VWbp(1-263) ) (blue line), or 639 nM Pre 1 activated in the 
presence of 353 nM of VWbp(1-474) (red line). 
 
 
production of Pre 1 from ProT has been detected in reaction mixtures at both high and 
low concentrations of ProT, with detection of a species called Pre 2’ after extended 
incubations at high ProT concentrations (15).  Both of these species have been 
produced in vitro through autocatalytic release of one or both of the fragment domains of 
ProT through proteolysis by thrombin, but in physiological ProT activation, the rapid 
formation of active MzT(-F1) from MzT by loss of fragment 1 through cleavage at Arg155 
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is the more common pathway of domain release (44-45).  A second site at Arg284 can 
also be targeted, producing the Pre 2’ variant that lacks the first 13 NH2-terminal 
residues normally found in Pre 2 and thrombin (46-47).  The sequential and temporal 
characteristics of cleavage in ProT-VWbp mixtures accurately correspond with what is 
known about the mechanisms of feedback proteolysis in MzT and MzT(-F1), where both 
intramolecular and intermolecular events contribute to formation of proteolysis products 
(44), indicating that the proteolytic activity is consistent with ProT·VWbp exhibiting 
thrombin-like behavior.  Loss of fragment 1 characteristically takes place though direct 
cleavage by the resident active site on each MzT molecule, most likely due to the 
inherent flexibility in the targeted region between the domains, allowing this 
intramolecular process to occur quickly after MzT production.  The much slower time-
course for appearance of Pre 2’ stems from a greater dependence on intermolecular 
proteolysis, originating from a more constrained orientation of the cleavage site that 
limits the possibility for self-cleavage.   
Due to the potential ramifications of autocatalysis of ProT while bound to VWbp, 
generation of the proteolytic intermediates was assessed in human plasma to establish 
whether they can actually be produced in a milieu of physiological ligands.  Because the 
potent procoagulant activity of VWbp leads to fast clotting of plasma, which could 
interfere with complex and ligand accessibility, the reactions were examined in the near-
absence of fibrinogen by using plasma from a congenitally deficient donor and the fibrin 
polymerization inhibitor peptide Gly-Pro-Arg-Pro.  Over a time-course of 1 h, a control 
plasma sample without VWbp did produce a detectable amount of thrombin (not shown), 
which is not unexpected after recalcification of citrated plasma.  Production of thrombin 
was not seen in reactions where a saturating level of VWbp was present, suggesting that 
binding of the activator to the zymogen prevents production of thrombin itself.  
Disappearance of ProT was observed with VWbp(1-474) over time, with corresponding 
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low-level detection of a band the same size as the Pre 1 standard (Fig. 8B).  While the 
results of incubation of plasma with VWbp(1-263) were less dramatic, with a less 
distinguishable Pre 1 band (Fig. 8A), the pattern of cleavage with VWbp is consistent 
with that observed with purified proteins in vitro.  Recognition of the Pre 1 band on the 
blots by the ProT antibody is likely less than expected from the rate of disappearance of 
ProT due to the presence of human serum albumin which migrates at nearly the same 
molecular weight as Pre 1.  This issue will be resolved in future experiments utilizing 
immunoprecipitation of the ProT·VWbp complexes before separation on the gels, and 
the effect of fibrinogen on VWbp-initiated autocatalysis will also be examined in normal 
human plasma. 
If VWbp is capable of eliciting formation of a procoagulant complex with ProT that 
is not only capable of cleaving fibrinogen into fibrin, but also contains the potential to rid 
itself of its regulatory zymogen fragment domains, what implications would this have for 
the pathological capacity of VWbp in a blood-borne staphylococcal infection?  The most 
vital function of fragment 1 for ProT is to mediate binding of the zymogen to the platelet 
membrane, permitting association with factor Xa and factor Va in the prothrombinase 
complex for thrombin production.  If VWbp can bind to membrane-bound ProT, as well 
as free ProT in the blood, premature release of high affinity procoagulant Pre 1*·VWbp 
complexes from platelet membranes could occur in a pathological dissemination 
mechanism (32).  This would have the amplified effect of liberating serpin-insensitive 
protein complexes to downstream locations where they could freely associate with both 
von Willebrand factor and fibrinogen, setting up new foci for fibrin deposition and 
bacterial colonization.  In addition to the role of VWbp on the activity of the complexes, 
indirect effects related to other regulatory ligands would also occur, including blockage of 
all exosite I-specific ligands by the presence of VWbp and a reduction in exosite II 
interactions from the presence of either fragment 1.2 or fragment 2.  The end result 
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would be ProT·VWbp or Pre1·VWbp complexes with thrombin-like activity that are nearly 
impervious to inhibition or downregulation, but exhibit high specificity for the single 
substrate fibrinogen, due to the driving force of the substrate-mediated mechanism of 
VWbp zymogen activation. 
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Determination of molecular weights of VWbp and ProT·VWbp 
 Molecular weights (MW) of VWbp(1-263), VWbp(1-474), and Oregon Green-488-
FPR-prothrombin ([OG]FPR-ProT) were determined separately and for a 1:1 ProT·VWbp 
complex by sedimentation velocity in a Beckman-Coulter XL-1 Analytical Ultracentrifuge 
(Dr. Cynthia Peterson, University of Tennessee-Knoxville).  Continuous interference 
scans were collected for ~4 h at 50,000 rpm, 25-26 oC, and the refractive index data was 
used to calculate the approximate MW in SEDFIT v10.3 (Peter Schuck, NIH).  
Parameters used in analysis included:  buffer viscosity, density = 0.01014, 1.00326; 
calculated partial specific volumes = 0.7241 (ProT), 0.7322 (VWbp(1-263)), 0.7278 
(VWbp(1-474)).  VWbp(1-263), VWbp(1-474), and [OG]FPR-ProT were prepared for 
analysis by simultaneous dialysis against two changes (4 L each) of 50 mM HEPES, 110 
mM NaCl, 5 mM CaCl2, pH 7.4, for at least 6 h before each change to ensure complete 
equilibration of the same buffer for all three proteins.  Concentrations were measured by 
absorbance at 280 nm, and proteins were stored at -80 oC until use. 
 Empirical molecular masses of the two VWbp constructs were in good agreement 
with the theoretical values calculated from the amino acid compositions, giving values of 
33 kDa for VWbp(1-263) and 56 kDa for VWbp(1-474) (calculated values = 31 kDa and 
55 kDa).  Native ProT has an empirical molecular mass of 72 kDa, and the value for 
[OG]FPR-ProT was nearly identical (74 kDa, Fig. 1S A). An equimolar mixture of 
VWbp(1-263) and [OG]FPR-ProT gave a molecular mass of 108 kDa for the complex 
(Fig. 1S B, theoretical = 103 kDa), with no indication of any unassociated protein, 
indicating that the NH2-terminal half of VWbp is able to form a 1:1 complex with ProT.  
Identical stoichiometry was found for an equimolar reaction of VWbp(1-474) and 
[OG]FPR-ProT, resulting in a complex of 125 kDa (theoretical = 130 kDa).  These 
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stoichiometries support the values calculated through equilibrium binding and confirm 
that ProT·VWbp complexes do not dimerize in solution. 
 
 
Figure 1S.  Approximate molecular masses and sedimentation coefficient 
distributions (c(s)) from sedimentation velocity experiments.  (A) c(s) distribution for 
Oregon Green-488-FPR-prothrombin (0.3 mg/mL).  (B) c(s) distribution for a mixture of 
Oregon Green-488-FPR-prothrombin (4.2 μM) and VWbp(1-263) (4.2 μM). 
 
 
Preliminary fluorescence equilibrium binding experiments 
 The following experimental results represent preliminary analyses of the binding 
of VWbp to native and active site-blocked (FPR-) ProT derivatives.  The significant 
enhancement of affinity upon active site-inhibition made it impossible to use a single 
 108
experimental design for all the analogs, due to the necessity for a fluorescent reporter 
which bound in the same range of affinity as the targeted competitive ligand.  For 
example, fluorescently-labeled ProT (Oregon Green-488-FPR-ProT) successfully 
reported high-affinity binding (KD ~2 pM) of VWbp(1-263), but the relatively weak KD of 
native ProT for VWbp(1-263) (KD 2.5 μM) precluded its use as a competitive binding 
ligand.  In contrast, the observation that VWbp could bind other proteolytic derivatives of 
ProT (e.g., Pre 1 and thrombin) with higher affinity allowed initial characterization of their 
affinities using similar experimental designs.  Preliminary analysis of binding of VWbp(1-
474) was also possible due to a change in the intrinsic (tryptophan) fluorescence of 
native ProT.   
Competitive equilibrium binding of VWbp(1-263) to [OG]FPR-ProT and native/FPR-Pre 1 
 Single-point fluorescence measurements were taken of mixtures of [OG]FPR-
ProT and VWbp(1-263) and varying concentrations of native Pre 1 (Fig. 2S A) or FPR-
Pre 1 (Fig. 2S B).  VWbp bound native Pre 1 with an ~280-fold weaker affinity (KD 565  
 
 
A B 
Figure 2S.  Binding of VWbp(1-263) to 102 pM [OG]FPR-ProT and native or FPR-
Pre 1.  The fractional change in fluorescence (∆F/Fo) as a function of total Pre 1 
concentration. (A) Native Pre 1 with 1 nM (●) and 7 nM (○) VWbp.  (B) FPR-Pre 1 with 1 
nM (●),7 nM (○), and 72 nM (▲) VWbp.  The lines represent the simultaneous fit by the 
cubic competitive binding equation. 
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pM) than FPR-Pre 1 (KD 2 pM), but the relatively weak KD for native Pre 1 resulted in  
poorly-determined complex stoichiometry.  In addition, an extended time was required to  
reach equilibrium in the native assays, which introduced the potential for proteolysis in 
the reaction mixtures.  This indicated that native Pre 1 was not able to successfully 
compete with the fluorescently-labeled ProT analog, and as such, could not be 
investigated with this experimental design. 
Competitive equilibrium binding of VWbp(1-263) and [5F]Hir(54-65) to FPR-ProT 
 Titrations of FPR-ProT were performed in the presence of [5F]Hir(54-65) and 
several set concentrations of VWbp(1-263) (Fig. 3S).  Global analysis of the data 
resulted in excellent stoichiometry (0.96 ± 0.01), but very poor determination of the KD 
for VWbp and FPR-ProT (0.80 ± 1.09 nM).  Simulation of additional higher values for KD 
(up to 10 nM) gave fit lines nearly identical to each other, indicating that the true affinity 
could not be determined.  This was likely a result of the over 100-fold difference in  
affinity between VWbp and [5F]Hir(54-65) for FPR-ProT, which excluded the use of the 
labeled hirudin as a competitive ligand in this system. 
Competitive equilibrium binding of VWbp(1-263) and [5F]Hir(54-65) to native or FPR-T 
Titrations of either native T (Fig. S4A) or FPR-T (Fig. 4S B) were performed in 
the presence of [5F]Hir(54-65) and several fixed concentrations of VWbp(1-263).  Global 
analysis of the data gave essentially indistinguishable affinities for the native (KD 1.8 ± 
0.9 nM) and FPR-blocked analog (KD 750 ± 0.2 pM), and complex stoichiometries of 
about 1.  This result was the first confirmation of the very high affinity of VWbp for the 
active enzyme, and revealed that competition with the fluorescently-labeled hirudin 
peptide could be successfully carried out with all of the native prothrombin derivatives.  
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 Figure 3S.  Binding of VWbp(1-263) and 48 nM [5F]Hir(54-65) to FPR-ProT.  The 
fractional change in fluorescence (∆F/Fo) as a function of total FPR-ProT concentration 
at 0 (●), 3.5 (○), and 7.5 μM (▲) VWbp.  The solid lines represent the simultaneous fit by 
the cubic competitive binding equation, and the dotted line simulates a KD of 10 nM. 
 
 
 
Figure 4S.  Binding of VWbp(1-263) and 48 nM [5F]Hir(54-65) to native or FPR-T.  
The fractional change in fluorescence (∆F/Fo) as a function of total T concentration. (A) 
Native T with 0 (●), 1 (○), and 2 μM (▲) VWbp.  (B) FPR-T with 0 (●), 3 (○), and 6 μM 
(▲) VWbp.  The lines represent the simultaneous fit by the cubic competitive binding 
equation. 
 
 
Direct equilibrium binding of VWbp(1-474) to native or FPR-ProT 
 ProT contains several tryptophan residues within its fragment and catalytic 
domains which fundamentally contribute to the intrinsic fluorescence of the protein with 
excitation at 295 nm.  The structural changes associated with prothrombin activation and 
 111
membrane binding have been shown to affect the magnitude of the intrinsic tryptophan 
fluorescence (48-49), and preliminary observations with VWbp(1-474) demonstrated a 
concentration-dependent change in native ProT fluorescence upon binding of VWbp.  
Consequently, this experimental approach was used to determine the affinity of VWbp(1-
474) for both native ProT (Fig. 5S A) and FPR-ProT (Fig. 5S B).  Titrations with VWbp(1-
474) and native ProT gave a relatively tight KD (31 nM) compared to that of VWbp(1-263) 
in competitive binding assays with [5F]Hir(54-65) (KD 2.5 μM), supporting kinetic data 
which showed higher activity of VWbp(1-474) with native ProT.  A comparable titration 
with VWbp(1-474) and FPR-ProT revealed extremely tight binding of the ligand, but due 
to the experimental noise inherent in tryptophan fluorescence, simulation of multiple 
values for the KD (1-15 nM) gave no indication of the true affinity value.  Unfortunately, 
no change in tryptophan fluorescence was observed in mixtures of VWbp(1-263) and 
native ProT, preventing direct comparison of the two VWbp constructs and implying that 
a higher affinity interaction was needed to change the environment of the target 
tryptophan enough to affect the fluorescence.   
 
 
Figure 5S.  Binding of VWbp(1-474) to native or FPR-Pre 1.  The fractional change in 
fluorescence (∆F/Fo) at λex = 295 nm and λem = 335 nm.  (A) Increasing [VWbp] at 50 nM 
(●), 250 nM (○), and 1 μM (▲) native ProT.  (B) Increasing [VWbp] at 250 nM (●) VWbp.  
The lines represent the simultaneous fit by the quadratic binding equation. 
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Abstract 
The specificity of thrombin for procoagulant and anticoagulant substrates is 
regulated allosterically by Na+. Ordered cleavage of prothrombin (ProT) at Arg320 by the 
prothrombinase complex generates proteolytically active, meizothrombin (MzT), followed 
by cleavage at Arg271 to produce thrombin and fragment 1.2.  The alternative pathway of 
initial cleavage at Arg271 produces the inactive zymogen form, the prethrombin 2 (Pre 2)-
fragment 1.2 complex, which is cleaved subsequently at Arg320.  Cleavage at Arg320 of 
ProT or prethrombin 1 (Pre 1) activates the catalytic site and the precursor form of 
exosite I (proexosite I).  To determine the pathway of expression of Na+-(pro)exosite I 
linkage during ProT activation, the effects of Na+ on the affinity of fluorescein-labeled 
hirudin-(54-65) ([5F]Hir-(54-65)(SO3-)) for the zymogens, ProT, Pre 1, and Pre 2, and for 
the proteinases, MzT and MzT-des-fragment 1 (MzT(-F1)) were quantitated.  The 
zymogens showed no significant linkage between proexosite I and Na+, whereas 
cleavage at Arg320 enhanced the affinities of MzT and MzT(-F1) for [5F]Hir-(54-65)(SO3-) 
8-10 fold and 5-6-fold, respectively.  MzT and MzT(-F1) showed kinetically different 
mechanisms of Na+ enhancement of chromogenic substrate hydrolysis. The results 
demonstrate for the first time that MzT is regulated allosterically by Na+. The results 
suggest that the distinctive procoagulant substrate specificity of MzT in activating factor 
V and factor VIII on membranes, and the anticoagulant, membrane-modulated activation 
of protein C by MzT bound to thrombomodulin are regulated by Na+-induced allosteric 
transition.  Further, the Na+ enhancement in MzT activity and exosite I affinity may 
function in directing the sequential ProT activation pathway by accelerating thrombin 
formation from the MzT fast form. 
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Introduction 
 The blood coagulation proteinase, thrombin, is generated after cleavage of two 
peptide bonds in its zymogen precursor, prothrombin (ProT)1, by the membrane-bound 
factor Xa-factor Va (prothrombinase) complex (1).  The rate of thrombin generation from 
ProT catalyzed by factor Xa alone is accelerated ~300,000-fold by calcium ion-
dependent assembly of factor Xa with its protein cofactor, factor Va.  Factor Va in the 
prothrombinase complex directs the order of peptide bond cleavage in the activation 
pathway, resulting in sequential cleavage of ProT first at Arg320 in the catalytic domain to 
form the catalytically active intermediate, meizothrombin (MzT), followed by cleavage at 
Arg271 between the catalytic domain and ProT fragment 1.2 to produce the reaction 
products, thrombin and fragment 1.2 (2-7).  In the absence of factor Va, the alternative, 
slower pathway of bond cleavage predominates, in which initial cleavage at Arg271 forms 
the inactive intermediate prethrombin 2 (Pre 2), bound noncovalently to fragment 1.2, 
followed by cleavage at Arg320 to form thrombin.  Recent studies of the sequential 
pathway of ProT activation indicate that substrates are bound to prothrombinase in two 
alternate conformations that present the two peptide bonds sequentially to factor Xa for 
cleavage (7-14).  Conformational changes accompanying catalytic site expression in the 
conversion of ProT to MzT direct the activation pathway by switching substrate bound to 
prothrombinase between alternate zymogen and proteinase conformations (8). 
  On conversion of ProT to thrombin, two electropositive surface sites, exosites I 
and II, become expressed on thrombin, which provide recognition sites for specific 
physiological substrates, inhibitors, and regulatory molecules (7, 15-18).  Exosite I 
mediates fibrinogen and protease activated receptor-1 and -4 substrate interactions, 
fibrin binding, and binding of the COOH-terminal hirudin-(54-65) peptide (Hir-(54-
65)(SO3-)).  Exosite II binds heparin and the fragment 2 domain of ProT.  Both exosites 
are involved in factor V and VIII activation, glycoprotein Ib binding, thrombomodulin 
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binding, and inactivation of thrombin by heparin cofactor II (15-18).  The substrate 
specificity of MzT is different from that of thrombin, in that it exhibits ≤10% activity toward 
fibrinogen and ≤2% activity in activating platelets (19-20).  MzT, however, is a potent 
procoagulant activator of factor V and factor VIII in reactions that are dependent on 
phospholipid membranes (21-22).  MzT bound to thrombomodulin activates the 
anticoagulant, protein C, at a rate equal to or greater than thrombin. Protein C activation 
by thrombomodulin-bound MzT is also stimulated by membranes (19-20). 
Exosite I interactions are allosterically linked to binding of a single sodium ion to 
thrombin (23-24).  Binding of Na+ converts thrombin from a “slow” to a “fast” form (25).  
The fast form has higher catalytic efficiency (kcat/Km) for the procoagulant substrates, 
fibrinogen and protease activated receptor-1, greater reactivity toward antithrombin, and 
increased amidolytic chromogenic substrate activity, notably towards D-Phe-Pro-Arg-
pNA (15, 24).  Alanine substitution mutagenesis and analysis of high resolution crystal 
structures of the fast and slow forms in their free states have identified four structural 
features critical to the allosteric transition to the fast form (23, 26-28): (a) alignment of 
residues stabilizing the Na+ binding site; (b) a change in orientation of Asp189 in the 
primary substrate specificity site; (c) a shift in the Glu192 side chain that links a network of 
water molecules to Ser195; and; (d) a change in Ser195 orientation, all of which optimize 
catalysis.  Comparison of these structures with those of thrombin either inactivated with 
the transition state analog, D-Phe-Pro-Arg-CH2Cl (FPR-CH2Cl), or in which exosite I is 
occupied by the COOH-terminal hirudin peptide, hirugen (hirudin-(53-64)), show that 
thrombin adopts the fast conformation in these complexes (27, 29). Recent structural 
studies (30-31), consistent with kinetic studies of Na+ binding (31-33), suggest that the 
catalytically active Na+-free slow form is in  equilibrium with a low level of an inactive 
thrombin in which the catalytic site and Na+ site are occluded. 
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Previous studies of exosite I expression on ProT activation intermediates 
characterized a precursor form of exosite I on ProT (proexosite I), with a ~100-fold lower 
affinity for the model exosite I-specific ligand Hir-(54-65)(SO3-) (34-36).  Removal of 
fragment 1 from ProT to form prethrombin 1 (Pre 1) is accompanied by a ~7-fold 
increase in proexosite I affinity (35).  The further 11-20-fold increase in affinity, 
representing full exosite I expression, occurs in concert with expression of catalytic 
activity during formation of MzT and thrombin (35-36).  Quantitative analysis of binding 
of the ProT activation fragments 2 and 1.2 to exosite II on Pre 2 and thrombin indicates 
that this exosite becomes unmasked upon cleavage at Arg271 and subsequent 
dissociation of the fragments (35-36).  How linkage between the Na+ site and 
(pro)exosite I is expressed during ProT activation has not been investigated. 
In the present studies, fluorescein-labeled Hir-(54-65)(SO3-) ([5F]Hir-(54-65)(SO3-
)) was used as a (pro)exosite I-specific probe to examine the linkage between Na+ 
binding and (pro)exosite I affinity (34-37). The goal was to determine if Na+ regulates the 
affinity of proexosite I for ProT, Pre 1, and Pre 2 zymogen forms, and the catalytically 
active intermediates of ProT and Pre 1 activation, MzT and meizothrombin des-fragment 
1 (MzT(-F1)), respectively.  The results demonstrate no significant effect of Na+ on ProT, 
Pre 1, or Pre 2 proexosite I affinity for [5F]Hir-(54-65)(SO3-).  Allosteric linkage between 
Na+ binding and exosite I affinity occurred concomitantly with activation to MzT and 
MzT(-F1). The Na+ enhancement of the rate of chromogenic substrate hydrolysis for 
MzT compared to MzT(-F1) and thrombin, however, followed a kinetically different 
mechanism. The results demonstrate for the first time that MzT and MzT(-F1) are 
allosterically regulated by Na+-exosite I interactions, suggesting that the unique 
substrate specificity of MzT may be Na+-regulated. 
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Experimental Procedures 
Protein and Peptide Purification and Characterization 
Human ProT, factor Xa, and thrombin were purified and characterized as 
described previously (38-39).  Pre 1 was purified from products of ProT cleavage by 
thrombin (38).  FPR-MzT(-F1) was prepared by activation of 20 µM Pre 1 with 2 units/ml 
(based on the manufacturers specifications) of purified ecarin from Echis carinatus 
venom (Sigma) in the presence of a 10-fold excess of FPR-CH2Cl (40).  FPR-MzT was 
prepared from ProT at the same reactant concentrations followed by chromatography on 
Resource Q (Amersham) in 20 mM sodium citrate buffer, pH 6.0.  The column was 
washed with 10 ml of equilibration buffer, and eluted with a 50 ml NaCl gradient in the 
same buffer up to 0.5 M to remove ecarin.  Pre 2 was purified from factor Xa-ProT 
activation reactions as described (36).  The R155A substitution mutant of ProT 
(ProTR155A) was prepared as described (21). Protein concentrations were determined by 
absorbance at 280 nm using the following absorption coefficients ((mg/ml)-1cm-1) and 
molecular weights (4, 41-42): ProT, ProTR155A, and FPR-MzT, 1.47, 71,600; Pre 1 and 
FPR-MzT(-F1), 1.78, 49,900; Pre 2, 1.73, 37,000; and thrombin, 1.74, 36,600.  [5F]Hir-
(54-65)(SO3-) was prepared as described previously (37). 
Fluorescence Titrations 
Binding of [5F]Hir-(54-65)(SO3-) was measured by titrating the labeled peptide 
with the protein of interest and monitoring the change in fluorescence at 520 nm with 
excitation at 491 nm (4 nm or 8 nm band passes), using acrylic cuvettes coated with 
polyethylene glycol (PEG) 20,000.  Fluorescence changes expressed as (Fobs-
Fo)/Fo=F/Fo, as a function of total protein concentration were fit by the quadratic binding 
equation to obtain the maximum fluorescence change ((Fmax-Fo)/Fo=Fmax/Fo), and the 
dissociation constant (KD), with the stoichiometric factor fixed at 1(37).  Fluorescence 
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measurements were corrected for background signal by subtraction of a buffer blank, 
and for dilution, which was not more than 10%. 
Exosite Linkage Analysis   
The effect of Na+ on binding of [5F]Hir-(54-65)(SO3-) to (pro)exosite I was 
characterized in fluorescence titrations with ProT species in 50 mM Tris-Cl, 110 mM 
NaCl or 110 mM Choline Cl (ChCl), 5 mM CaCl2, 1 mg/ml PEG 8000, pH 7.4 at 25 oC.  
Linkage between Na+ and [5F]Hir-(54-65)(SO3-) (H) binding to thrombin, MzT(-F1), and 
MzT (designated P) was analyzed according to the thermodynamic cycle in Scheme 1, 
where Na+ binding affects the affinity of peptide binding and vice versa. 
 
 
   P + H                       P•H 
      +                             + 
     Na+                          Na+ 
 
 
 P•Na+ + H                    P•Na+
KH,Ch 
 
 
Scheme 1. 
 
Because of the relatively small differences in fluorescence between titrations in NaCl 
and ChCl, it was not possible to determine accurately the dissociation constant for Na+ 
binding from the Na+ concentration dependence at a fixed thrombin concentration.  
Titrations in 110 mM NaCl and 110 mM ChCl were fit independently by the quadratic 
binding equation to obtain the maximum fluorescence change Fmax, PH/Fo and KH, Ch from 
the titration in ChCl, and Fmax, PNaH/Fo and KH, Na from the titration in the presence of 
NaCl.   
Kinetic and Endpoint Fluorescence Titrations  
To quantitate the effects of Na+ on binding of [5F]Hir-(54-65)(SO3-) to exosite I on 
active MzT(-F1) and MzTR155A, it was necessary to employ a kinetic approach to 
 KNa,P KNa,PH 
•H 
KH, Na 
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separate the ecarin-catalyzed formation of MzT(-F1) and MzTR155A from slower 
autocatalytic cleavages that process the products further (43).  Experiments were 
performed for Pre 1 by measuring Fo for 20 nM [5F]Hir-(54-65)(SO3-), the instantaneous 
decrease in fluorescence on addition of Pre 1 due to peptide binding to (pro)exosite I, 
and the time dependence of the subsequent fluorescence decrease initiated by addition 
of 2 units/ml of ecarin.  The ecarin-initiated fluorescence time-courses were fit by the 
sum of a single exponential decay and a straight line to determine the fluorescence 
endpoint corrected for any slow linear drift, and the results were expressed as F/Fo.  
For analysis of the progress curves, the integrated Michaelis-Menten equation was used 
to represent the ecarin (E)-catalyzed conversion of Pre 1 or ProTR155A (C) into MzT(-F1) 
or MzTR155A (P), respectively (Scheme 2).  Comparison of this analysis with the 
integrated rate equation including competitive product inhibition showed no evidence for 
product inhibition with MzT(-F1), while including product inhibition for MzTR155A improved 
the fit modestly. 
 
Km Vmax 
 
 
   E + C                    E•C                   E + P Scheme 2. 
 
Under the experimental conditions used, the fluorescence change accompanying 
peptide (H) binding is not a linear function of the concentration of P or C.  Moreover, 
these species compete for the peptide, and binding is accompanied by unequal 
fluorescence changes for the P•H and C•H complexes (Scheme 3).  To analyze the time 
courses, the cubic competitive binding equation derived previously for Scheme 3 (44) in 
combination with the integrated Michaelis-Menten equation was used for nonlinear least-
squares fitting.  Fluorescence versus time data collected as a function of the 
concentration of C (Pre 1) in NaCl- or ChCl-containing buffers were analyzed with the 
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parameters determined independently for H ([5F]Hir-(54-65)(SO3-)) binding to C (Pre 1) 
fixed.  The fitted parameters were the maximum fluorescence change for the  
 
     
     H +  P                    P•H 
     + 
     C   
 
 
    C•H  
 
 
 
Scheme 3. 
 
MzT(-F1)•[5F]Hir-(54-65)(SO3-) complex (Fmax, PH/Fo), KP,H , Km, and Vmax.  The 
fluorescence and binding parameters determined from this analysis were compared to 
those obtained by fitting of the quadratic binding equation to the reaction endpoints as a 
function of C (Pre 1) concentration determined in a model-independent manner by the 
exponential fit described above.  The same approaches were used in kinetic and 
endpoint titrations of the activation of ProTR155A to MzTR155A by ecarin and FPR-MzT(-F1) 
from activation of Pre 1 in the presence of 24 µM FPR-CH2Cl.  The presence of 20 nM 
[5F]Hir-(54-65)(SO3-) in these reactions did not influence the results because ≤6 % of the 
total Pre 1 or ProTR155A was bound at any time, over the protein concentration range 
studied. 
Pre 1 Activation Assay 
 Assays specific for MzT(-F1) were performed by modifications of the published 
methods (2, 5).  This approach enables differential measurement of thrombin and MzT(-
F1) based on the much faster rate of thrombin inactivation by antithrombin-heparin 
complex compared to MzT(-F1).  Aliquots of activation reactions of Pre 1 in the buffers 
containing NaCl or ChCl initiated at 25 oC by addition of ecarin were quenched by 
dilution to 10 nM Pre 1 in 250 mM Hepes, 150 mM NaCl, 75 mM EDTA, 1 mg/ml PEG 
8000, pH 7.70 (for NaCl reactions) or 250 mM Hepes, 590 mM NaCl, 75 mM EDTA, 1 
 
 
KP,H 
Fmax, PH/Fo 
Fmax, CH/Fo KC,H 
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mg/ml PEG 8000, pH 7.65 (for ChCl reactions) containing 50 nM antithrombin and 18 
µg/ml heparin (Sigma) for exactly 30 s.  An aliquot of the quenched reaction was diluted 
tenfold in 50 mM Hepes, 125 mM NaCl, 1 mM EDTA, 1 mg/ml PEG 8000, pH 7.4 
containing 100 µM D-Phe-Pip-Arg-pNA, and the initial rate of chromogenic substrate 
hydrolysis was measured from the linear increase in absorbance at 405 nm.  Thrombin 
was confirmed to be >99.9% inactivated during the 30 s quenching time.  To correct for 
the differences in kinetic parameters of thrombin and MzT(-F1) and the small loss of 
MzT(-F1) during quenching, the rates obtained for Pre 1 fully activated by incubation 
with 2 units/ml ecarin for 60 min were measured as a function of time after quenching, 
relative to an equivalent concentration of thrombin.  Extrapolation of the slow, linear 
decrease in MzT(-F1) activity with time due to antithrombin-heparin inactivation and 
possible autocatalytic thrombin formation to zero-time was taken to represent the total 
MzT(-F1) concentration.  The extrapolated chromogenic substrate activity of MzT(-F1) 
relative to thrombin was determined to be 1.21 and 1.23 in the NaCl and ChCl 
experiments, respectively, and the correction for loss of MzT(-F1) activity was 10% and 
6% in the NaCl and ChCl experiments, respectively 
Na+ Dependence of Chromogenic Substrate Hydrolysis 
 Initial rates of hydrolysis of 200 µM (saturating) D-Phe-Pip-Arg-pNA were 
measured at 25 oC as a function of Na+ concentration using mixtures of buffers 
containing 110 mM NaCl or ChCl.  These experiments measured the Na+ dependence of 
kcat, reflecting Na+ binding to the enzyme-substrate complex. The initial rates at zero and 
saturating Na+ concentration, and the apparent KD for Na+ binding were obtained by 
least-squares fitting of the hyperbolic titrations. To estimate the affinities of Na+ for the 
free enzymes, kcat, Km, and Ki for product were determined by full progress curve 
analysis of D-Phe-Pip-Arg-pNA hydrolysis as a function of Na+ concentration (45). Five 
progress curves at 5-15 µM substrate were fit simultaneously to obtain the kinetic 
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parameters. The KD for Na+ binding to thrombin and MzT(-F1) was obtained by fitting the 
hyperbolic dependence of kcat/Km on Na+ concentration (45).  In the case of MzTR155A for 
which this was not possible, an estimate of the KD for Na+ binding to the free enzyme 
was obtained from the dependence of the observed Km (Km obs) on Na+ concentration, 
where Km was assumed to be equivalent to the dissociation constant for substrate 
binding. Equation 1 described by Segel (46) for the rapid equilibrium, nonessential 
activator mechanism was fit to the data to obtain Km, KNa, and α, which represents the 
linkage factor by which KNa is changed by substrate binding. 
 
o
o
[Na]1
[Na]1
Na
m obs m
Na
K
K K
K
      
  Eqn. 1 
 
Results 
Na+-exosite I Linkage for ProT Zymogen Forms   
To assess the linkage between Na+ binding and proexosite I, the effect of Na+ on 
the affinity of proexosite I for the 5-fluorescein-labeled Tyr63-sulfated hirudin-(54-65) 
peptide ([5F]Hir-(54-65)(SO3-)) was determined in fluorescence titrations in buffers 
containing 110 mM NaCl or 110 mM ChCl at constant 0.17 M ionic strength.  As shown 
in Figure 1, ProT, Pre 1, and Pre 2 bound the peptide with virtually the same affinity in 
NaCl and ChCl.  Although the titrations consistently showed a small increase in affinity 
by Na+ (1.3-1.6-fold), this was within the experimental error of the binding parameters 
(Table I). 
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Figure 1.  Effect of Na+on [5F]Hir-(54-65)(SO3-) binding to ProT zymogen forms.  
Changes in fluorescence (F/Fo) of 50 nM [5F]Hir-(54-65)(SO3-) as a function of the total 
concentrations of A, ProT ([ProT]o), B, Pre 1 ([Pre 1]o), and C, Pre 2 ([Pre 2]o) are shown 
for experiments in buffers containing NaCl (●) or ChCl (○).  The solid lines represent the 
nonlinear least-squares fits by the quadratic binding equation with the parameters listed 
in Table I.  Titrations were performed and analyzed as described in “Experimental 
Procedures”. 
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Na+-exosite I Linkage for Thrombin and FPR-thrombin  
As expected, thrombin affinity for [5F]Hir-(54-65)(SO3-) increased 5.6-fold from 
dissociation constants of 270 ± 20 nM in the absence of Na+ to 48 ± 4 nM in NaCl (Fig. 
2, Table I).  Inactivation of thrombin with FPR-CH2Cl virtually obliterated the effect of Na+ 
on affinity and normalized the dissociation constants in the presence and absence of 
Na+ to values indistinguishable from those of the fast form of native thrombin (Fig. 2, 
Table I). 
 
 
Figure 2. Effect of Na+ on [5F]Hir-(54-65)(SO3-) binding to thrombin and FPR-
thrombin.  Titrations of the change in fluorescence (F/Fo) of 20 nM [5F]Hir-(54-
65)(SO3-) as a function of total concentrations of FPR-thrombin or thrombin ([FPR-T or 
T]o).  Titrations with native thrombin in buffers containing NaCl (●) or ChCl (○), and FPR-
thrombin in NaCl (▲) or ChCl ().  The solid lines represent the non-linear least-squares 
fit by the binding equation with the parameters listed in Table I. Titrations were 
performed and analyzed as described in “Experimental Procedures”. 
 
 
Analysis of Na+-exosite I Linkage for MzT(-F1) 
MzT and MzT(-F1) are unstable in their active forms as a result of autocatalytic 
cleavage (43).  To characterize the effect of Na+ on active MzT(-F1), a kinetic approach 
was used to quantitate [5F]Hir-(54-65)(SO3-) binding to MzT(-F1) during its generation by 
ecarin activation of Pre 1 (see “Experimental Procedures”).  The integrated Michaelis-
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Menten equation was used to calculate the full time-course of ecarin-catalyzed MzT(-F1) 
formation.  The fluorescence change accompanying peptide binding is not a linear 
function of MzT(-F1) or Pre 1 concentration, and it was also necessary to account for the 
fluorescence changes due to competitive [5F]Hir-(54-65)(SO3-) binding to Pre 1 as its  
concentration decreased during the reaction.  A binding equation for a model in which 
two ligands (Pre 1 and MzT(-F1)) bind competitively to a common fluorescent acceptor 
([5F]Hir-(54-65)(SO3-)) with unequal fluorescence changes (44) was used to convert the 
fluorescence data into the concentrations of MzT(-F1) and Pre 1 with time.  Figure 3 
shows fluorescence traces in reaction mixtures containing NaCl or ChCl during 
activation of 1 µM Pre 1 by ecarin in the presence of 20 nM [5F]Hir-(54-65)(SO3-).  The 
initial decrease in fluorescence corresponds to binding of the peptide to Pre 1 and the 
subsequent time-dependent decrease to generation of a product with a higher affinity for 
the peptide.  To validate the experiments, a chromogenic substrate assay which enables 
quantitation of MzT(-F1) formation in the presence of thrombin was used to follow MzT(-
F1) formation.  Progress curves of MzT(-F1) generation in the absence and presence of 
Na+ were in good agreement with the calculated progress curves (Fig. 3). 
To confirm that the product of Pre 1 activation was MzT(-F1), SDS-gel time-
courses were done under the same experimental conditions in the absence and 
presence of Na+ (Fig. 4).  The reduced samples showed the disappearance of Pre 1 and 
formation of the MzT(-F1) B-chain and fragment 2-A-chain.  The nonreduced samples 
showed a single band representing Pre 1 and co-migrating MzT(-F1) for at least 20 min, 
corresponding to the longest activation reactions performed (Fig. 4).  Traces of thrombin 
only appeared after 40 min incubation in the reaction mixture containing Na+ as can be 
seen by the faint band around 36,000 molecular weight in Figure 4A.  The results  
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Figure 3.  Time courses of [5F]Hir-(54-65)(SO3-) fluorescence changes and MzT(-
F1) activity accompanying activation of Pre 1 by ecarin.  A. The initial change in 
fluorescence (F/Fo) of 20 nM [5F]Hir-(54-65)(SO3-) on addition of 1 µM Pre 1 and the 
subsequent time-course of the fluorescence change initiated by 2 units/ml ecarin (○) are 
shown for a reaction in the presence of Na+.  The solid line represents is the nonlinear 
least-squares fit of the data by the model described in “Experimental Procedures” with 
the parameters obtained from the simultaneous analysis of the progress curves as a 
function of Pre 1 concentration listed in Table I.  The time-course of MzT(-F1) formation 
([MzT(-F1)]o) measured by activity assays (●) is shown with the progress curve (solid 
line) calculated with the same parameters listed in Table I.  B. Progress curves of the 
fluorescence change (○) and increase in MzT(-F1) concentration measured by activity 
(●) are shown for reactions in ChCl, with the other conditions as described in A.  The 
lines represent the fits of the fluorescence data with the parameters determined from 
simultaneous analysis of progress curves in ChCl listed in Table I, and the calculated 
progress curve of MzT(-F1) formation using the same parameters.  Fluorescence and 
activity measurements, and data analysis were performed as described under 
“Experimental Procedures”. 
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Figure 4. Time courses of Pre 1 activation monitored by SDS gel-electrophoresis.  
A and B. Activation of 1 µM Pre 1 initiated with 2 units/ml ecarin in buffer containing 
NaCl.  Aliquots (~1 µg) were removed at the indicated reaction times, denatured under 
non-reducing (A) or reducing (B) conditions, and analyzed using 4-15% SDS gradient 
gels.  Protein-stained bands corresponding to Pre 1, the MzT(-F1) B-chain (B), and 
fragment 2-A-chain (F2-A) are indicated for the reduced samples.  Migration of 
molecular weight markers is indicated by the molecular weights in thousands.  C and D. 
SDS gel-electrophoresis of non-reduced (C) and reduced (D) samples from Pre 1 
activation in buffer containing ChCl as described in A and B.  Reactions were performed 
as described under “Experimental Procedures”. 
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demonstrated that the observed fluorescence changes were well described by [5F]Hir-
(54-65)(SO3-) binding with increased affinity for MzT(-F1), and that the results could be 
analyzed quantitatively. 
Regulation of MzT(-F1) Exosite I Affinity by Na+  
Fluorescence-monitored time-courses at varied Pre 1 concentration in NaCl or 
ChCl (Fig. 5A and 5C) were fit simultaneously as described in “Experimental 
Procedures”.  The independently determined dissociation constant and maximum 
fluorescence change for [5F]Hir-(54-65)(SO3-) binding to Pre 1 (see Fig. 1) were fixed 
parameters, whereas Km and Vmax for the ecarin catalyzed reaction, the maximum 
fluorescence change, and the dissociation constant for labeled peptide binding to MzT(-
F1) were fitted parameters.  The Km and Vmax for MzT(-F1) formation were 128 ± 8 nM 
and 2.1 ± 0.03 nM/s in NaCl and 470 ± 60 nM and 2.9 ± 0.2 nM/s in ChCl.  [5F]Hir-(54-
65)(SO3-) bound to MzT(-F1) with a dissociation constant of 210 ± 5 nM in ChCl, which 
was decreased 5.1-fold to 41 ± 1 nM in NaCl, with indistinguishable changes in 
fluorescence (Table I). 
Model-independent values for the affinity and fluorescence change maxima for 
MzT(-F1) were obtained by fitting of the quadratic binding equation to the reaction 
endpoints, representing a titration of [5F]Hir-(54-65)(SO3-) with MzT(-F1) (Fig. 5B and 
5D).  The parameters from this analysis were in excellent agreement with those obtained 
for the kinetic analysis, and indicated that the affinity of exosite I for [5F]Hir-(54-65)(SO3-) 
increased 5.7-fold in the presence of Na+ (Table I). 
Na+-exosite I Linkage for FPR-MzT and FPR-MzT(-F1)   
As was the case for FPR-thrombin, FPR-MzT and FPR-MzT(-F1) had essentially 
the same affinities for [5F]Hir-(54-65)(SO3-) determined in direct titrations in the absence 
and presence of Na+ (Fig. 6).  The dissociation constants corresponded closely to the 
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Figure 5.  Kinetic and endpoint titrations of [5F]Hir-(54-65)(SO3-) binding to MzT(-
F1) in the absence and presence of Na+.  A. Kinetic titration of fluorescence changes 
(ΔF/Fo) of 20 nM [5F]Hir-(54-65)(SO3-) during activation of Pre 1 at concentrations 
ranging from 58 nM to 1000 nM, initiated by 2 units/ml ecarin in buffer containing NaCl 
(○).  The lines represent the fit of the fluorescence data with the parameters listed in 
Table I.  B. Analysis of the reaction endpoints as a function of the total Pre 1 
concentration ([Pre 1]o).  The line represents the fit by the quadratic binding equation 
with the parameters listed in Table I.  C. Kinetic titrations for activation of 116-1450 nM 
Pre 1 in buffer containing ChCl (○) otherwise as described in A, along with the 
simultaneous fit with the parameters listed in Table I.  D. Endpoint titration for the 
reactions in buffer containing ChCl as described in B.  Reactions were performed and 
analyzed as described in “Experimental Procedures”. 
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affinity of the peptide for the Na+-bound active MzT(-F1) and the thrombin fast form 
(Table I). 
 
 
Figure 6. Effect of Na+ on [5F]Hir-(54-65)(SO3-) binding to FPR-MzT and FPR-MzT(-
F1).  Titrations of the change in fluorescence (ΔF/Fo) of 20 nM [5F]Hir-(54-65)(SO3-) in 
buffers containing NaCl (closed symbols) or ChCl (open symbols) as a function of the 
total concentrations of FPR-MzT (●, ○) and FPR-MzT(-F1) (▲, Δ) ([FPR-MzT or FPR-
MzT(-F1)]o).  The solid lines represent the nonlinear least-squares fits of the titrations by 
the quadratic binding equation with the parameters listed in Table I.  Titrations were 
performed and analyzed as described in “Experimental Procedures”. 
 
 
Effect of Na+ on Exosite I of Active MzT 
 Intact, native MzT generated from ProT could not be studied because of rapid 
autocatalytic conversion to MzT(-F1) during ecarin activation (results not shown).  A 
ProT mutant in which the fragment 1 cleavage site at Arg155 was substituted with Ala was 
activated to stable MzTR155A, which allowed Na+-exosite I linkage to be characterized.  In 
direct titrations (not shown), ProTR155A bound [5F]Hir-(54-65)(SO3-) with KD 1.9 ± 0.3 µM 
in ChCl and 1.1 ± 0.4 µM in NaCl.  Results of kinetic titrations of MzTR155A formation in 
Na+ and Ch+ are shown in Figure 7A and 7C, respectively.  SDS-gel electrophoresis 
confirmed that MzTR155A was the product of the reactions and was stable at 
concentrations and incubation times in excess of the experimental conditions (not 
shown).  Full-length MzTR155A behaved similarly to MzT(-F1), but with a few  
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Figure 7.  Kinetic and endpoint titrations of [5F]Hir-(54-65)(SO3-) binding to 
MzTR155A in the absence and presence of Na+.  A. Kinetic titration of fluorescence 
changes (ΔF/Fo) of 20 nM [5F]Hir-(54-65)(SO3-) during activation of ProTR155A at 
concentrations ranging from  28 to 760  nM, initiated by 2 units/ml ecarin in buffer 
containing NaCl (○).  Thirteen reactions out of a total of 19 analyzed are shown.  The 
lines represent the simultaneous fit of the fluorescence data with the parameters listed in 
Table I.  B. Analysis of the reaction endpoints as a function of the total ProTR155A 
concentration ([ProTR155A]o).  The line represents the fit by the quadratic binding equation 
with the parameters listed in Table I.  C. Kinetic titrations for activation of 91-1198 nM 
ProTR155A in buffer containing ChCl (○) otherwise as described in A, along with the fit with 
the parameters listed in Table I.  Twelve reactions out of a total of 21 analyzed are 
shown.  D. Endpoint titration for the reactions in buffer containing ChCl as described in B 
except that the line represents the fit of the binding equation with ΔFmax/Fo fixed at -35%.  
Reactions were performed and analyzed as described in “Experimental Procedures”. 
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distinguishing features.  Unlike the results for MzT(-F1), the fit of the kinetics of MzTR155A 
formation was improved modestly by including competitive product inhibition of ecarin.  
The fitted KD for [5F]Hir-(54-65)(SO3-) binding to MzTR155A was 81 ± 3 nM in NaCl and 
was 10-fold higher (830 ± 40 nM) in ChCl.  The kinetic parameters for ProTR155A 
activation by ecarin in NaCl were Vmax 2.1 ± 0.2 nM/s, Km 110 ± 30 nM, and Ki 100 ± 50 
nM, and were indistinguishable for Vmax, Km, and Ki, determined in ChCl at 2.0 ± 0.3 
nM/s, 80 ± 40 nM, and 210 ± 160 nM, respectively.  Analysis of the reaction endpoints 
for [5F]Hir-(54-65)(SO3-) binding to MzTR155A in NaCl gave a KD of 100 ± 30 nM (Fig. 7B).  
The endpoint results in ChCl could not be fit independently due to continued slow 
decreases in fluorescence at high ProT concentrations and long reaction times.  
Assuming an endpoint equivalent to that determined kinetically, gave a KD of 770 ± 120 
nM (Fig. 7D).  Together, the results demonstrated slightly larger effects of Na+ on the 
affinity of [5F]Hir-(54-65)(SO3-) for MzTR155A (8 to 10-fold) compared to MzT(-F1) (5 to 6-
fold). 
Na+ Binding Affinity Estimated from the Kinetics of Chromogenic Substrate Hydrolysis  
To compare the apparent affinity of Na+ for thrombin, MzT(-F1), and MzTR155A, 
the initial rate of 200 µM (saturating) D-Phe-Pip-Arg-pNA hydrolysis was determined as 
a function of Na+ concentration. Na+ produced hyperbolic increases in rate of 4.9-fold, 
3.1-fold, and 3.3-fold, from which apparent KD’s of 12 ± 4, 9 ± 2, and 14 ± 4 mM were 
obtained for the substrate bound forms of thrombin, MzT(-F1), and MzTR155A, 
respectively.  The apparent affinities were the same and in reasonable agreement with 
the published KD of 10 mM for Na+ binding to the chromogenic substrate-thrombin 
complex at 25 oC, but at higher pH and ionic strength (25).  
The KD’s for Na+ binding to the free forms of thrombin and MzT(-F1) were 
estimated from the dependence of kcat/Km on Na+ concentration (45).  Despite the 
analysis of five progress curves at each Na+ concentration, the error in the dissociation 
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constants was large (Fig. 8A).  This was due to the necessity of fitting three parameters 
(kcat, Km, and Ki) to the progress curves and three parameters to kcat/Km as a function of 
Na+ concentration (kcat/Km in the absence and at saturating Na+, and KD).  The KD’s for 
thrombin and MzT(-F1) were both 26 ± 20 mM, roughly consistent with the value of 22 
mM, determined at higher ionic strength and pH (25, 45). By contrast, kcat/Km for 
MzTR155A increased linearly up to 110 mM NaCl.  This was accompanied by a ~12-fold 
decrease in Km, whereas this parameter decreased only ~2-3-fold for thrombin and 
MzT(-F1) (Fig. 8B).  Analysis of the dependence of Km on Na+ concentration according to 
the nonessential activation mechanism as described in Experimental Procedures, gave 
an estimate of ~185 mM for the dissociation constant for Na+ binding to free MzTR155A 
and a linkage factor (α) of ~0.085, corresponding to a ~12-fold increase in Na+ affinity at 
saturating substrate concentration.  The value of αKNa of ~16 mM from this analysis was 
in agreement with 14 ± 4 mM determined directly at saturating substrate concentration.  
The dependence of kcat on Na+ concentration for all of the enzymes was consistent with 
the directly measured dissociation constants for the substrate-saturated forms described 
above.  The results demonstrated distinctly different kinetic behavior and a much higher 
KD for Na+ binding to MzTR155A, which contains the fragment 1 domain, compared to 
thrombin and MzT(-F1) which do not. 
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Figure 8.  Effects of Na+  on chromogenic substrate hydrolysis by thrombin, MzT(-
F1), and MzTR155A.  A. Dependence of kcat/Km for D-Phe-Pip-Arg-pNA hydrolysis on Na+ 
concentration for thrombin (), MzT(-F1) (○), and MzTR155A (▲).  The solid lines for 
thrombin and MzT(-F1) represent the least squares fits of the data as described in 
Experimental Procedures, with indistinguishable KD’s for Na+ binding of  26 ± 20 mM.  
The fit of a straight line is shown for MzTR155A.  B. Na+ concentration dependence of the 
observed Km (Km obs) for hydrolysis of D-Phe-Pip-Arg-pNA by thrombin (●), MzT(-F1) (○), 
and MzTR155A (▲).  The  solid lines represent the fits of Equation  1 with the parameters 
Km, α, and KNa of 2.2 µM, 0.39, and 34 mM for thrombin; 2.4 µM, 0.5, and 21 mM for 
MzT(-F1); and 14 µM, 0.085, and 185 mM for MzTR155A.  Experiments were performed 
and analyzed as described in “Experimental Procedures”.
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Table I 
Summary of binding parameters 
 
Dissociation constants are listed for binding of [5F]Hir-(54-65)(SO3-) to ProT and Pre 1 species in buffers containing 110 mM NaCl 
(KH, Na), 110 mM ChCl (KH, Ch), their ratio (KH, Ch/ KH, Na), and the corresponding maximum fluorescence changes ((Fmax/Fo)Na and 
(Fmax/Fo)Ch).  Results were obtained by direct, kinetic, and endpoint titrations as described under “Experimental Procedures”. 
 
Protein Method Dissociation Constant KH, Ch/ KH, Na Fluorescence Change 
KH, Ch  (Fmax/Fo)Na   KH, Na (Fmax/Fo)Ch 
  (nM) (nM)  (%) (%) 
       
ProT Direct titration 4000±700 5400±900 1.4 -18±1 -19±1 
ProTR155A Direct titration 1100±300 1900±300 1.7 -20±3 -20±2 
Pre 1 Direct titration 510±70 830±140 1.6 -19±1 -20±1 
Pre 2 Direct titration 640±90 850±120 1.3 -27±1 -26±1 
Thrombin Direct titration 48±4 270±20 5.6 -30±1 -32±1 
FPR-thrombin Direct titration 35±6 51±2 1.5 -31±1 -30±1 
MzT(-F1) Kinetic titration 41±1 210±5 5.1 -29±1 -29±1 
MzT(-F1) Endpoint titration 35±6 200±4 5.7 -28±1 -29±2 
FPR-MzT(-F1) Direct titration 26±5 34±3 1.3 -35±1 -34±1 
FPR-MzT(-F1) Kinetic titration 40±2   -32±1  
FPR-MzT(-F1) Endpoint titration 40±20   -32±3  
MzTR155A Kinetic titration 80±3 830±40 10.4 -33±1 -35±2 
MzTR155A Endpoint titration 100±30 770±120a 7.7 -34±5 -35a 
FPR-MzT Direct titration 35±4 41±5 1.2 -34±1 -34±1 
       
  
a The KD for peptide binding to MzTR155A from the reaction endpoints in the absence of Na+ was obtained by fixing ΔFmax/Fo  
at -35%
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Discussion 
Examination of the appearance of Na+-exosite I linkage on ProT and its activation 
products supports the conclusion that proexosite I on ProT, Pre 1, and Pre 2 is not linked 
to Na+ binding.  Expression of linkage accompanies activation of the thrombin, MzT(-F1), 
and MzT catalytic sites by cleavage at Arg320.  Exosite I affinity and catalytic activity of 
MzT and MzT(-F1) are shown for the first time to be allosterically regulated by Na+.  The 
well-established coupling of protein substrate specificity to Na+ binding for thrombin 
suggests that the distinctly different specificity of MzT will be regulated by the MzT slow 
form to fast form transition.  Increasing MzT exosite I affinity and catalytic activity in the 
allosteric transition by Na+ binding may also affect recognition of MzT as a substrate of 
the prothrombinase complex. 
Linkage between Na+ binding and exosite I affinity for [5F]Hir-(54-65)(SO3-) is 
expressed after cleavage at Arg320 of ProT and the ensuing conformational changes that 
activate the catalytic site and (pro)exosite I.  The magnitudes of the effects of Na+ on the 
enhancement of [5F]Hir-(54-65)(SO3-) affinity for exosite I on thrombin (5.6-fold) and 
MzT(-F1) (5.1-5.7-fold) were not significantly different, whereas MzTR155A showed a 
slightly larger effect (7.7-10.4-fold).  The 5.6-fold increase in affinity for thrombin is in 
reasonable agreement with previously reported values for acetyl-Hir-(55-65) (2-fold; 
(47)), Hir-(55-65) (2.3 and 6.4 fold; (24, 48)), and acetyl-Hir-(53-64) (5.4-fold; (32)), 
determined at different ionic strength, pH, and temperature. 
The affinity of [5F]Hir-(54-65)(SO3-) for (pro)exosite I on the zymogen forms, 
ProT, ProTR155A, Pre 1, and Pre 2 was consistently 1.3-1.7 fold higher in the presence of 
Na+.  This difference is well within the experimental error and may not be significant. As 
shown in the crystal structure of the Pre 2-hirugen complex, the Na+ site is not properly 
formed on Pre 2 (49).  On this basis, the results demonstrate that the absence of linkage 
between Na+ and proexosite I is due to the inability of all zymogen forms to bind Na+. 
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The conformational changes that complete the folding of the catalytic domain and 
formation of the catalytic site are necessary for expression of allosteric linkage. 
In a recent structural analysis of human thrombin, crystal packing interactions 
were identified that have influenced interpretation of previous structures of the fast, slow, 
and inactive forms (31).  The structure of the D102N thrombin mutant in the absence of 
Na+ lacks crystal packing interactions, and is thought to represent more closely the 
inactive slow form in equilibrium with the active slow form and fast form.  In the D102N 
thrombin structure, the catalytic site is blocked by large movements of Trp215 and Arg221a 
to occlude the catalytic and primary specificity sites, while the guanidinium group of 
Arg187 occupies the Na+ site (31). Rapid-reaction kinetic studies of Na+ binding indicated 
that 23% of wild type thrombin is in the inactive slow form at 15 ºC, and that this form is 
not significantly populated at 37 ºC (31, 33).  Presumably this form was also present at 
some level in the studies done here at 25 ºC, suggesting that binding of [5F]Hir-(54-
65)(SO3-) to exosite I contains some contribution from inactive slow forms.  Whether 
such inactive slow forms exist for MzT(±F1) is not known.   
Inactivation of thrombin, MzT(-F1), and MzT with FPR-CH2Cl virtually obliterated 
Na+-exosite I linkage as probed by [5F]Hir-(54-65)(SO3-) binding affinity, and normalized 
all of the affinities to values indistinguishable from that of the fast form of thrombin.  This 
is fully consistent with an analysis of the structures of the thrombin slow and fast forms, 
free and FPR-inactivated, which demonstrated that active site labeling locks thrombin in 
a fast form (26), and the essentially identical structures of FPR-thrombin and the Hir-(53-
64)-thrombin complex (29).  The Na+ independence of the exosite I affinities is explained 
by binding of the transition state analog to the S1-S42 specificity sites, formation of a 
hemiketal with Ser195, and subsequent alkylation of His57.  Although FPR-thrombin does 
bind Na+ (26), the relaxation of Asp189 in the S1 site, Ser195, and His57 to their 
conformations in the slow form in the absence of Na+ cannot take place.  It should be 
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noted that this finding does not compromise the conclusions of our previous studies of 
exosite I expression using FPR-inactivated thrombin and MzT(-F1) because, as shown 
here, these inactivated enzymes have affinities for the hirudin peptide essentially the 
same as the active fast forms.  The affinities of MzTR155A for the peptide, however, are 2-
3-fold lower at 110 mM NaCl. 
Kinetic analysis of Na+ binding to MzTR155A revealed a lower affinity compared to 
thrombin and MzT(-F1), which was associated with a larger decrease in Km for the 
chromogenic substrate, and not significantly larger increases in kcat.  This unexpected 
behavior suggests that the presence of the fragment 1 domain attenuates affinity for Na+ 
binding.  The large effect of the presence of fragment 1 on the Na+-dependent apparent 
substrate binding affinity may be due to steric or conformational differences affecting the 
active site or the Na+ binding site, and indirectly exosite I.  Further studies are needed to 
define the kinetic and molecular mechanism of MzT regulation by Na+. 
Although the mechanism of Na+ regulation of MzTR155A is not resolved, the results 
demonstrate for the first time that MzT(-F1) and MzTR155A are Na+-regulated proteinases 
exhibiting linkage to exosite I.  Na+ regulates the specificity of thrombin for procoagulant 
and anticoagulant substrates and effectors (15, 17-18, 23-24).  The fast form has higher 
specificity (kcat/Km) than the slow form for the procoagulant substrates, fibrinogen and 
protease activated receptors, whereas relative to the fast form, the slow form is more 
specific for protein C activation (48).  Compared to thrombin, MzT(±F1) has ≤10% 
activity toward fibrinogen and ≤2% activity in platelet activation despite having an active 
catalytic site and exosite I (19-20).  Thrombin activates factor V in solution and factor V 
bound to phospholipid membranes in exosite I- and II-dependent reactions (22, 44, 50-
52), whereas MzT activates factor V at a significant rate only when the substrate and 
enzyme are membrane-bound (21-22).  It has been suggested that MzT may play an 
important procoagulant role as a specific physiological activator of membrane-bound 
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factor V during initiation of blood coagulation (21-22).  Based on the present results, and 
the observation that factor V activation is catalyzed more efficiently by the thrombin fast 
form (52), MzT-catalyzed factor V activation is predicted to be regulated by Na+.  The 
dissociation constant for Na+ binding to thrombin under physiological conditions is 110 
mM, indicating an equilibrium of 60% fast and 40% slow forms (25, 53-54).  The KD for 
Na+ binding to MzTR155A at 37 ºC was not determined for the reasons cited above, but 
depending on the temperature dependence of Na+ binding, MzT may be similarly poised 
for Na+ regulation physiologically. 
In the thrombin-thrombomodulin complex, the slow form of thrombin becomes a 
potent anticoagulant proteinase due in part to the loss of specificity for fibrinogen and 
other procoagulant substrates, whereas the capacity for protein C activation is greatly 
increased (15-18, 48, 55). Activation of protein C by MzT and MzT(-F1) is also 
stimulated by thrombomodulin to rates comparable to thrombin, and even faster rates 
when MzT is bound to phospholipid membranes (19-20).  This has been suggested to 
represent an important physiological role for MzT as an anticoagulant (19-20).  The 
present studies suggest that, like thrombin, Na+-bound and free forms of MzT may 
exhibit higher procoagulant and anticoagulant activities, respectively. 
ProT activation is dependent on expression of exosites on factor Xa in the factor 
Xa-Va-membrane complex that mediate a substrate recognition mechanism consisting 
of initial exosite binding and a subsequent conformational change engaging the catalytic 
site in peptide bond cleavage (7-14).  Other studies support the hypothesis that 
(pro)exosite I on ProT also contributes to substrate recognition by mediating productive 
ProT binding and/or affecting the subsequent conformational change through 
interactions with the ProT binding site on factor Va in the prothrombinase complex (56-
59).  ProT activation catalyzed by prothrombinase proceeds sequentially, with initial 
cleavage at Arg320 to form MzT, followed by cleavage at Arg271 to generate thrombin and 
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fragment 1.2 (2-7).  Recent studies of the activation pathway support a mechanism in 
which substrates in the zymogen and proteinase states bind in alternate conformations 
that direct sequential cleavage at the two activation sites (8).  The ProT zymogen is 
positioned for optimal cleavage at Arg320, whereas the product, MzT in the proteinase 
conformation ratchets to a different bound conformation for cleavage at Arg271.  On the 
basis of the evidence for the role of (pro)exosite I in substrate recognition through factor 
Va (56-59), and the differential expression of the exosite on ProT zymogen and 
proteinase forms (35-36), expression of exosite I on MzT may contribute to ratcheting of 
the bound substrate for presentation of Arg271 for cleavage.  The present studies show 
that the chromogenic substrate activity and affinity of MzT exosite I are enhanced by 
Na+, suggesting that coupling of Na+ binding and exosite I expression upon cleavage at 
Arg320 may contribute to recognition of this substrate.  Previous studies of the role of Na+ 
on the rate of Pre 1 activation in the absence of membranes by the Na+-insensitive factor 
Xa mutant, Y225P, also lacking the γ-carboxyglutamic acid domain, showed a 10-fold 
enhancement by Na+, which was correlated with a modest increase  in affinity for factor 
Va (60).  On the other hand, with wild-type factor Xa assembled into prothrombinase the 
Na+ enhancement was only <1.5-fold (60). Whether Na+ affects the rate of MzT cleavage 
by prothrombinase remains an open question. 
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1.  Abbreviations used are: ProT, prothrombin; Pre 1, prethrombin 1; Pre 2, prethrombin 
2; F1, fragment 1; MzT, meizothrombin; MzT(-F1), meizothrombin-des-fragment 1; T, 
thrombin; FPR-CH2Cl, D-Phe-Pro-Arg-CH2Cl; Hir-(54-65)(SO3-), Gly-Asp-Phe-Glu-Glu-
Ile-Pro-Glu-Glu-Tyr(SO3-)-Leu-Gln; [5F]Hir-(54-65)(SO3-), Hir-(54-65)(SO3-) labeled at the 
amino terminus with 5-carboxy(fluorescein); hirugen, hirudin-(53-64); PEG, polyethylene 
glycol; pNA, p-nitroaniline. 
  
2.  Schechter-Berger (61) notation referring to the residues of a substrate (from the NH2-
terminal end) as …P4-P3-P2-P1-P1’-P2’… with the scissile bond at P1-P1’. 
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CHAPTER V 
 
SIGNIFICANCE AND FUTURE PATHWAYS 
 
Summary of research 
The preceding studies described the molecular mechanisms involved in the 
activation of ProT by the staphylococcal exoprotein VWbp, as well as some of the 
allosteric processes that are important for ligand recognition and regulation of substrate 
hydrolysis by the active ProT·VWbp complex.  First and foremost, VWbp can now be 
classified as one of the few proteins identified which function as non-proteolytic zymogen 
activators.  The unique process of conformational induction of the active site of the 
proenzyme is dependent upon both sequence mimicry in the NH2-terminus of the 
activator and high-affinity interactions with crucial regions of the zymogen activation 
domain.  In addition, hysteretic, substrate-dependent regulation of this activity provides a 
second level of specificity for recognition of the physiological thrombin substrate, 
fibrinogen, by the ProT·VWbp complex.  Potential steric and allosteric opposition 
provided by the small fragment domains of ProT further controls the activity of VWbp, 
but this effect may be mitigated in vivo by secondary autocatalysis which results in 
progressive loss of the fragment domains.  Proteolytic activation of the zymogen, and to 
an even greater extent, occupation of the active site by a highly-specific substrate, also 
enhances the affinity of VWbp for ProT and its derivatives.  The role of anion-binding 
(pro)exosite I and its activation state in the interaction of ProT and VWbp is very similar 
to that seen during the physiological pathway of ProT activation, where formation of a 
competent active site (such as in MzT) is linked to a high-affinity exosite expression, as 
well as other allosteric sites like the sodium binding site.  Taken together, these findings 
reveal a pattern of ligand and substrate recognition with VWbp that shows a strong 
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mechanistic resemblance to the normal pattern of thrombin activity, but the overall 
specificity of which is substantially constrained by structural alterations due to the 
presence of the activator itself. 
 
Significance of the Mechanism of Activation of ProT by VWbp 
 VWbp is only the third protein so far that has been demonstrated mechanistically 
to be a conformational activator of a zymogen.  The model of non-proteolytic activation 
through exploitation of the linkage between the canonical NH2-terminal binding cleft and 
the actual activation domain has been examined using tight-binding substrates and NH2-
terminal peptide mimetics (1), but it was not until recently (with SC) that any clear 
structural proof of this concept was established (2).  The ability of SC and streptokinase 
(SK) to bind their cognate zymogens and induce functional active sites, despite the vast 
differences in secondary and tertiary structure between the two activators, underscores 
the essential role of their NH2-terminal residues in the mechanism of activation.  
Corresponding mutational analysis of VWbp revealed strict dependence of its activity 
upon the initial Val-Val residues, comparable to that found with both SC and SK (2, 3), 
which firmly places VWbp into the class of bacterial non-proteolytic zymogen activators.  
In addition to their reliance upon the NH2-terminal insertion mechanism, these three 
bacterial proteins also produce other subtle functional differences in the complexes they 
form, compared to the analogous proteinases.  Even though they all induce an active 
site within the zymogen, the enzymatic specificity of the active site is not necessarily 
equivalent with respect to all of the potential substrates.  Either plasminogen or plasmin 
in complex with SK demonstrates the ability to convert other molecules of plasminogen 
to plasmin (4), whereas free plasmin lacks this capacity.  SC in complex with ProT 
retains high specificity for several thrombin substrates, including fibrinogen, but it also 
imparts resistance to macromolecular thrombin inhibitors and protein substrates which 
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normally interact with the active site (5).  Nearly identical limitation of substrates and 
resistance to inhibition is seen with VWbp, particularly in the inability of ProT·VWbp to 
activate a number of other thrombin-cleavable coagulation factors.  The pattern of 
changes in substrate and inhibitor specificity indicates that the conformational changes 
involved in folding of the zymogen activation domains do not exactly mirror those that 
follow proteolytic activation.  These differences may stem from direct interactions of the 
bacterial activators with the activation domain, as well as global conformational shifts in 
the zymogen, and the restricted specificity likely represents the foundation for the true 
function of the activator proteins in manipulating the host coagulation and fibrinolytic 
systems.  Although conformational, NH2-terminus-dependent activation of zymogens has 
only been experimentally demonstrated for these few exoproteins, identification of 
several SC-homologous activators (the ZAAPs) from staphylococci and streptococci 
suggests that other exoproteins may also be able to directly interact with blood 
coagulation zymogens (6).  As such, non-proteolytic activation of host enzymes could be 
a valid mechanistic approach for bacteria during infection.  
In addition to the distinctive conformational mechanism of activation of ProT, 
VWbp also demonstrates strict regulation of its activity by way of additional cofactor 
requirements for complete zymogen activation.  While SC alone is able to bind ProT with 
very high affinity and induce a fully functional active site, VWbp recognizes the zymogen 
with a comparatively low affinity, resulting in incomplete activation of ProT in equimolar 
mixtures with VWbp.  The behavior of VWbp in complex with ProT is consistent with a 
kinetically slow, hysteretic step in the ultimate conversion of zymogen ProT to the 
conformationally activated form.   The proposed hysteretic kinetic model for VWbp-
mediated activation of ProT includes a crucial slow and unfavorable equilibrium between 
inactive and active forms of the ProT·VWbp complex, produced by a suboptimal 
interaction between the two proteins which likely results in partial NH2-terminal insertion 
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or folding of the activation domain.  Association of a tight-binding substrate with the 
induced active site stabilizes the fully-active complex, increasing the rate of substrate 
hydrolysis through a positive change in the conformational equilibrium.  Based on what 
is known about cooperative linkage between NH2-terminal insertion and the active site, 
this outcome in the presence of a substrate would not be unexpected, but the rate at 
which it occurs indicates the true uniqueness of the hysteretic kinetic mechanism of 
VWbp.  By definition, hysteresis in enzyme kinetics occurs when a system has a slow 
response to a sudden stimulus that changes the biochemical conditions, which includes 
processes such as slow isomerization of an enzyme or displacement of one ligand by 
another (7).  Only upon addition of substrate does the inactive-active equilibrium of the 
ProT·VWbp complex shift towards the active form, with a slow observable rate.  As a 
result, the kinetic process actually requires two cofactors for ProT activation, both VWbp 
and a substrate, an unusual characteristic in the relatively small field of hysteretic 
enzymes and the first example of hysteresis in serine proteinase zymogen activation.   
 
Allostery and Thrombin Specificity 
Despite the fact that other thrombin ligands can induce small conformational 
changes in the enzyme to affect its activity, the activity of VWbp with ProT could be 
characterized as the definitive allosteric interaction.  There are many examples of 
ligands that can allosterically change the activity of thrombin, such as binding of 
thrombomodulin, which allows thrombin to recognize and cleave protein C, and hirudin-
mediated alteration of the active site to generally inhibit thrombin activity (8, 9).  One or 
both of exosites I and II are typically involved in binding of the various thrombin ligands, 
and any allosteric effects are, in general, targeted toward specific alterations in substrate 
recognition.  We have shown that formation of the proteinase active site and exosite I is 
allosterically linked to binding of a sodium ion, a process known to influence the pro- and 
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anti-coagulant substrate specificity of different sodium-bound forms of thrombin (10).  
Identical regulation by sodium has been recently identified for MzT(-F1) (11), and ProT 
in complex with SC also demonstrates sodium-dependent effects on activity (12).  VWbp 
likely exhibits analogous behavior with ProT in the presence of sodium, an indication of 
how effectively these activators can exploit the normal regulatory mechanisms of 
thrombin.     
Although VWbp also modifies the substrate profile of the ProT complex, 
seemingly restricting it to fibrinogen and small tripeptide substrates, VWbp most 
significantly differs in the magnitude of change it induces in the zymogen.  Complete 
conformational activation of ProT by VWbp relies on manipulation of multiple interactions 
between the NH2-terminus of the activator and critical residues involved in folding of the 
activation domain, as well as direct exosite and active site contact.  Not only does VWbp 
bind directly to (pro)exosite I, it also interacts with the NH2-terminal binding cleft (and 
potentially the nearby autolysis loop); the COOH-terminal half of VWbp may also 
specifically interact with the ProT fragment domains or activation domain.  Through 
these interactions with VWbp, the catalytic site and substrate-specificity cleft can be 
completely converted to a thrombin-like configuration, an effect that can be triggered by 
only one other known ligand—SC.  The proteinase substrate also acts as a cofactor in 
this process through stabilization of the active site, connecting with the activating 
conformational changes initiated by VWbp to produce a potent procoagulant complex.   
The cooperativity between VWbp and substrate in inducing an enzymatically active 
complex actually mirrors other rare examples of cofactor-induced enzyme activation.  
Analogous conversion from a partially activated to fully competent enzyme form occurs 
in the factor VIIa-tissue factor complex, where initial proteolytic “activation” of factor VIIa 
results in a protein with very low enzymatic activity.  It is only upon binding of its 
cofactor, tissue factor, that the active site of factor VIIa properly folds, allowing the serine 
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proteinase to recognize and hydrolyze its target substrates, factors IX and X (13).  
Similarly, substrate cofactors are required during activation of complement protease 
factor D, where only binding of a specific substrate relieves steric distortion within the 
active site of the enzyme (14).  The behavior of VWbp in complex with ProT resembles 
both of these cofactor-dependent mechanisms, with VWbp itself serving as a cofactor in 
induction of an “inactive” ProT form that is converted to a fully functional complex upon 
binding of a substrate to the active site.  Due to the clear role of cofactors in temporally 
and spatially regulating the activity of factor VIIa and complement factor D, it is 
reasonable to speculate that the cofactor requirements for formation of active 
ProT*·VWbp would also be a primary influence on complex activity.  This is in clear 
contrast to the more straightforward mechanisms of activation demonstrated by SC and 
SK, where direct and rapid interaction of the activator alone with the zymogen results in 
an active species.  The complexity exhibited by VWbp in activation of ProT, in particular 
the substrate-dependent hysteretic changes in complex conformation, sets VWbp apart 
mechanistically, even within the very small class of non-proteolytic zymogen activators.  
Whether VWbp or SC has the dominant mechanistic characteristics of other ZAAPs is 
not established, although preliminary studies of SfbX suggest a hysteretic mechanism 
(Jonathan Creamer, Ph.D., personal communication).  
 
The Role of von Willebrand Factor in Hemostasis 
 Specific association with one or more adhesion or extracellular matrix proteins is 
one of the most significant characteristics of many exoproteins in both the MSCRAMM 
and SERAM families, but only a relatively small number of bacterial products have been 
shown to have a pathological function for these interactions.  Studies on cell-surface 
localized proteins such as ClfA and FnBP showed moderate success in linking protein 
expression to bacterial colonization in in vivo models of infection (15, 16), but secreted 
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factors may have more indirect or synergistic effects that make correlation with a specific 
disease difficult.  Neither VWbp nor SC has had a significant role assigned to their 
COOH-terminal adhesion protein binding motifs, apart from basic specificity for VWF 
(VWbp) or fibrinogen (SC).  The promiscuity of interactions displayed by proteins such 
as fibrinogen creates an intricate meshwork of potential protein or cellular targets for 
bacterial factors.  Hence, the capacity of bacterial exoproteins for binding adhesive 
molecules remains an important area of investigation in both biochemical systems and 
animal models of human diseases. 
 The contribution of VWF to the progression of infectious vascular disease has not 
been examined as frequently as more ubiquitous adhesion proteins like fibrinogen and 
fibronectin, despite its unique roles in mediating platelet function and thrombus 
formation.  VWF is a large (~250 kDa) glycoprotein which forms disulfide-bonded 
multimers up to 20,000 kDa in size, and it is either secreted by endothelial cells, from 
which the plasma population of VWF originates, or stored in intracellular cytoplasmic 
granules (Weibel-Palade bodies) for later induced secretion (17).  Release of VWF from 
endothelial cells can be triggered by several agonists common to coagulation and 
inflammatory responses, including thrombin and fibrin (18), resulting in increased local 
concentrations of the adhesion protein.  The first major function of VWF is to tether free 
platelets to the subendothelium following an injury, a process that depends upon binding 
of two of the type A structural domains of VWF (A1 and A3; Figure 1) to several different 
forms of collagen found in exposed extracellular matrices (19).  Conformational changes 
within VWF are induced by this interaction and the shear force of blood flow, exposing 
regions of the protein that can interact with two different targets on the platelet surface: 
the GPIbα-IX-V receptor complex and the integrin αIIbβ3 (20).  These actions are most 
significant in high shear rate environments, such as small arteries and capillaries, where 
other adhesion proteins cannot bind platelets with sufficient force to arrest the movement 
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of the cells.  Initial adhesion occurs through the GPIbα component of the platelet 
receptor, which allows the platelets to roll across the surface of the exposed matrix.  
Once the momentum is reduced, secondary interactions between αIIbβ3 and a specific 
Arg-Gly-Asp (RGD) sequence in VWF activates the platelets and enhances affinity and 
subsequent aggregation of platelets at the site of injury.  The second role for VWF in 
thrombus formation is to serve as a carrier protein for blood clotting factor VIII, a cofactor 
in factor X activation by factor IXa.  Association of factor VIII with the residues near the 
A3 domain of VWF serves to stabilize the coagulation factor by increasing its half-life in 
circulation and protecting it from inactivating proteolysis by activated protein C (21).  As 
a result of these vital roles, quantitative deficiencies or defects in VWF multimerization 
can have wide-spread consequences for hemostasis, ranging from relatively minor 
bleeding phenotypes to the severe symptoms of hemophilia A (17). 
 
 
Figure 1.  Domain organization of VWF propeptide and mature protein.  Adapted 
from (19). 
 
  
Recognition of von Willebrand Factor by Pathogens 
In view of the multiple functions of VWF in the vasculature, what would be the 
potential benefit for a bacterial pathogen to secrete an exoprotein that recognizes VWF?  
Secretion of proteins from the Weibel-Palade bodies of aortic endothelial cells has been 
shown to be upregulated by components of bacterial cell walls, including lipoteichoic 
acid from gram-positive organisms (22).  Release of several vascular mediators, 
including VWF, is triggered by recognition of the pathogen by the Toll-like receptor 2, 
 159
which has a role in the innate immune response.  Subsequent vascular inflammation 
could then set the stage for a number of pathologic responses, from both the 
endogenous host systems and the bacteria themselves.  Studies have also been 
performed with several species of bacteria to examine any direct involvement of VWF in 
altering pathological coagulation or hemostasis.  Platelet aggregation by one clinical 
strain of Streptococcus sanguis, an oral bacterium that is often linked with infective 
endocarditis, was initially linked to a VWF-independent interaction with GPIbα (23).  
Later reports contest this conclusion by demonstrating that plasma from patients with 
von Willebrand’s disease could not support platelet activation by certain other strains of 
S. sanguis, suggesting a role for VWF in platelet activity, perhaps through noncanonical 
interactions with other platelet receptors (24).  Staphylococcus aureus directly interacts 
with VWF in solution, as well as VWF adsorbed to surfaces, providing this species with 
multiple adhesive targets in an intravascular environment (25).  S. aureus expresses the 
surface-localized receptor protein A, or Spa, which directly binds VWF (26), and this 
protein has been shown to be a major determinant of bacterial adhesion to immobilized 
platelets at high shear rates (27, 28).  In general, binding of VWF by bacteria could allow 
localization to newly-exposed subendothelium, as well as pre-existing platelet-rich 
thrombi.  Regulation of expression of VWF-specific receptors, such as protein A, would 
influence the mechanisms of cellular adhesion at different bacterial growth cycles (29), 
consequently affecting the time- and flow-dependent pattern of dissemination.  The 
multimeric and multi-domain structure of VWF also presents numerous binding sites for 
simultaneous interactions with cellular receptors and other extracellular matrix proteins, 
all of which could also control bacterial colonization. 
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VWbp:  A Bifunctional Staphylococcal Exoprotein 
As a secreted protein, VWbp could use its interaction with VWF to not only 
localize fibrin deposition to VWF-rich areas of the vasculature, but also directly alter the 
function of VWF.  VWF contains a number of different domains that can be classified into 
several homologous types.  The A1-A2-A3 domains are responsible for interactions with 
many of the VWF ligands, such as GPIbα, and the multimerization site for VWF is 
located immediately before the A1 domain.  There are smaller groups of B and C 
domains, and larger D-type domains which govern factor VIII and collagen recognition 
(30).  Exposure of varying binding sites in the domains, dependent on shear rate and 
secondary binding of other ligands, is known to induce different functions for VWF, and 
bacterial proteins could exploit similar mechanisms to manipulate the adhesive 
properties of VWF.  Protein A contains four or five repeat domains, each individually 
forming a three-helical bundle structure which recognizes the A1 domain of VWF; 
contact between these two proteins could potentially block binding of GPIbα and 
collagen (VWF), as well as the Fc region of IgG (protein A), significantly changing the 
specificity of both proteins (31).  The domain specificity of a cell-surface receptor from 
Staphylococcus lugdenensis, which also recognizes VWF, has not been fully defined, 
but no sequence homology with protein A has been uncovered (32).  A specific binding 
site for VWbp on VWF has not been identified, and the disordered 26-residue region 
within the COOH-terminus of VWbp that is responsible for binding of VWF shares no 
sequence (or structural) homology with these other known bacterial VWF ligands.  As 
such, the possible consequences of the VWbp-VWF interaction are presently unknown.  
The fact that VWbp can bind to VWF under static conditions (33) indicates that either 
binding occurs through a region of VWF that is accessible in its globular, unextended 
form, or that VWbp can change the conformation of VWF to expose cryptic binding sites.  
If binding of VWbp can reveal regions of VWF that are only normally exposed at high 
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shear flow or after binding of collagen, this would enhance the platelet-binding functions 
of VWF in low shear environments to produce abnormal platelet aggregation and 
activation.  A combination of increased platelet-induced thrombus growth with escalating 
fibrin deposition from procoagulant zymogen-activator complexes would have the 
potential to quickly occlude smaller vessels or cause harmful embolisms.  
 The multiple functions of exoproteins like VWbp and SC may play synergistic 
roles in bacterial colonization and protection of S. aureus from the host immune 
response.  Fibrin elicits the activation of endothelial cells, prompting direct engulfment of 
bacteria by host cells, and fibrin clots also serve as a physical barrier to pathogen-
recognizing cells of the innate and adaptive systems (34).  S. aureus can not only 
survive phagocytosis, but it can also use the host cells themselves as a line of defense 
against antibody and complement molecules.  Any mechanisms that lead to increased 
fibrin deposition and recognition would be beneficial, but the overall effect of these 
processes on the life cycle of the bacteria would be determined by the specificity and 
localization of the different fibrin receptors.  During a blood-borne S. aureus infection, the 
bacteria would produce at least two secreted factors that recognize fibrinogen, SC and 
VWbp, as well as several cell-surface proteins, the most significant of which is ClfA.  
Binding of free fibrinogen by surface receptors would cover the bacteria in a non-
antigenic coating of host proteins, essentially making the pathogens invisible to the 
immune cells.  In addition, existing transient deposits of fibrin in the vasculature would 
support initial localization of the bacteria through receptors such as ClfA.   
In concert with the bacterial surface proteins, secreted factors like VWbp may 
contribute to more widespread dissemination of the bacteria during an infection.  If 
VWbp can recognize both free and immobilized VWF, it could bind the adhesion protein 
at any presented opportunity.  Transient sites of injury, with exposed endothelium, would 
be obvious targets of the procoagulant ProT·VWbp complex, and succeeding fibrin 
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formation and platelet activation would offer protection to the spreading pathogen.  In 
turn, VWbp could also interact with the portion of VWF present in the plasma and be 
transported to distant sites in the vasculature, quickly setting up a base of fibrin for 
subsequent thrombus development.  Once a favorable site is established, surface 
receptors on the bacteria would allow bacterial recognition and localization.  This may be 
an important mechanism at low bacterial densities, because VWbp is secreted during 
the exponential growth phase.  Besides the ability to initiate thrombus growth, VWbp is 
also able to affect the innate immune response through autocatalytic cleavage of the 
fragment domains of ProT·VWbp.  Fragments 1 and 2 have been shown to stimulate the 
chemokine receptors on neutrophils, modulating migration of the cells (35).  Release of 
the fragment domains could either desensitize the immune cells to other stimuli or 
induce chemotaxis, depending on the signaling microenvironment.  Furthermore, it is 
important to note that the COOH-terminal half of VWbp contributes to both VWF 
recognition and ProT affinity, and this region seems to be quite sensitive to cleavage.  
Contact of VWbp with VWF could provide protection from proteolysis, stabilizing higher 
affinity interactions between ProT and VWbp and enhancing the procoagulant activity of 
the ProT·VWbp complex.   
 
VWbp and Staphylococcal Pathology 
 There are a considerable number of pathologies which could be produced by an 
intravascular staphylococcal infection, ranging from minor vasculitis to severe 
hematogenous pneumonia.  The expression of a plethora of staphylococcal proteins 
which recognize adhesion proteins underlines the importance of extracellular matrix in 
establishing and propagating bacterial colonization of the host.  Vulnerable areas of the 
vasculature, such as congenitally dysfunctional heart valves or narrowed arteries with 
high shear flow rates, are susceptible targets for bacterial adhesion because of host 
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repair processes which rely on proteins such as fibrinogen and VWF to protect injured 
endothelium.  Exogenous surfaces such as prosthetic heart valves and intravenous 
catheters are even more at risk for bacterial contamination, due to the propensity of 
adhesion proteins to adsorb to artificial surfaces. 
The staphylococcal pathology most clearly associated with uncontrolled fibrin 
deposition is a condition called infective endocarditis.  This often-fatal infection of the 
heart valves can be produced by many species of bacteria, but in recent years, 
staphylococcal species have become a predominant cause of endocarditis of normal 
heart valves (36, 37).  Several steps are needed to support colonization of a heart valve, 
including disruption of the endothelial cell surface, association of bacteria with the 
activated surface, and protection of adherent bacteria to maintain propagation (38).  
Once a valve is colonized, a vegetative growth composed of fibrin, platelets, and 
bacteria progressively builds up on the surface, diminishing the function of the valve 
(Figure 2).  The involvement of the coagulation cascade in this process is clear, and 
many species of pathogenic bacteria can sustain fibrin production through triggering the 
release of tissue factor from endothelial cells.  Many of the staphylococcal exoproteins 
could play a role in the development of endocarditis through their adhesion protein 
interactions, but S. aureus is unique in that it can specifically produce thrombin-like 
activity through expression of VWbp and SC.   
Based on its recognized interactions with ProT, fibrinogen, and VWF, VWbp is a 
likely candidate for involvement in the virulence of S. aureus infective endocarditis.  
Exposure of subendothelium would be common in areas of high shear stress, such as 
heart valves, along with transient deposition of VWF and platelets.  As an ideal stage for 
VWbp activity, the injured endothelial surface of the heart valve could quickly become 
colonized by bacteria through fibrin deposition mediated by VWbp and, eventually, SC.  
The connection between procoagulant exoproteins and endocarditis had been previously  
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 Figure 2.  Development of vegetative growths during bacterial infective 
endocarditis.  The presence of coagulase-positive S. aureus can exacerbate transient 
lesions on heart valves, leading to enhanced fibrin deposition and thrombus growth.   
 
 
examined in several rat models of staphylococcal endocarditis, using S. aureus strains 
which had the SC gene specifically knocked out (39, 40).  No clear correlation was found 
between expression of SC and disease progression, but these studies were performed 
before the gene for VWbp was identified.  If the S. aureus strains used in these 
experiments still expressed a procoagulant protein like VWbp, a significant alteration in 
overall pathology may not be detected.  The animal models also focused on relatively 
narrow windows during the progression of the disease, further limiting the conclusions of 
the studies.   
As a new potential virulence factor for S. aureus, it is important to understand the 
contribution of VWbp to not only altered hemostatic function during an infection, but also 
bacterial localization and propagation throughout the time-course of the disease.  With 
the increased prevalence of methicillin- and vancomycin-resistant strains of S. aureus, 
multiple therapeutic approaches will eventually be needed for effective treatment of 
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staphylococcal infections.  Awareness of the synergistic roles between the myriad of 
proteins expressed by S. aureus is essential for the development of therapies targeted 
towards the molecular mechanisms involved in bacterial survival and dissemination.    
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